var title_f15_39_15984="Ileocolic stapled anastomosis - end to side";
var content_f15_39_15984=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F78357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F78357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 476px\">",
"   <div class=\"ttl\">",
"    Ileocolic stapled anastomosis - end to side",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 456px; height: 410px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15984=[""].join("\n");
var outline_f15_39_15984=null;
var title_f15_39_15985="Fenticonazole: International drug information";
var content_f15_39_15985=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fenticonazole: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4369771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Falvin (IT);",
"     </li>",
"     <li>",
"      Fenizolan (DE);",
"     </li>",
"     <li>",
"      Fentiderm (IT);",
"     </li>",
"     <li>",
"      Fentigyn (IT);",
"     </li>",
"     <li>",
"      Fentizol (BR);",
"     </li>",
"     <li>",
"      Laurimic (ES);",
"     </li>",
"     <li>",
"      Lomexin (AR, AT, BR, DE, ES, FR, GB, GR, IT, SG, ZA);",
"     </li>",
"     <li>",
"      Micofulvin (ES);",
"     </li>",
"     <li>",
"      Mycodermil (CH);",
"     </li>",
"     <li>",
"      Terlomexin (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F2677698\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Fenticonazole Nitrate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2677699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F2677700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of fungal infections including dermatomycoses, pityriasis versicolor, or vaginal candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F2677702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream, gel, spray: Skin infections: Apply to skin daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaginal ovule: Vaginal candidiasis (thrush): Insert 1-600 mg ovule intravaginally at bedtime for 1 day or 200 mg ovule intravaginally at bedtime for 3 days",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F2677703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream 2%: 30 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel: 30 g",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Spray: 30 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaginal ovule: 200 mg, 600 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10491 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-37B631BF3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15985=[""].join("\n");
var outline_f15_39_15985=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4369771\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677698\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677699\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677700\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677702\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821068\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2677703\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10491\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10491|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_39_15986="Anatomy of the triangular fibrocartilage complex";
var content_f15_39_15986=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F63443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F63443&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 508px\">",
"   <div class=\"ttl\">",
"    Anatomy of the triangular fibrocartilage complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 488px; height: 419px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The triangular fibrocartilage complex is comprised of the triangular fibrocartilage, ulnar collateral ligament, dorsal and palmar radioulnar ligaments, ulnolunate and ulnotriquetral ligaments, and the extensor carpi ulnaris tendon sheath. This figure shows the dorsal surface of the wrist.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15986=[""].join("\n");
var outline_f15_39_15986=null;
var title_f15_39_15987="Purpura fulminans large lesion";
var content_f15_39_15987=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Purpura fulminans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A large, retiform, purpuric lesion is present on the leg. Purpura fulminans is characterized by the presence of extensive purpura.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15987=[""].join("\n");
var outline_f15_39_15987=null;
var title_f15_39_15988="Islet cell tumor Gross";
var content_f15_39_15988=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F56960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F56960&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreatic endocrine tumor",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 435px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross specimen of a pancreatic endocrine tumor that has been surgically removed. The type of tumor cannot be determined from gross examination.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert Odze, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15988=[""].join("\n");
var outline_f15_39_15988=null;
var title_f15_39_15989="Fosinopril: Patient drug information";
var content_f15_39_15989=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Fosinopril: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=see_link\">",
"     see \"Fosinopril: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42647?source=see_link\">",
"     see \"Fosinopril: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F174408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Fosinopril&reg;;",
"     </li>",
"     <li>",
"      Jamp-Fosinopril;",
"     </li>",
"     <li>",
"      Monopril&reg;;",
"     </li>",
"     <li>",
"      Mylan-Fosinopril;",
"     </li>",
"     <li>",
"      PMS-Fosinopril;",
"     </li>",
"     <li>",
"      RAN&trade;-Fosinopril;",
"     </li>",
"     <li>",
"      Riva-Fosinopril;",
"     </li>",
"     <li>",
"      Teva-Fosinopril",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10020809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700281",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take if you are pregnant. Use during pregnancy may cause birth defects or loss of the unborn baby. If you get pregnant or plan on getting pregnant while taking this drug, call your doctor right away.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10020811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691384",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help a weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691575",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to protect kidney function in diabetic patients who have protein loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691388",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to help heart function after a heart attack.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10020810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702167",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to fosinopril or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3915366",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes) and are taking aliskiren.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10020815\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking this drug and have high blood pressure, talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10020816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10020818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10020813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10020814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10020819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10020820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12498 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15989=[""].join("\n");
var outline_f15_39_15989=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F174408\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020809\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020811\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020810\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020815\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020816\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020818\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020813\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020814\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020819\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10020820\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?16/30/16872?source=related_link\">",
"      Fosinopril: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/41/42647?source=related_link\">",
"      Fosinopril: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_39_15990="Sodium oxybate (gamma hydroxybutyrate): Drug information";
var content_f15_39_15990=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Sodium oxybate (gamma hydroxybutyrate): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/32/31237?source=see_link\">",
"    see \"Sodium oxybate (gamma hydroxybutyrate): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15827678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Adds New Contraindication to Xyrem&reg; (Sodium Oxybate)",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The U.S. Food and Drug Administration (FDA) added a new contraindication against the concomitant use of alcohol with sodium oxybate (Xyrem&reg;). The use of sodium oxybate is already contraindicated with insomnia agents, and its use with other CNS depressant drugs (eg, such as opioid analgesics, benzodiazepines, sedating antidepressants or antipsychotics, general anesthetics, muscle relaxants), should generally be avoided. Concomitant use of sodium oxybate with alcohol or CNS depressant drugs may impair consciousness and lead to respiratory depression. After evaluating reports of death in patients taking sodium oxybate with alcohol or other CNS depressants, the FDA suggested that the recommendations in the sodium oxybate drug label be strengthened to remind patients and healthcare providers of the risks associated with concomitant use.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information and label revisions can be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm332029.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm332029.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F175564\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Xyrem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F3011947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Xyrem&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F175586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Central Nervous System Depressant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F175566\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     <b>",
"      Narcolepsy:",
"     </b>",
"     Oral: Initial: 4.5 g daily, in 2 equal doses; first dose to be given at bedtime after the patient is in bed, and second dose to be given 2.5-4 hours later. Usual dosage range: 6-9 g daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <i>",
"      Dose titration:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     U.S. labeling: Dose may be increased by 1.5 g daily in weekly intervals (maximum dose: 9 g daily)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: Dose may be increased  by 1.5 g daily at 2-week intervals (maximum dose: 9 g daily)",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F175567\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. Use with caution; initiate at lower dosage range. Limited studies available in patients &gt;65 years.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F175568\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied); consider sodium content.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F175569\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decrease starting dose to half and titrate doses carefully in patients with hepatic dysfunction.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F175540\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Xyrem&reg;: 500 mg/mL (180 mL) [contains sodium 91 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F175527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F175588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-I (illicit use); C-III (medical use)",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11234332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium oxybate is deemed to have an approved REMS program. As a requirement of the REMS program, access to this medication is restricted. Sodium oxybate oral solution will be available only to prescribers and patients enrolled in the Xyrem&reg; Patient Success Program&reg; and dispensed to the patient through the designated centralized pharmacy (1-866-997-3688). Prior to dispensing the first prescription, prescribers will be sent educational materials to be reviewed with the patient and enrollment forms for the postmarketing surveillance program. Patients must be seen at least every 3 months; prescriptions can be written for a maximum of 3 months (the first prescription may only be written for a 1-month supply).",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089830.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/ucm089830.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F175542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer on an empty stomach; separate last meal (or food) and first dose by &ge;2 hours; try to take at similar time each day. Doses should be administered while patient is sitting up in bed. Both doses should be prepared prior to bedtime. The first dose is taken at bedtime and the second dose is taken 2.5-4 hours later; an alarm clock may need to be set for the second dose. After taking the dose, patient is to lie down and remain in bed.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F175541\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F175584\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (9% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (8% to 20% dose related), vomiting (2% to 11%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (1% to 8%), attention disturbance (&le;4%; dose related), drunk feeling (&le;3%; dose related), irritability (&le;3%; dose related), pain (&le;3%), sleep paralysis (&le;3%), sleepwalking (&le;3%; dose related), disorientation (1% to 3%; dose related), anxiety (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Hyperhidrosis (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (3% to 4%), abdominal pain (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Enuresis (3% to 7%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor (&le;5%), pain in extremity (1% to 3%), paresthesia (1% to 3%; dose related)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Arthralgia, appetite decreased, blurred vision, falling, fluid retention, hangover effect, headache, hypersensitivity, hypertension, memory impairment, panic attack, weight loss",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F175545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use with ethanol or sedative-hypnotic agents; succinic semialdehyde dehydrogenase deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F175530\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause anxiety, confusion, psychosis, paranoia, hallucinations, agitation, depression and sleepwalking; use caution with history of depression or suicide attempt. Patients should be instructed not to engage in hazardous activities requiring mental alertness for at least 6 hours after taking the second nightly dose of this medication;  CNS effects may carry over to the next day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression:",
"     <b>",
"      [U.S. Boxed Warning]: Sodium oxybate may cause respiratory depression.",
"     </b>",
"     Use with caution in patients with compromised respiratory function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with heart failure or hypertension; contains significant amounts of sodium. Concomitant use with CNS depressants may increase risk of syncope and hypotension; dosage adjustments should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment is recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment due to significant amounts of sodium in the product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sleep-related breathing disorders: Sleep-related breathing disorders (eg, sleep apnea) may occur during therapy; may be more common in patients that are obese, postmenopausal (not on hormone replacement therapy), or narcoleptic.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depressants: Use is contraindicated with alcohol and sedative hypnotics. Concurrent use with CNS depressants (eg, benzodiazepines, general anesthetics, muscle relaxants, sedating antidepressants or antipsychotics) may increase the risk of respiratory depression, hypotension, excessive sedation, syncope, and death. Concomitant CNS depressant use should generally be avoided; however, if concomitant use is required, dosage adjustments or discontinuation of one or more CNS depressant agent (including sodium oxybate) should be considered. If short-term opioid use is required, consider temporarily discontinuing sodium oxybate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stimulant use: Most patients (&sim;80%) in clinical trials were also treated with stimulants; therefore, an independent assessment of the effects of sodium oxybate is lacking.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Although limited data exists, headache was observed at a higher incidence in older adults &ge;65 years of age compared to younger adults. Elderly may also be at increased risk for other CNS effects; use with caution and monitor cognitive/motor function closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse/diversion:",
"     <b>",
"      [U.S. Boxed Warning]: Sodium oxybate is a CNS depressant controlled substance with abuse potential. Seizures, respiratory depression, decreases in level of consciousness, coma, and death have been reported when used for nonprescription purposes.",
"     </b>",
"     Healthcare provider should be alert to problems of abuse, misuse, and diversion. Patients should be evaluated for a history of drug abuse and should be monitored for signs of misuse, abuse, and addiction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Restricted access:",
"     <b>",
"      [U.S. Boxed Warning]: Sodium oxybate oral solution will be available only to prescribers and patients enrolled in the Xyrem&reg; Patient Success Program&reg; and dispensed to the patient through the designated centralized pharmacy (1-866-997-3688).",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium: Contains high sodium content: Use with caution in patients sensitive to high sodium intake (eg, renal impairment, HF, hypertension).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tolerance/withdrawal: Tolerance to sodium oxybate, or withdrawal following its discontinuation, has not been clearly defined in controlled clinical trials, but has been reported at larger doses used for illicit purposes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F175534\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines: May enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: Sodium Oxybate may enhance the CNS depressant effect of CNS Depressants.  Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypnotics (Nonbenzodiazepine): May enhance the CNS depressant effect of Sodium Oxybate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F175561\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Contraindicated with use due to increased CNS depression and respiratory depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: High-fat meal decreases bioavailability, delays absorption, and decreases peak serum level. Management: Administer on an empty stomach, separated from last meal or food of the day by at least 2 hours.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Management: Avoid any products that may cause CNS depression (eg, kava kava or valerian).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F175536\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F175548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse effects have been reported with maternal use throughout pregnancy. The injection formulation, when used as an anesthetic during labor and delivery, was shown to cross the placenta in concentrations &le;25% of maternal levels; a slight decrease in Apgar scores due to sleepiness in the neonate was observed. Sodium oxybate was not detected in infant blood 30 minutes after delivery.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F175572\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F15891875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if sodium oxybate is excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F175549\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take on an empty stomach; separate last meal (or food) and first dose by &ge;2 hours; try to take at similar time each day. Contains sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Xyrem Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     500 mg/mL (180 mL): $2707.44",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F2182042\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Signs and symptoms of depression or suicidality, drug abuse",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F175550\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alcover (HN, HU);",
"     </li>",
"     <li>",
"      Anetamin (JP);",
"     </li>",
"     <li>",
"      Xyrem (AT, BE, BG, CH, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HN, IE, IT, MT, NL, NO, PL, PT, RU, SE, SK, TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F175529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Sodium oxybate is derived from gamma aminobutyric acid (GABA) and acts as an inhibitory chemical transmitter in the brain. May function through specific receptors for gamma hydroxybutyrate (GHB) and GABA (B).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F175544\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 190-384 mL/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &lt;1%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily via the Krebs cycle to form water and carbon dioxide; secondarily via beta oxidation; significant first-pass effect; no active metabolites; metabolic pathways are saturable",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~88%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 30-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 30-75 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily pulmonary (as carbon dioxide); urine (&lt;5% as unchanged drug); feces (negligible)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Morgenthaler TI, Kapur VK, Brown T, et al, \"Practice Parameters for the Treatment of Narcolepsy and Other Hypersomnias of Central Origin,\"",
"      <i>",
"       Sleep",
"      </i>",
"      , 2007, 30(12):1705-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15990/abstract-text/18246980/pubmed\" id=\"18246980\" target=\"_blank\">",
"        18246980",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Teter CJ and Guthrie SK, &ldquo;A Comprehensive Review of MDMA and GHB: Two Common Club Drugs,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2001, 21(12):1486-513.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15990/abstract-text/11765302/pubmed\" id=\"11765302\" target=\"_blank\">",
"        11765302",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tunnicliff G, \"Sites of Action of Gamma-hydroxybutyrate (GHB) -- A Neuroactive Drug With Abuse Potential,\"",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 1997, 35(6):581-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15990/abstract-text/9365423/pubmed\" id=\"9365423\" target=\"_blank\">",
"        9365423",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wong CG, Chan KF, Gibson KM, \"Gamma-hydroxybutyric Acid: Neurobiology and Toxicology of a Recreational Drug,\"",
"      <i>",
"       Toxicol Rev",
"      </i>",
"      , 2004, 23(1):3-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15990/abstract-text/15298489/pubmed\" id=\"15298489\" target=\"_blank\">",
"        15298489",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8817 Version 42.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-424AE69C25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15990=[""].join("\n");
var outline_f15_39_15990=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15827678\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709423\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175564\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3011947\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175586\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175566\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175567\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175568\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175569\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175540\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175527\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175588\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11234332\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874990\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175542\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175541\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175584\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175545\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175530\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300063\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175534\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175561\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175536\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175548\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175572\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15891875\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175549\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323168\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2182042\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175550\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175529\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F175544\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8817\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8817|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/32/31237?source=related_link\">",
"      Sodium oxybate (gamma hydroxybutyrate): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_39_15991="Evaluation of hypervolemia in peritoneal dialysis patients";
var content_f15_39_15991=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of hypervolemia in peritoneal dialysis patients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15991/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15991/contributors\">",
"     John M Burkart, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15991/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15991/contributors\">",
"     Thomas A Golper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15991/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15991/contributors\">",
"     Alice M Sheridan, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/39/15991/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maintenance of euvolemia is of primary importance in the treatment of patients with chronic kidney disease and is a principal goal of renal replacement therapies. Achievement of this goal is dependent upon a complex interplay between the intake and loss of fluid, which relies upon patient- and treatment-related features.",
"   </p>",
"   <p>",
"    Due to its continuous nature that potentially allows for a steady state and the avoidance of fluctuating volume status, peritoneal dialysis (PD) has historically been considered superior to hemodialysis (HD) with respect to maintaining adequate volume control among patients with end-stage renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/1\">",
"     1",
"    </a>",
"    ]. Despite this advantage, many patients on PD are hypertensive and volume overloaded [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/2\">",
"     2",
"    </a>",
"    ]. This is most frequently due to a preventable or treatable process.",
"   </p>",
"   <p>",
"    With PD patients, attainment of euvolemia or \"target weight\" is usually based upon clinical judgment. However, because PD is a home therapy, this clinical judgment is often determined by the patient. Since the target weight is usually set during PD training, the importance of the dynamic nature of a patients actual body mass (eg, muscle mass, fat mass) and therefore the person's target weight cannot be underestimated.",
"   </p>",
"   <p>",
"    In standard clinical practice, since patients may lose or gain weight while on PD, their target weight is not based upon a measurement obtained from a scale during training. Instead, it results from the compilation of clinical parameters such as blood pressure, presence of peripheral edema, and body weight. During monthly clinic visits, reevaluation of target weight is indicated and guided by changes in cardiovascular or nutritional status. Investigators are looking at more precise measurements of true body weight such as body impedance studies, but these can be used only during the clinical visit, are time-consuming and, in most countries, are non-reimbursable.",
"   </p>",
"   <p>",
"    If the patient is found to be volume overloaded based upon clinical assessment, one needs to consider the following pathophysiologic processes as causes: too much sodium or water intake, too little sodium or water removal, or a new comorbid condition. Based on this approach, the following questions should be asked:",
"   </p>",
"   <p>",
"    Too much in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is there a failure of the patient to comply with dietary restrictions?",
"     </li>",
"     <li>",
"      Is there a failure of the PD prescription to provide adequate osmotic stimulus for ultrafiltration to occur so that during some or all dwells fluid absorption occurs?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Too little out:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Is there a failure of the PD prescription to provide adequate osmotic stimulus for ultrafiltration to occur?",
"     </li>",
"     <li>",
"      Has there been a loss of residual kidney function and the PD prescription not adjusted to compensate for this?",
"     </li>",
"     <li>",
"      Is there a failure of the peritoneal membrane to respond to the osmotic stimulus?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A new comorbid condition:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Did the patient have a new cardiovascular event or worsening of underlying heart disease?",
"     </li>",
"     <li>",
"      Does the patient have hypoalbuminemia and decreased oncotic pressure?",
"     </li>",
"     <li>",
"      Is there a mechanical or anatomical problem, which is masquerading as ultrafiltration failure?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    To achieve euvolemia, the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for peritoneal dialysis adequacy suggest that some of the following should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Restriction of dietary sodium and water intake",
"     </li>",
"     <li>",
"      Use of diuretics in those with residual renal function",
"     </li>",
"     <li>",
"      Optimization of ultrafiltration volume and removal of sodium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines also recommend that every center develop a systemic and thorough approach for fluid management and blood pressure control as an integral part of the monthly clinic visit [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/3\">",
"     3",
"    </a>",
"    ]. One such approach has been outlined [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The different causes of volume overload in a patient undergoing maintenance peritoneal dialysis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An exacerbation or new onset of a comorbid disease or condition, such as heart failure or hypoalbuminemia.",
"     </li>",
"     <li>",
"      Input dependent problems, such as excessive salt and water intake.",
"     </li>",
"     <li>",
"      Output dependent issues. These include an uncompensated loss of residual renal function, inadequate provision of conditions that result in ultrafiltration, increased lymphatic reabsorption, failure of peritoneal membrane to respond to appropriate ultrafiltration stimuli, and mechanical failures of the dialysis system.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A systemic approach to the problem of volume overload can be developed. Most cases of volume overload in a PD patient are not due to peritoneal membrane failure. Rather, it most commonly results from reversible problems that are unrelated to peritoneal dialysis and, therefore, do not require transfer to hemodialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A structured approach to the volume overloaded PD patient is shown in this figure (",
"    <a class=\"graphic graphic_algorithm graphicRef61571 \" href=\"UTD.htm?0/54/864\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;First, the clinical history should be obtained, with particular attention to the presence or absence of any new disease states.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Does the patient have previously unsuspected cardiovascular disease?",
"     </li>",
"     <li>",
"      Has there been any loss of body mass so that the target weight is now artificially high?",
"     </li>",
"     <li>",
"      Has there been nonadherence with the dialysis prescription or salt and water intake? Examples of nonadherence to the dialysis prescription include shortening the overnight dwell time which would allow less time for ultrafiltration, or not adjusting the percent dextrose per dwell as instructed.",
"     </li>",
"     <li>",
"      Has there been a decrease in urine volume or have any new medications been added that are nephrotoxic?",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;On physical examination, the following should be performed:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The exit site is examined for the presence of fluid that is dextrose positive on dipstick.",
"     </li>",
"     <li>",
"      The presence of hernias, particularly in the peri-catheter, genital, inguinal, and femoral areas, is assessed.",
"     </li>",
"     <li>",
"      Whether the retained fluid is generalized, unilateral, or localized to certain areas, particularly the pleural space, abdominal wall, inguinal areas,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      genitalia is determined.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Fill and drain test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should next ascertain whether there are any mechanical or anatomical problems by performing a quick 2 liter \"fill and drain\" under direct visualization, which permits the observation of the nature and rate of dialysate flow. The following can be ascertained, which may suggest particular difficulties:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Are fibrin clots present?",
"     </li>",
"     <li>",
"      Is there difficulty with inflow?",
"     </li>",
"     <li>",
"      Is drainage incomplete or is the drainage positional?",
"     </li>",
"     <li>",
"      Is the drain volume at least 2 L?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of the different mechanical and anatomical abnormalities associated with peritoneal dialysis catheters is found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Peritoneal equilibration test",
"    </span>",
"    &nbsp;&mdash;&nbsp;To adequately assess peritoneal membrane abnormalities, a peritoneal equilibration test (PET) is performed, which permits the characterization of peritoneal transport, ultrafiltration capacity, and the presence of sodium sieving or change from prior PET tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .) Urinary volume should also be assessed.",
"   </p>",
"   <p>",
"    If a PET test is performed, we prefer that the examination use 4.25 percent dextrose fluid, which is more sensitive than a 2.5 percent solution in detecting the early membrane changes associated with the loss of ultrafiltration capabilities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]; laboratory values from the peritoneal fluid are obtained at baseline, 30 minutes (for dialysate sodium) and at one, two, and four hours [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/5\">",
"     5",
"    </a>",
"    ]. Parameters measured, obtained, or calculated should include the ratio of solute concentrations in dialysate and plasma",
"    <span class=\"nowrap\">",
"     (D/P)",
"    </span>",
"    values for the creatinine, urea, and sodium, and the ratio of dialysate concentrations at specific times (t) to the initial level in the dialysis solution",
"    <span class=\"nowrap\">",
"     (Dt/Do)",
"    </span>",
"    values for glucose and drain volumes.",
"   </p>",
"   <p>",
"    Our laboratory definition of membrane failure is an ultrafiltration volume less than 400 mL after a four-hour dwell with 2 L of 4.25 percent dextrose (3.86 percent glucose). The reason to also obtain dialysate sodium values is to evaluate water movement across small transcellular channels demonstrated to be aquaporin channels. If such movement is present under glucose-induced crystalloid ultrafiltration, dialysate sodium should decrease during the first 30 to 60 minutes of the dwell. Then, as transcellular aquaporin-induced UF diminishes, sodium will move from plasma to dialysate by diffusion, so that if the dwell is long enough, the dialysate sodium concentration will eventually reach equilibrium with plasma.",
"   </p>",
"   <p>",
"    We then look at the new PET results to see if UF is less than expected (four-hour drain volume result), if peritoneal transport has changed (by comparing baseline and follow-up",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    ratios for creatinine), and if transcellular water channels are intact (evaluate drop in dialysate sodium early in the dwell).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic evaluation may also be indicated, particularly if peritoneal dialysis catheter malpositioning or a peritoneal dialysate leak is suspected. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link&amp;anchor=H2#H2\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\", section on 'Outflow failure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link&amp;anchor=H14#H14\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\", section on 'Pericatheter leakage'",
"    </a>",
"    .) A flat plate of the abdomen can be used to evaluate Tenckhoff placement and positioning, and reveal constipation, even if denied by the patient. Constipation may cause failure to drain if it causes the tip of the Tenckhoff to be located in a \"pseudo\" pocket in the pelvis due to the rigid sigmoid. At times, a lateral film will also be required to exclude a rotation or kink in the subcutaneous portion of the catheter.",
"   </p>",
"   <p>",
"    An abdominal computerized tomography (CT) examination with intraperitoneal contrast may also be required, particularly for the detection of a dialysate leak [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/7\">",
"     7",
"    </a>",
"    ]. To best utilize this modality, a baseline CT with no intraperitoneal fluid or contrast is first obtained; subsequently, 100 to 200 mL of nonionic contrast is added to a 2 L bag, which is instilled. The patient then ambulates for at least 30 minutes; we prefer to wait at least two hours. The CT is repeated, which must include visualization of the pelvis and genital areas.",
"   </p>",
"   <p>",
"    Magnetic resonance imaging (MRI) may also be helpful in evaluating leaks. Contrast is NOT needed in this case. Peritoneal fluid itself looks different from tissue or interstitial fluid, and leaks can be noted with this technique. In fact, when comparing CT and MRI, the CT study can only demonstrate fluid that just leaked (after instillation of IP contrast). However, MRI can demonstrate fluid that has been leaking in the last hours to day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41477?source=see_link\">",
"     \"Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with moderate to advanced renal failure (dialysis-dependent or estimated GFR less than 30",
"    <span class=\"nowrap\">",
"     mL/min),",
"    </span>",
"    the administration of gadolinium has been associated with the potentially severe syndrome of nephrogenic systemic fibrosis. In such patients, gadolinium-based imaging should be avoided. This is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     OVERVIEW OF DIFFERENT DISEASE STATES OR CONDITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following is a general overview of some common conditions associated with hypervolemia in the patient undergoing peritoneal dialysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Comorbid disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of heart failure should be determined via a careful history, physical examination,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    echocardiographic or radiographic studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"     \"Evaluation of the patient with suspected heart failure\"",
"    </a>",
"    .) If detected, the underlying heart disease is treated, and the dialysis prescription is appropriately adjusted to optimize ultrafiltration and cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=see_link\">",
"     \"Myocardial dysfunction in end-stage renal disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If hypervolemia is due in part to hypoalbuminemia, the cause of a low serum albumin must be ascertained. In this setting, intravascular volume depletion may be precipitated if all excess volume is removed with aggressive ultrafiltration. In our experience, volume overload from hypoalbuminemia usually does not occur unless the serum albumin concentration is less than 2.8",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Input-dependent states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Generally, although patients undergoing maintenance PD have a less restrictive diet than those on hemodialysis, some individuals still require sodium and fluid restriction. In the absence of other possible causes, sodium and fluid intake should therefore be evaluated. Fluid intake is usually not an issue if a patient has significant residual renal volume. However, once urine volume decreases or ceases, the amount of fluid intake becomes important if ultrafiltration is not optimized with dialysis. It is not unusual for a patient to become volume overloaded if the peritoneal prescription (dwell times, percent dextrose, or use of alternative osmotic agents) is not adjusted as residual urine volume decreases.",
"   </p>",
"   <p>",
"    In general, we usually do not restrict fluid intake unless necessary. We typically restrict sodium to 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    or use a no added salt diet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Output-dependent states",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a large number of reasons for output volume to be less than optimal in a patient on PD. As an example, the uncompensated loss of residual renal function can result in volume overload if the patient has not been instructed to adequately increase ultrafiltration or restrict fluid intake.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Inadequate provision of conditions that result in ultrafiltration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inadequate provision of conditions to allow optimal ultrafiltration is related to either a lack of patient training or an inappropriate dialysis prescription. Therefore, the clinical history is helpful in this setting. In addition, the following results are found with testing:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The quick \"fill and drain\" is normal.",
"     </li>",
"     <li>",
"      The drainage volume with a hypertonic 2 liter PET is normal (ie, greater than 2400 mL at four hours).",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      values on the PET are unchanged.",
"     </li>",
"     <li>",
"      The drop in dialysate sodium (from sodium sieving) at 30 minutes and one hour is normal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the long overnight dwells in continuous ambulatory peritoneal dialysis (frequently nine hours) or the long daytime dwells for continuous cycler peritoneal dialysis (frequently 15 hours), osmotic equilibrium is eventually reached. When this occurs, ultrafiltration ceases and lymphatic absorption predominates. Thus, the drain volume may be less than the instilled volume, thereby resulting in a net positive fluid balance for that dwell. Close attention to initial drain volume (after daytime dwell) for cycler patients is important.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Increased lymphatic reabsorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, patients present with a marked increase in lymphatic absorption of fluids. Normally, the rate of reabsorption is approximately 1",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    with hypervolemia problems occurring with ultrafiltration rates greater than 3",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    In these cases, the history is not helpful, the rapid \"in and out\" drain is normal, the drain volume on a hypertonic PET is usually less than 2400 mL at four hours, the",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    values on the PET are unchanged, and the sodium sieving test at one hour is normal. Although increased lymphatic reabsorption can be detected by adding a marker to dialysate when doing the PET test (labeled albumin), the diagnosis is usually made by exclusion. Increased duration of peritoneal dialysis does not appear to increase the risk of increased lymphatic reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/9\">",
"     9",
"    </a>",
"    ]. Anecdotally increased lymphatic reabsorption occasionally occurs when large instilled volumes are used in small patients; reducing instilled volume (which will reduce intraperitoneal pressure) will resolve the problem in such cases.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The quick \"fill and drain\" is normal.",
"     </li>",
"     <li>",
"      The drainage volume with a hypertonic PET is usually less than expected (ie, less than 2400 mL at four hours).",
"     </li>",
"     <li>",
"      The",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      values on the PET are unchanged.",
"     </li>",
"     <li>",
"      The sodium sieving result at one and two hours is normal.",
"     </li>",
"     <li>",
"      If a radiolabeled tracer (albumin) is used, one should see rapid uptake from the peritoneal cavity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Peritoneal membrane failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peritoneal membrane failure can be due to an increase in peritoneal membrane transport (rapid or high transporter), loss of effective surface area, or loss of transcellular water channels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"     \"Peritoneal equilibration test\"",
"    </a>",
"    .) In all of these cases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The quick \"fill and drain\" is normal.",
"     </li>",
"     <li>",
"      The drainage volume with a hypertonic PET is usually less than 2400 mL at four hours.",
"     </li>",
"     <li>",
"      The sodium sieving result at 30 minutes, one and two hours is normal.",
"     </li>",
"     <li>",
"      The history may or may not be helpful.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     D/P",
"    </span>",
"    values on the PET are most helpful in distinguishing among the three different possibilities:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      With rapid transporters (those with an increase in effective surface area and those with recent peritonitis), there is an increase in",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      creatinine, due to an increase in the effective surface area. Although sodium sieving occurs, it is observed so early in the dwell that the dialysate sodium value at one hour may only be minimally low, and evidence of sieving may not be noted at two hours. If sieving is suspected, one may be able to see the decrease in dialysate sodium at 30 minutes and one hour.",
"     </li>",
"     <li>",
"      In patients with a decrease in effective surface area (due to adhesions or sclerosing peritonitis), the",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      decreases from baseline values, and there may be no sodium sieving.",
"     </li>",
"     <li>",
"      In patients with a loss of transcellular water channels, the",
"      <span class=\"nowrap\">",
"       D/P",
"      </span>",
"      is unchanged, and there is no sodium sieving at 30 minutes one or two hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Mechanical failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with mechanical failure of the dialysis procedure should be diagnosed by an appropriate history and the results of radiographic studies",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the rapid \"in and out\" exchange. By comparison, PET testing is not helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"     \"Noninfectious complications of peritoneal dialysis catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MONITORING AND PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dialysate prescription and ultrafiltration volumes should be reviewed with the patient on a monthly basis. Routine standardized monitoring to identify patients with changes in urine volume and peritoneal membrane transport properties is recommended during clinic visits:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Urine volume should be measured monthly or at least every other month.",
"     </li>",
"     <li>",
"      Overnight drain volume (CAPD) or daytime drain volume (APD) should be noted and monitored during each monthly clinic visit.",
"     </li>",
"     <li>",
"      Historically, it was recommended that peritoneal transport (via PET) be monitored twice a year. Current",
"      <span class=\"nowrap\">",
"       K/DOQI",
"      </span>",
"      guidelines recommend obtaining a baseline study and repeating the PET test when clinically indicated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    General measures to help prevent volume issues in the patient undergoing maintenance peritoneal dialysis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Consider diuretics to optimize urine volumes.",
"     </li>",
"     <li>",
"      Avoid nephrotoxic agents, if possible.",
"     </li>",
"     <li>",
"      Perform routine monthly dietary counseling. This is of paramount importance in achieving euvolemia, but is frequently overlooked.",
"     </li>",
"     <li>",
"      Enhance compliance.",
"     </li>",
"     <li>",
"      Optimize serum glucose control (to maximize osmotic gradients).",
"     </li>",
"     <li>",
"      Match dwell time to transport type.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     OVERVIEW OF MANAGEMENT AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Effective management is based upon an accurate diagnosis of the underlying problem principally responsible for the hypervolemia. Nevertheless, there are therapeutic issues that are generally applicable. With all patients, dwell time should always be matched to transport type. As an example, high transporters optimize ultrafiltration (and solute clearance) with short dwells &mdash; cycler therapies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=see_link\">",
"     \"Rapid transporters on maintenance peritoneal dialysis\"",
"    </a>",
"    .) In addition, the tonicity of each dwell can be increased, especially during the long dwells, which should result in enhanced ultrafiltration.",
"   </p>",
"   <p>",
"    The long overnight dwell with continuous ambulatory peritoneal dialysis (CAPD) and the daytime dwell with continuous cycler peritoneal dialysis (CCPD) must also be carefully prescribed, including consideration of hypertonic solutions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For CAPD, consider a procedure that breaks up the long overnight dwell into two equal parts via the use of a nightly exchange device.",
"     </li>",
"     <li>",
"      For cycler therapies (such as CCPD) utilizing daytime dwells, consider a midday exchange or a midday drain without further instillation of fluid, thereby resulting in a dry period.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In Europe, Canada, the United States, and many other countries, larger molecular weight osmotic agents, which are poorly absorbed from the peritoneal cavity, such as polyglucose-containing or icodextrin-containing solutions, are available. These are very helpful during long dwells because of the slow but sustained ultrafiltration associated with their use with minimal carbohydrate absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. These solutions are especially helpful in high transporters and patients with aquaporin deficiency.",
"   </p>",
"   <p>",
"    To treat patients with increased lymphatic absorption, one must maximize all possible ways to enhance ultrafiltration. Therefore, dwells should be shortened and hypertonic polyglucose solutions (if available) considered. As mentioned above, the increased lymphatic absorption may simply be due to high intraperitoneal pressures associated with excessively large (for the patient) peritoneal dwell volumes. Reducing instilled volumes cases may reduce the rates of lymphatic absorption in such cases. There are anecdotal reports of short-term response to intraperitoneal phosphatidylcholine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15991/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A detailed discussion of the treatment of the different disorders resulting in ultrafiltration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    solute failure is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=see_link\">",
"     \"Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <br/>",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17117446\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume overload in peritoneal dialysis (PD) patients is most frequently due to a preventable or treatable process. Causes of volume overload include excessive sodium or water intake, too little sodium or water removal, or a new comorbid condition. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of excessive salt and water intake include lack of compliance with dietary restrictions and absorption of fluid during some or all dwells caused by a failure of the PD prescription to provide adequate osmotic (or oncotic) stimulus for ultrafiltration. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Input-dependent states'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Causes of insufficient salt and water removal include a failure of the PD prescription to provide adequate osmotic (or oncotic) stimulus for ultrafiltration, a failure of the peritoneal membrane to respond to the osmotic stimulus, and a loss of residual kidney function. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Output-dependent states'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      New comorbid conditions may include a new cardiovascular event or worsening of underlying heart disease, hypoalbuminemia and decreased oncotic pressure or a mechanical or anatomical problem. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Causes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Comorbid disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of the volume overloaded PD patient includes history and physical examination, a fill and drain test, a peritoneal equilibration test (PET), and occasionally, radiographic studies. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical history is directed toward excluding cardiovascular disease, determining the possible loss of body mass, and assessing adherence with the dialysis prescription or salt and water intake. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination should include examination of the exit site for the presence of fluid that is dextrose positive on dipstick, determining the presence of hernias, particularly in the peri-catheter, genital, inguinal, and femoral areas, and determining whether the retained fluid is generalized, unilateral, or localized to certain areas. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mechanical or anatomical problems may be quickly excluded by performing a quick two liter \"fill and drain\" to determine the nature and rate of dialysate flow. Fibrin clots, difficulty with inflow, or incomplete or positional drainage may be observed. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Fill and drain test'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=see_link\">",
"       \"Noninfectious complications of peritoneal dialysis catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A peritoneal equilibration test (PET) allows the characterization of peritoneal transport, ultrafiltration capacity, and evidence of sodium sieving (early drop in dialysate sodium concentration) or change from prior PET tests. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Peritoneal equilibration test'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=see_link\">",
"       \"Peritoneal equilibration test\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Radiographic evaluation is indicated if peritoneal dialysis catheter malpositioning or a peritoneal dialysate leak is suspected. A flat plate of the abdomen may be used to evaluate Tenckhoff placement and positioning and may reveal constipation. A lateral film may exclude a rotation or kink in the subcutaneous portion of the catheter. An abdominal computerized tomography (CT) examination with intraperitoneal contrast or magnetic resonance imaging (MRI) without contrast may be used to exclude a dialysate leak. Gadolinium-based imaging should be avoided. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Radiographic studies'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41477?source=see_link\">",
"       \"Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dialysate prescription and ultrafiltration volumes should be reviewed with the patient on a monthly basis. Routine monitoring of all patients on PD should include measurement of urine volume and determination of overnight drain volume (CAPD) or daytime drain volume (APD). A baseline PET test should be obtained at the initiation of dialysis and repeated when clinically indicated. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Monitoring and prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Measures to help prevent volume overload include the use of diuretics, avoidance of nephrotoxic agents, monthly dietary counseling, enhancing compliance, optimizing serum glucose control (to maximize osmotic gradients), and matching dwell time to transport type. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Monitoring and prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/1\">",
"      Gokal, R. Fluid management and cardiovascular outcome in peritoneal dialysis patients. Semin Dial 1999; 12:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/2\">",
"      Coles GA. Have we underestimated the importance of fluid balance for the survival of PD patients? Perit Dial Int 1997; 17:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/3\">",
"      K/DOQI Clinical Practice Guidelines for Peritoneal Dialysis Adequacy. Am J Kidney Dis 2006; 47(Suppl 4):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/4\">",
"      Mujais S, Nolph K, Gokal R, et al. Evaluation and management of ultrafiltration problems in peritoneal dialysis. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20 Suppl 4:S5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/5\">",
"      Pannekeet MM, Imholz AL, Struijk DG, et al. The standard peritoneal permeability analysis: a tool for the assessment of peritoneal permeability characteristics in CAPD patients. Kidney Int 1995; 48:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/6\">",
"      Pride ET, Gustafson J, Graham A, et al. Comparison of a 2.5% and a 4.25% dextrose peritoneal equilibration test. Perit Dial Int 2002; 22:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/7\">",
"      Lam MF, Lo WK, Chu FS, et al. Retroperitoneal leakage as a cause of ultrafiltration failure. Perit Dial Int 2004; 24:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/8\">",
"      Abu-Alfa AK, Burkart J, Piraino B, et al. Approach to fluid management in peritoneal dialysis: a practical algorithm. Kidney Int Suppl 2002; :S8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/9\">",
"      Michels WM, Zweers MM, Smit W, et al. Does lymphatic absorption change with the duration of peritoneal dialysis? Perit Dial Int 2004; 24:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/10\">",
"      Posthuma N, ter Wee PM, Verbrugh HA, et al. Icodextrin instead of glucose during the daytime dwell in CCPD increases ultrafiltration and 24-h dialysate creatinine clearance. Nephrol Dial Transplant 1997; 12:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/11\">",
"      Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/12\">",
"      Davison SN, Jhangri GS, Jindal K, Pannu N. Comparison of volume overload with cycler-assisted versus continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2009; 4:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15991/abstract/13\">",
"      Chan PC, Tam SC, Robinson JD, et al. Effect of phosphatidylcholine on ultrafiltration in patients on continuous ambulatory peritoneal dialysis. Nephron 1991; 59:100.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1914 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-200.150.3.100-EF161DC620-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15991=[""].join("\n");
var outline_f15_39_15991=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17117446\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Fill and drain test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      OVERVIEW OF DIFFERENT DISEASE STATES OR CONDITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Comorbid disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Input-dependent states",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Output-dependent states",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Inadequate provision of conditions that result in ultrafiltration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Increased lymphatic reabsorption",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Peritoneal membrane failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Mechanical failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MONITORING AND PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      OVERVIEW OF MANAGEMENT AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17117446\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/1914\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/1914|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?0/54/864\" title=\"algorithm 1\">",
"      Evaluation UF failure in PD",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/32/41477?source=related_link\">",
"      Modalities for the diagnosis of abdominal and thoracic cavity defects in peritoneal dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26584?source=related_link\">",
"      Myocardial dysfunction in end-stage renal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7528?source=related_link\">",
"      Noninfectious complications of peritoneal dialysis catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/31/5623?source=related_link\">",
"      Peritoneal equilibration test",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/50/23337?source=related_link\">",
"      Problems with solute clearance and ultrafiltration in continuous peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36215?source=related_link\">",
"      Rapid transporters on maintenance peritoneal dialysis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_39_15992="Diagnostic staging laparoscopy: General principles for staging primary digestive malignancies";
var content_f15_39_15992=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Diagnostic staging laparoscopy: General principles for staging primary digestive malignancies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15992/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15992/contributors\">",
"     Jeffrey Marks, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15992/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15992/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15992/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15992/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/39/15992/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1757598013\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diagnostic staging laparoscopy (DSL) is performed to determine the feasibility of the proposed curative cancer operation. DSL complements the preoperative assessment of radiographic imaging, which has limitations for identifying regional extension of the primary tumor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic disease, such as peritoneal involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The general principles and approach for performing a DSL for patients with a primary digestive malignancy are reviewed here. Laparoscopic assessment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    resection of other malignant and benign diseases are discussed in separate topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7185349\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of diagnostic staging laparoscopy (DSL) for primary digestive malignancies is to identify",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    disprove the presence of local, regional,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic disease. DSL aids in identifying extra-organ disease that would preclude an attempt for an intended curative resection.",
"   </p>",
"   <p>",
"    Indications for DSL include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Assessment for resectability with curative intent of the following primary digestive cancers:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Esophageal cancer at the gastroesophageal junction",
"     </li>",
"     <li>",
"      Gastric cancer",
"     </li>",
"     <li>",
"      Pancreatic cancer located in the body or tail &nbsp;",
"     </li>",
"     <li>",
"      Biliary tract cancer located in the proximal bile duct (cholangiocarcinoma) or gall bladder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Staging prior to administration of neoadjuvant chemotherapy or radiation therapy",
"     </li>",
"     <li>",
"      Assessment of equivocal MRI, CT scan, or PET scan findings for primary, regional, or distant disease",
"     </li>",
"     <li>",
"      Assessment of inconclusive histology following radiographic-guided fine needle aspirations of suspicious sites of disease",
"     </li>",
"     <li>",
"      Assessment for resectability of liver metastasis in patients with colon or rectal cancer in combination with laparoscopic ultrasound (See",
"      <a class=\"local\" href=\"#H22894891\">",
"       'Laparoscopic ultrasound'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Selective rather than routine use of DSL is warranted. DSL is cost effective if unresectable disease is identified and the patient is spared a laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2\">",
"     2",
"    </a>",
"    ]. However, DSL performed routinely increases the overall cost of the operative procedure. Patient selection is based on primary tumor site and is discussed below. (See",
"    <a class=\"local\" href=\"#H7185906\">",
"     'Diagnostic accuracy and yield for specific disease sites'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971658\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;DSL is not a debulking procedure and should not be used for that purpose. It is not performed unless the treatment plan will be altered. Other contraindications include inability to tolerate laparoscopy and previously confirmed metastatic or unresectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971261\">",
"    <span class=\"h1\">",
"     SURGICAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section reviews the basic surgical principles for performing a diagnostic staging laparoscopy (DSL).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971269\">",
"    <span class=\"h2\">",
"     Incision placement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The access point for the initial trocar placement should be remote from prior surgical incisions or suspected metastatic disease. Open techniques, Veress needle insufflation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    optical ports can be utilized at the discretion of the surgeon. An overview of the techniques for laparoscopic surgery is reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link\">",
"     \"Abdominal access techniques used in laparoscopic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971277\">",
"    <span class=\"h2\">",
"     Staging procedure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H91039794\">",
"    <span class=\"h3\">",
"     One versus two stage approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two approaches to utilizing DSL. The first is to perform DSL as the sole intended procedure. The advantage of this approach includes identifying patients who may be more appropriately treated with chemotherapy or radiation therapy as the first cancer treatment. The disadvantage is that a second procedure will be required for the definitive cancer operation.",
"   </p>",
"   <p>",
"    The second approach involves performing DSL first, in the same setting where the definitive cancer operation will be performed if no unresectable",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distant disease is identified. The advantage of this approach includes one operative setting with one anesthetic administration. The disadvantages include the possible uncertainty of a frozen section report on a biopsy, need for final pathology to confirm a suspicious finding, and operating room time scheduling.",
"   </p>",
"   <p>",
"    For any patient with a suspicion for metastatic or otherwise unresectable disease that cannot be confirmed with laparoscopy, conversion to an open laparotomy should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971285\">",
"    <span class=\"h3\">",
"     Collection of fluid for cytology",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with ascites, fluid is sampled for cytologic analysis. Peritoneal washing in patients with primary digestive malignancy without ascites is typically not performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971299\">",
"    <span class=\"h3\">",
"     Exploratory principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic exploration should be performed in an orderly fashion, evaluating for distant, regional, and local disease as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      After obtaining access into the peritoneal cavity, a generalized exploration of the peritoneal surfaces of the abdominal cavity is performed. An angled 30 or 45 degree laparoscope will aid in evaluation of surfaces in the pelvis, colic gutters, and the initial survey of the surface of the liver.",
"     </li>",
"     <li>",
"      A thorough assessment of the local and regional sites should be performed next. For example, the gastrocolic ligament is divided in order to obtain entry into the lesser sac for evaluation of primary pancreatic and gastric malignancies. Abnormal lymphadenopathy should be adequately sampled via the laparoscope. A single suspicious lymph node should be resected in its entirety if technically possible.",
"     </li>",
"     <li>",
"      Finally, a complete evaluation of the liver surface is performed using a combination of altered patient positioning and offsetting the angled laparoscope. Intraoperative laparoscopic ultrasound of the liver can be performed expeditiously to aid in identification of metastatic disease. (See",
"      <a class=\"local\" href=\"#H22894891\">",
"       'Laparoscopic ultrasound'",
"      </a>",
"      below.) Alteration in patient positioning and port placement will assist with the ultrasound evaluation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971337\">",
"    <span class=\"h3\">",
"     Biopsies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biopsies are performed on suspicious lesions. If DSL is performed immediately before the planned definitive resection, a frozen section is obtained. Otherwise, the biopsy tissue is submitted for a final histologic evaluation.",
"   </p>",
"   <p>",
"    Minimizing the use of electrocautery at the time of the biopsy will minimize thermal artifact effect. Laparoscopic graspers, cup biopsy forceps,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    scissors can be used to aid in sampling of tissue. If metastatic disease is confirmed on the frozen section and no palliative procedure is indicated, the operation is concluded.",
"   </p>",
"   <p>",
"    If the frozen section results are uncertain, ideally histologic confirmation with permanent hematoxylin and eosin (H&amp;E) staining of tissue or other special stains will be obtained, as needed, before proceeding with a definitive operative procedure. For those patients with inconclusive results from laparoscopic biopsies, several options are available, including a second pathologist evaluation, repeat laparoscopy, or proceeding to an open laparotomy with the intent for treatment if no metastatic disease is subsequently identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971366\">",
"    <span class=\"h2\">",
"     Risks and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are few additional risks associated with DSL, other than the general risks of laparoscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H922054\">",
"    <span class=\"h3\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall morbidity and mortality rates of DSL for patients with primary digestive cancers are low in comparison to an open laparotomy. The morbidity associated with DSL for esophageal, gastric, and pancreatic cancer patients ranges from 0 to 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/3-5\">",
"     3-5",
"    </a>",
"    ], while no mortality was related to DSL. In comparison, the operative morbidity and mortality rates of a diagnostic laparotomy for patients with unresectable gastric cancer range from 13 to 23 percent and 10 to 21 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Therefore, DSL can be performed safely to identify patients who are candidates for a primary resection versus other modalities of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971374\">",
"    <span class=\"h3\">",
"     Port site tumor implantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Port site tumor implantation following laparoscopic intervention for upper gastrointestinal malignancy is less than 1 percent, with a median time to occurrence of eight months [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/9\">",
"     9",
"    </a>",
"    ]. In a review of 1650 procedures, almost all patients who developed a port site recurrence also had developed a local recurrence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    distant disease. The contemporary risk of port site implantation is comparable to that of a laparotomy incision as the site of tumor implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approaches suggested to reduce the risk of port site implantation include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/11\">",
"     11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Place trocars perpendicular to the peritoneum",
"     </li>",
"     <li>",
"      Prevent carbon dioxide leakage around trocars",
"     </li>",
"     <li>",
"      Minimize handling of tumor tissue",
"     </li>",
"     <li>",
"      Protect extraction sites",
"     </li>",
"     <li>",
"      Bag specimens intra-abdominally to avoid spillage",
"     </li>",
"     <li>",
"      Remove entire lesion rather than an excisional biopsy if possible",
"     </li>",
"     <li>",
"      Drain the peritoneal cavity before deflating",
"     </li>",
"     <li>",
"      Deflate the abdomen with trocars in place",
"     </li>",
"     <li>",
"      Close the fascia of the trocar port site while avoiding liquid spillage into the wound",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971382\">",
"    <span class=\"h3\">",
"     False negative explorations",
"    </span>",
"    &nbsp;&mdash;&nbsp;DSL is associated with a false negative rate ranging from approximately 6 to 40 percent, depending on the size and location of the primary cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7185906\">",
"     'Diagnostic accuracy and yield for specific disease sites'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4971390\">",
"    <span class=\"h3\">",
"     Vascular and organ injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to other laparoscopic interventions, vascular and organ injury may occur at the time of port placement, organ manipulation for assessment of extensiveness of disease, or while performing a biopsy on a suspicious lesion.",
"   </p>",
"   <p>",
"    Complications associated with diagnostic and therapeutic laparoscopic surgery are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=see_link&amp;anchor=H736267272#H736267272\">",
"     \"Abdominal access techniques used in laparoscopic surgery\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22894891\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC ULTRASOUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic ultrasound (LUS) serves as an adjunct to preoperative radiographic imaging studies and DSL for staging of select cancers. The utility of LUS may be in identifying patients who are not candidates for a primary resection because of misdiagnosis or misinterpretation of radiographic imaging. No randomized trials or large reviews have been performed to determine if LUS offers a significant advantage over laparoscopy alone for detecting of unresectable disease.",
"   </p>",
"   <p>",
"    In our institution, we use LUS for planning a resection of primary and metastatic liver cancer. We also use LUS to plan the appropriate tissue margins of resection and evaluate for occult disease prior to performing a laparoscopic resection of gastric and pancreatic cancers.",
"   </p>",
"   <p>",
"    The following studies illustrate the utility of LUS in staging pancreatic and hepatobiliary cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 53 patients with pancreatic cancer, LUS altered management in 28 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/12\">",
"       12",
"      </a>",
"      ]. The positive predictive value of LUS for determining resectability was 91 percent.",
"     </li>",
"     <li>",
"      In a series of 50 consecutive patients with pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/14\">",
"       14",
"      </a>",
"      ], there was no significant difference for sensitivity, specificity, or overall accuracy between preoperative CT scan and LUS; and the false negative rate for the DSL component of the study was 6 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a retrospective review of 75 patients with presumed pancreatic cancer and no evidence of regional or distant disease by good quality preoperative imaging, LUS found three patients to have no pancreatic mass,; two patients with chronic pancreatitis; and five patients with sarcomas, lymphoma, or ampullary cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/13\">",
"       13",
"      </a>",
"      ]. Only 53 percent were confirmed to be suitable for resection, and only 15 of 36 patients (42 percent) who underwent a laparotomy were resected. Overall, 44 percent of patients were spared an open laparotomy based on the LUS findings.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7185906\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC ACCURACY AND YIELD FOR SPECIFIC DISEASE SITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conventional imaging studies (eg, MRI, CT scan) often understage the intra-abdominal extent of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2\">",
"     2",
"    </a>",
"    ]. In the setting of a negative high-quality radiographic preoperative evaluation, DSL performed prior to a planned major resection may spare the patient an unnecessary laparotomy and decrease the time to chemotherapy or radiation therapy.",
"   </p>",
"   <p>",
"    Accuracy of DSL is defined as the number of unresectable patients detected by DSL divided by the total number of unresectable cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/15\">",
"     15",
"    </a>",
"    ]. Yield is defined as the number of unresectable patients detected by DSL divided by the total number of patients undergoing DSL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/15\">",
"     15",
"    </a>",
"    ]. The yield",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    accuracy of DSL for primary digestive cancers are illustrated by the following disease specific examples.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4972548\">",
"    <span class=\"h2\">",
"     Esophageal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of DSL for patients with esophageal cancer is to identify those patients who can undergo a surgical resection and those who should receive neoadjuvant chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    radiation therapy.",
"   </p>",
"   <p>",
"    A review of 195 patients with esophageal cancer, including proximal, middle, middle and distal, and distal esophageal cancer locations, found that the DSL altered treatment plans in 29 patients (15 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/16\">",
"     16",
"    </a>",
"    ]. No patient with a proximal or middle esophageal cancer had unresectable or treatment-altering disease identified. However, 17 percent of patients with a distal esophageal cancer had regional or metastatic disease identified which altered the initial treatment plan.",
"   </p>",
"   <p>",
"    In our institution, DSL is performed in patients with equivocal radiographic imaging with suspicion for metastatic disease but a nondiagnostic FNA. In addition, patients with esophagogastric junction cancers, but not proximal and mid-esophageal cancer, routinely undergo DSL.",
"   </p>",
"   <p>",
"    The diagnosis, staging, and treatment of esophageal cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=see_link\">",
"     \"Diagnosis and staging of esophageal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=see_link\">",
"     \"Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7186030\">",
"    <span class=\"h2\">",
"     Gastric cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrospective and prospective studies on the yield of DSL in gastric cancer found that peritoneal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metastatic disease was identified in 30 to 53 percent of patients with a negative preoperative CT or MRI evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/4,17,18\">",
"     4,17,18",
"    </a>",
"    ]. When large tumors (T3 or T4) only are considered, the diagnostic accuracy increases. A prospective study of 100 patients undergoing DSL found peritoneal spread",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    liver metastases in 21 patients, all of whom had T3 or T4 locally advanced cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/1\">",
"     1",
"    </a>",
"    ]. The positive and negative predictive value for resectability was 96 and 50 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our institution, DSL is routinely performed for patients with gastric cancer who are otherwise asymptomatic and have equivocal radiographic imaging. Many patients with gastric cancer present with bleeding or obstruction and require, at the minimum, a palliative procedure. For those with obstructive symptoms only, endoscopic stenting in conjunction with DSL can be used to provide appropriate palliation and diagnosis and spare patients an unnecessary laparotomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=see_link\">",
"     \"Enteral stents for the palliation of malignant gastroduodenal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The diagnosis, staging, and accuracy of radiographic imaging are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=see_link\">",
"     \"Clinical features, diagnosis, and staging of gastric cancer\"",
"    </a>",
"    .) See individual topic reviews for treatment of gastric cancer based on stage of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1757598027\">",
"    <span class=\"h2\">",
"     Pancreatic and periampullary cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic cancers are described by their location in the organ (ie, head, body, tail). Periampullary (peripancreatic) cancers include the ducts of the head and uncinate process of the pancreas, the ampulla of Vater, the distal common bile duct, and the area of the ductal insertion site in the duodenum. Many studies evaluating the yield of DSL have not differentiated pancreatic from nonpancreatic periampullary cancers.",
"   </p>",
"   <p>",
"    Assessment of the regional extent of retroperitoneal disease by conventional radiographic imaging is limited. However, DSL may not be beneficial for every patient with a suspected pancreatic or periampullary malignancy staged with high-quality radiographic imaging. The accuracy of CT imaging ranges from 84 to 100 percent for predicting unresectability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/19-23\">",
"     19-23",
"    </a>",
"    ] but is limited in its ability to predict resectability of pancreatic cancers, with failures occurring in 11 to 25 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/20,24-27\">",
"     20,24-27",
"    </a>",
"    ]. DSL has a greater than 90 percent accuracy for predicting resectability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/5,19,20\">",
"     5,19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective review all English language publications on the utility of DSL in 594 pancreatic cancer patients found that 4 to 15 percent of patients previously staged with high-quality radiographic imaging had regional or metastatic disease that precluded an open laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/28\">",
"     28",
"    </a>",
"    ]. Standard DSL offered limited information regarding involvement of major blood vessels (eg, portal vein, superior mesenteric artery) in retroperitoneal tumors. When DSL was extensive and opened all surgical resection planes, 13 percent (14 of 108) of patients had unresectable vascular encasement and thus were not resectable [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/5\">",
"     5",
"    </a>",
"    ]. Despite the extensive approach, DSL failed to identify metastatic lesions to the liver in five patients and portal vein encasement in another patient in the remaining 61 patients who had a laparotomy in preparation for a resection.",
"   </p>",
"   <p>",
"    Other studies suggest that patients with cancers of the body or tail of the pancreas are more likely to benefit from DSL than those with a pancreatic head cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2,20,28-30\">",
"     2,20,28-30",
"    </a>",
"    ]. DSL identified occult disease twice as frequently with cancers in the pancreatic body or tail compared with cancers in the pancreatic head [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Reasons for this difference may be related to the larger tumor size of cancers in the pancreatic body and tail and spread to the peritoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be little advantage of performing DSL for periampullary cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/20,21,27,31-34\">",
"     20,21,27,31-34",
"    </a>",
"    ]. Unnecessary laparotomy was avoided in only 2.3 percent of patients with nonpancreatic periampullary cancer compared with 35 percent for patients with cancer in the head of the pancreas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/34\">",
"     34",
"    </a>",
"    ]. The reasons for this finding are unclear.",
"   </p>",
"   <p>",
"    In our institution, we perform a DSL for all patients with a pancreatic body or tail cancer and for other patients when radiographic imaging is suspicious and a fine needle aspiration performed under radiographic guidance is inconclusive. We do not routinely perform DSL for patients with periampullary cancers or for cancers in the head of the pancreas. Selective use of laparoscopy may be more appropriate and will probably be a more cost-effective staging approach.",
"   </p>",
"   <p>",
"    The diagnosis and staging of pancreatic cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .) See individual topic reviews for treatment of pancreatic cancer based on stage of disease.",
"   </p>",
"   <p>",
"    The diagnosis and treatment of periampullary cancer is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=see_link\">",
"     \"Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3674?source=see_link\">",
"     \"Ampullary carcinoma: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1757598034\">",
"    <span class=\"h2\">",
"     Biliary tract cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Biliary tract cancers include cholangiocarcinoma and gall bladder cancer. The sensitivity and negative predictive value of DSL in identifying peritoneal and superficial liver metastases associated with biliary tract cancers are 60 percent and 52 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2,35\">",
"     2,35",
"    </a>",
"    ]. DSL identified peritoneal and superficial liver metastases in an additional 23 percent of patients who had a negative preoperative radiographic imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2,36\">",
"     2,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In retrospective and prospective studies, the overall yield for detecting unresectable biliary cancer using DSL ranges from 24 to 48 percent, and the diagnostic accuracy is approximately 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/15,37\">",
"     15,37",
"    </a>",
"    ]. The yield was greater for gall bladder cancers (48 percent) compared with cholangiocarcinoma (24 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/37\">",
"     37",
"    </a>",
"    ]. For patients with cholangiocarcinoma, approximately 40 percent were spared an unnecessary laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/15,35\">",
"     15,35",
"    </a>",
"    ], and the yield of DSL was greater for larger cancers compared with smaller cancers",
"    <span class=\"nowrap\">",
"     (T2/T3",
"    </span>",
"    <span class=\"nowrap\">",
"     12/33",
"    </span>",
"    versus",
"    <span class=\"nowrap\">",
"     T1/T2",
"    </span>",
"    <span class=\"nowrap\">",
"     2/23",
"    </span>",
"    patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/37\">",
"     37",
"    </a>",
"    ]. The additional value of laparoscopic ultrasound is inconclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our institution, we perform DSL for patients with cholangiocarcinoma of the proximal bile duct and gallbladder cancers but not for distal biliary cancers.",
"   </p>",
"   <p>",
"    The diagnosis, staging, and treatment of biliary tract cancers, including cholangiocarcinoma and gall bladder cancer, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=see_link\">",
"     \"Clinical manifestations and diagnosis of cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15082?source=see_link\">",
"     \"Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10761?source=see_link\">",
"     \"Systemic therapy for advanced cholangiocarcinoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=see_link\">",
"     \"Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22730?source=see_link\">",
"     \"Surgical management of gallbladder cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1757598041\">",
"    <span class=\"h2\">",
"     Colon or rectal cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;DSL is used infrequently in patients with colon or rectal cancer, as resection of the primary lesion is necessary in most patients to control or avoid bleeding or obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    perforation of the colon [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/2\">",
"     2",
"    </a>",
"    ]. The role of DSL for colorectal cancer patients may be in the setting of limited metastatic disease to the liver, which can be resected with curative intent. In a review of 56 consecutive patients with liver metastases from colorectal cancer, DSL identified only three of eight patients with unresectable disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15992/abstract/38\">",
"     38",
"    </a>",
"    ]. The additional value of DSL in the primary and metastatic disease setting has not been established.",
"   </p>",
"   <p>",
"    We do not routinely perform DSL for patients with primary colon or rectal cancer.",
"   </p>",
"   <p>",
"    The diagnosis, staging, and surgical management of colon cancer and rectal cancers are reviewed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of colorectal cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=see_link\">",
"     \"Overview of the management of primary colon cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=see_link\">",
"     \"Overview of surgical procedures for resectable primary rectal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35659574\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of DSL prior to a planned definitive resection of a primary digestive malignancy is to determine the feasibility of the proposed cancer operation. DSL is performed to identify any local, regional",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      metastatic disease that would preclude an attempt for an intended curative surgical procedure. (See",
"      <a class=\"local\" href=\"#H7185349\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4971658\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The DSL staging procedure should be performed in an orderly fashion, carefully assessing for occult local, regional, and distant sites of disease. We perform a biopsy for suspicious lesions and cytology in the presence of ascites. (See",
"      <a class=\"local\" href=\"#H4971277\">",
"       'Staging procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with primary esophageal cancer at the gastroesophageal junction, we routinely perform DSL. DSL should not be performed prior to a planned surgical resection or delivery of neoadjuvant therapy in patients with proximal or midesophageal tumors. (See",
"      <a class=\"local\" href=\"#H4972548\">",
"       'Esophageal cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with primary gastric cancer, DSL should be performed for all patients with potentially resectable disease. (See",
"      <a class=\"local\" href=\"#H7186030\">",
"       'Gastric cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When high quality radiographic imaging is available, there is little benefit for performing DSL for patients with cancers in the head of the pancreas or periampullary cancers. (See",
"      <a class=\"local\" href=\"#H1757598027\">",
"       'Pancreatic and periampullary cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with pancreatic cancer in the body or tail, we perform DSL. (See",
"      <a class=\"local\" href=\"#H1757598027\">",
"       'Pancreatic and periampullary cancer'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with primary biliary tract cancer, DSL is performed for proximal lesions and gall bladder cancer. (See",
"      <a class=\"local\" href=\"#H1757598034\">",
"       'Biliary tract cancer'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/1\">",
"      Blackshaw GR, Barry JD, Edwards P, et al. Laparoscopy significantly improves the perceived preoperative stage of gastric cancer. Gastric Cancer 2003; 6:225.",
"     </a>",
"    </li>",
"    <li>",
"     Guidelines for Diagnostic Laparoscopy. Practice/Clinical Guidelines published 11, 2007, by the Society of American Gastrointestinal and Endoscopic Surgeons. www.sages.org/publication/id/12 (Accessed on June 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/3\">",
"      Muntean V, Oniu T, Lungoci C, et al. Staging laparoscopy in digestive cancers. J Gastrointestin Liver Dis 2009; 18:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/4\">",
"      Muntean V, Mihailov A, Iancu C, et al. Staging laparoscopy in gastric cancer. Accuracy and impact on therapy. J Gastrointestin Liver Dis 2009; 18:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/5\">",
"      Conlon KC, Dougherty E, Klimstra DS, et al. The value of minimal access surgery in the staging of patients with potentially resectable peripancreatic malignancy. Ann Surg 1996; 223:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/6\">",
"      Viste A, Ha&ugrave;gstvedt T, Eide GE, S&oslash;reide O. Postoperative complications and mortality after surgery for gastric cancer. Ann Surg 1988; 207:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/7\">",
"      Irvin TT, Bridger JE. Gastric cancer: an audit of 122 consecutive cases and the results of R1 gastrectomy. Br J Surg 1988; 75:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/8\">",
"      Valen B, Viste A, Haugstvedt T, et al. Treatment of stomach cancer, a national experience. Br J Surg 1988; 75:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/9\">",
"      Shoup M, Brennan MF, Karpeh MS, et al. Port site metastasis after diagnostic laparoscopy for upper gastrointestinal tract malignancies: an uncommon entity. Ann Surg Oncol 2002; 9:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/10\">",
"      Ziprin P, Ridgway PF, Peck DH, Darzi AW. The theories and realities of port-site metastases: a critical appraisal. J Am Coll Surg 2002; 195:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/11\">",
"      Curet MJ. Port site metastases. Am J Surg 2004; 187:705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/12\">",
"      Taylor AM, Roberts SA, Manson JM. Experience with laparoscopic ultrasonography for defining tumour resectability in carcinoma of the pancreatic head and periampullary region. Br J Surg 2001; 88:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/13\">",
"      Doucas H, Sutton CD, Zimmerman A, et al. Assessment of pancreatic malignancy with laparoscopy and intraoperative ultrasound. Surg Endosc 2007; 21:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/14\">",
"      Pietrabissa A, Caramella D, Di Candio G, et al. Laparoscopy and laparoscopic ultrasonography for staging pancreatic cancer: critical appraisal. World J Surg 1999; 23:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/15\">",
"      Connor S, Barron E, Wigmore SJ, et al. The utility of laparoscopic assessment in the preoperative staging of suspected hilar cholangiocarcinoma. J Gastrointest Surg 2005; 9:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/16\">",
"      de Graaf GW, Ayantunde AA, Parsons SL, et al. The role of staging laparoscopy in oesophagogastric cancers. Eur J Surg Oncol 2007; 33:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/17\">",
"      Yano M, Tsujinaka T, Shiozaki H, et al. Appraisal of treatment strategy by staging laparoscopy for locally advanced gastric cancer. World J Surg 2000; 24:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/18\">",
"      Kapiev A, Rabin I, Lavy R, et al. The role of diagnostic laparoscopy in the management of patients with gastric cancer. Isr Med Assoc J 2010; 12:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/19\">",
"      Holzman MD, Reintgen KL, Tyler DS, Pappas TN. The role of laparoscopy in the management of suspected pancreatic and periampullary malignancies. J Gastrointest Surg 1997; 1:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/20\">",
"      Stefanidis D, Grove KD, Schwesinger WH, Thomas CR Jr. The current role of staging laparoscopy for adenocarcinoma of the pancreas: a review. Ann Oncol 2006; 17:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/21\">",
"      Nieveen van Dijkum EJ, Romijn MG, Terwee CB, et al. Laparoscopic staging and subsequent palliation in patients with peripancreatic carcinoma. Ann Surg 2003; 237:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/22\">",
"      Ellsmere J, Mortele K, Sahani D, et al. Does multidetector-row CT eliminate the role of diagnostic laparoscopy in assessing the resectability of pancreatic head adenocarcinoma? Surg Endosc 2005; 19:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/23\">",
"      Maire F, Sauvanet A, Trivin F, et al. Staging of pancreatic head adenocarcinoma with spiral CT and endoscopic ultrasonography: an indirect evaluation of the usefulness of laparoscopy. Pancreatology 2004; 4:436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/24\">",
"      Burdiles P, Rossi RL. Laparoscopy in pancreatic and hepatobiliary cancer. Surg Oncol Clin N Am 2001; 10:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/25\">",
"      Clarke DL, Thomson SR, Madiba TE, Sanyika C. Preoperative imaging of pancreatic cancer: a management-oriented approach. J Am Coll Surg 2003; 196:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/26\">",
"      Takhar AS, Palaniappan P, Dhingsa R, Lobo DN. Recent developments in diagnosis of pancreatic cancer. BMJ 2004; 329:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/27\">",
"      Brooks AD, Mallis MJ, Brennan MF, Conlon KC. The value of laparoscopy in the management of ampullary, duodenal, and distal bile duct tumors. J Gastrointest Surg 2002; 6:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/28\">",
"      Pisters PW, Lee JE, Vauthey JN, et al. Laparoscopy in the staging of pancreatic cancer. Br J Surg 2001; 88:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/29\">",
"      Jimenez RE, Warshaw AL, Rattner DW, et al. Impact of laparoscopic staging in the treatment of pancreatic cancer. Arch Surg 2000; 135:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/30\">",
"      Liu RC, Traverso LW. Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally unresectable by computed tomography. Surg Endosc 2005; 19:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/31\">",
"      Tilleman EH, Kuiken BW, Phoa SS, et al. Limitation of diagnostic laparoscopy for patients with a periampullary carcinoma. Eur J Surg Oncol 2004; 30:658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/32\">",
"      Vollmer CM, Drebin JA, Middleton WD, et al. Utility of staging laparoscopy in subsets of peripancreatic and biliary malignancies. Ann Surg 2002; 235:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/33\">",
"      White R, Winston C, Gonen M, et al. Current utility of staging laparoscopy for pancreatic and peripancreatic neoplasms. J Am Coll Surg 2008; 206:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/34\">",
"      Barreiro CJ, Lillemoe KD, Koniaris LG, et al. Diagnostic laparoscopy for periampullary and pancreatic cancer: what is the true benefit? J Gastrointest Surg 2002; 6:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/35\">",
"      Tilleman EH, de Castro SM, Busch OR, et al. Diagnostic laparoscopy and laparoscopic ultrasound for staging of patients with malignant proximal bile duct obstruction. J Gastrointest Surg 2002; 6:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/36\">",
"      van Delden OM, de Wit LT, Nieveen van Dijkum EJ, et al. Value of laparoscopic ultrasonography in staging of proximal bile duct tumors. J Ultrasound Med 1997; 16:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/37\">",
"      Weber SM, DeMatteo RP, Fong Y, et al. Staging laparoscopy in patients with extrahepatic biliary carcinoma. Analysis of 100 patients. Ann Surg 2002; 235:392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15992/abstract/38\">",
"      Koea J, Rodgers M, Thompson P, et al. Laparoscopy in the management of colorectal cancer metastatic to the liver. ANZ J Surg 2004; 74:1056.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15106 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15992=[""].join("\n");
var outline_f15_39_15992=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35659574\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1757598013\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7185349\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4971658\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4971261\">",
"      SURGICAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4971269\">",
"      Incision placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4971277\">",
"      Staging procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H91039794\">",
"      - One versus two stage approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4971285\">",
"      - Collection of fluid for cytology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4971299\">",
"      - Exploratory principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4971337\">",
"      - Biopsies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4971366\">",
"      Risks and complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H922054\">",
"      - Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4971374\">",
"      - Port site tumor implantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4971382\">",
"      - False negative explorations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4971390\">",
"      - Vascular and organ injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22894891\">",
"      LAPAROSCOPIC ULTRASOUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7185906\">",
"      DIAGNOSTIC ACCURACY AND YIELD FOR SPECIFIC DISEASE SITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4972548\">",
"      Esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7186030\">",
"      Gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1757598027\">",
"      Pancreatic and periampullary cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1757598034\">",
"      Biliary tract cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1757598041\">",
"      Colon or rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35659574\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/1/31770?source=related_link\">",
"      Abdominal access techniques used in laparoscopic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/52/43848?source=related_link\">",
"      Ampullary carcinoma: Epidemiology, clinical manifestations, diagnosis and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/37/3674?source=related_link\">",
"      Ampullary carcinoma: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/36/11850?source=related_link\">",
"      Clinical features, diagnosis, and staging of gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/43/40633?source=related_link\">",
"      Clinical manifestations and diagnosis of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/33/17946?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of colorectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/45/7898?source=related_link\">",
"      Diagnosis and staging of esophageal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/0/37895?source=related_link\">",
"      Enteral stents for the palliation of malignant gastroduodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/46/15082?source=related_link\">",
"      Gallbladder cancer: Epidemiology, risk factors, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38137?source=related_link\">",
"      Overview of surgical procedures for resectable primary rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30489?source=related_link\">",
"      Overview of the management of primary colon cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/31/39418?source=related_link\">",
"      Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/12/22730?source=related_link\">",
"      Surgical management of gallbladder cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/32/10761?source=related_link\">",
"      Systemic therapy for advanced cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/33/25114?source=related_link\">",
"      Treatment of localized cholangiocarcinoma: Surgical management and adjuvant therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_39_15993="Esomeprazole: Drug information";
var content_f15_39_15993=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Esomeprazole: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?24/25/24981?source=see_link\">",
"    see \"Esomeprazole: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/38/21095?source=see_link\">",
"    see \"Esomeprazole: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F16572476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Bone Fracture Risk with Proton Pump Inhibitors: Health Canada Issues Alert",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Health Canada has informed healthcare professionals that proton pump inhibitors (PPIs) may increase the risk of bone fractures. The risk of fracture was observed to be higher in patients receiving multiple daily doses for &ge;1 year; age, gender, and concomitant health conditions may also be a factor. Patients with risk factors for osteoporosis should be closely monitored and should receive a PPI at the lowest effective dose and for the shortest duration of therapy appropriate for the condition.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For more information, refer to file://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2013/26523a-eng.php.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F166971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      NexIUM&reg;;",
"     </li>",
"     <li>",
"      NexIUM&reg; I.V.",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F166972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Esomeprazole&reg;;",
"     </li>",
"     <li>",
"      Mylan-Esomeprazole;",
"     </li>",
"     <li>",
"      Nexium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F166993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Proton Pump Inhibitor;",
"     </li>",
"     <li>",
"      Substituted Benzimidazole",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F166975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Erosive esophagitis (healing):",
"     </b>",
"     Oral: Initial: 20-40 mg once daily for 4-8 weeks; if incomplete healing, may continue for an additional 4-8 weeks; maintenance: 20 mg once daily (controlled studies did not extend beyond 6 months)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nonerosive reflux disease (NERD)",
"     </b>",
"     (Canadian labeling): Initial: 20 mg once daily for 2-4 weeks; lack of symptom control after 4 weeks warrants further evaluation; maintenance (in patients with successful initial therapy): 20 mg once daily as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Symptomatic gastroesophageal reflux:",
"     </b>",
"     Oral: 20 mg once daily for 4 weeks; may consider an additional 4 weeks of treatment if symptoms do not resolve",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Treatment of GERD (short-term):",
"     </b>",
"     I.V.: 20 mg or 40 mg once daily.",
"     <b>",
"      Note:",
"     </b>",
"     Indicated only in cases where oral therapy is inappropriate or not possible;safety/efficacy &ge;10 days has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of recurrent peptic ulcer bleeding postendoscopy",
"     </b>",
"     (unlabeled use; Sung, 2009): I.V. 80 mg over 30 minutes, followed by 8 mg/hour infusion for 72 hours, then 40 mg",
"     <i>",
"      orally",
"     </i>",
"     once daily for 27 additional days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"     </b>",
"     <b>",
"      eradication:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Manufacturer labeling: 40 mg once daily administered with amoxicillin 1000 mg",
"     <i>",
"      and",
"     </i>",
"     clarithromycin 500 mg twice daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     American College of Gastroenterology guidelines (Chey, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Nonpenicillin allergy: 40 mg once daily administered with amoxicillin 1000 mg",
"     <i>",
"      and",
"     </i>",
"     clarithromycin 500 mg twice daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Penicillin allergy: 40 mg once daily administered with clarithromycin 500 mg",
"     <i>",
"      and",
"     </i>",
"     metronidazole 500 mg twice daily for 10-14 days",
"     <b>",
"      or",
"     </b>",
"     40 mg once daily administered with bismuth subsalicylate 525 mg",
"     <i>",
"      and",
"     </i>",
"     metronidazole 250 mg",
"     <i>",
"      plus",
"     </i>",
"     tetracycline 500 mg 4 times daily for 10-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Canadian labeling: 20 mg twice daily for 7 days; requires combination therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Prevention of NSAID-induced gastric ulcers:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     U.S. labeling: 20-40 mg once daily for up to 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Canadian labeling: 20 mg once daily for up to 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     40 mg daily did not show additional benefit over 20 mg daily in clinical trials.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of NSAID-induced gastric ulcers",
"     </b>",
"     (Canadian labeling; unlabeled in U.S.): 20 mg once daily for 4-8 weeks (Goldstein, 2007)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pathological hypersecretory conditions (Zollinger-Ellison syndrome):",
"     </b>",
"     40 mg twice daily; adjust regimen to individual patient needs; doses up to 240 mg daily have been administered",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F2934196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/38/21095?source=see_link\">",
"      see \"Esomeprazole: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Symptomatic GERD:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-11 years: 10 mg once daily for up to 8 weeks;",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy of doses &gt;1 mg/kg/day and/or therapy beyond 8 weeks have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents 12-17 years: 20-40 mg once daily for up to 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of GERD (short-term):",
"     </b>",
"     I.V.:",
"     <b>",
"      Note:",
"     </b>",
"     Indicated only in cases where oral therapy is inappropriate or not possible; safety/efficacy &ge;10 days has not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1 month to &lt;1 year: 0.5 mg/kg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children 1-17 years: &lt;55 kg: 10 mg once daily; &ge;55 kg: 20 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Erosive esophagitis (healing):",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1 month to &lt;1 year:",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy of doses &gt;1.33 mg/kg/day and/or therapy beyond 6 weeks have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     3-5 kg: 2.5 mg once daily for up to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;5-7.5 kg: 5 mg once daily for up to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &gt;7.5 kg: 10 mg once daily for up to 6 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-11 years:",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy of doses &gt;1 mg/kg/day and/or therapy beyond 8 weeks have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &lt;20 kg: 10 mg once daily for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     &ge;20 kg: 10-20 mg once daily for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Nonerosive reflux disease (NERD)",
"     </b>",
"     (Canadian labeling): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 1-11 years: 10 mg once daily for up to 8 weeks.",
"     <b>",
"      Note:",
"     </b>",
"     Safety and efficacy of doses &gt;1 mg/kg/day and/or therapy beyond 8 weeks have not been established.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adolescents 12-17 years: 20-40 mg once daily for up to 8 weeks",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F166976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing. No dosage adjustment needed.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F166977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F166978\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy not established in children with hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Dose should not exceed 20 mg daily.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F166946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, delayed release, oral, as magnesium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NexIUM&reg;: 20 mg, 40 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Granules for suspension, delayed release, oral, as magnesium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NexIUM&reg;: 10 mg/packet (30s); 20 mg/packet (30s); 40 mg/packet (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as sodium [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     NexIUM&reg; I.V.: 20 mg, 40 mg [contains edetate disodium]",
"    </p>",
"   </div>",
"   <div class=\"block foccan drugH1Div\" id=\"F5940148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: Canada",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Strength expressed as base",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Granules, for oral suspension, delayed release, as magnesium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Nexium&reg;: 10 mg/packet (28s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Tablet, extended release, as magnesium:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-right:0em;margin-top:0em;text-align:justify;\">",
"     Nexium&reg;: 20 mg, 40 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F166932\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F15241701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     NexIUM&reg; capsules, granules for oral suspension:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322355.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM322355.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F166948\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: Should be swallowed whole and taken at least 1 hour before eating (best if taken before breakfast). Capsule can be opened and contents mixed with 1 tablespoon of applesauce. Swallow immediately; mixture should not be chewed or warmed. For patients with difficulty swallowing, use of granules may be more appropriate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Granules: Empty the 2.5 mg or 5 mg packet into a container with 5 mL of water or the 10 mg, 20 mg, or 40 mg packet into a container with 15 mL of water and stir; leave 2-3 minutes to thicken. Stir and drink within 30 minutes.  If any medicine remains after drinking, add more water, stir and drink immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet (Canadian formulation, not available in U.S.): Swallow whole or may be dispersed in a half a glass of noncarbonated water. Stir until tablets disintegrate, leaving a liquid containing pellets. Drink contents within 30 minutes. Do not chew or crush pellets. After drinking, rinse glass with water and drink.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Flush line prior to and after administration with NS, LR, or D",
"     <sub>",
"      5",
"     </sub>",
"     W.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: Administer by intermittent infusion (10-30 minutes); the manufacturer recommends that children receive intravenous esomeprazole by intermittent infusion only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: May be administered by injection (&ge;3 minutes), intermittent infusion (10-30 minutes), or continuous infusion for up to 72 hours (Sung, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nasogastric tube:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: Open capsule and place intact granules into a 60 mL catheter-tip syringe; mix with 50 mL of water. Replace plunger and shake vigorously for 15 seconds. Ensure that no granules remain in syringe tip. Do not administer if pellets dissolve or disintegrate. Use immediately after preparation. After administration, flush nasogastric tube with additional water.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Granules: Delayed release oral suspension granules can also be given by nasogastric or gastric tube. If using a 2.5 mg or 5 mg packet, first add 5 mL of water to a catheter-tipped syringe, then add granules from packet.  If using a 10 mg, 20 mg, or 40 mg packet, first add 15 mL of water to a catheter-tipped syringe, then add granules from packet. Shake the syringe, leave 2-3 minutes to thicken. Shake the syringe and administer through nasogastric or gastric tube (size 6 French or greater) within 30 minutes. Refill the syringe with equal amount (5 mL or 15 mL) of water, shake and flush nasogastric/gastric tube.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Tablet (Canadian formulation, not available in U.S.): Disperse tablets in 50 mL of noncarbonated water. Stir until tablets disintegrate leaving a liquid containing pellets. After administration, flush with additional 25-50 mL of water to clear the syringe and tube.",
"    </p>",
"   </div>",
"   <div class=\"block uica drugH1Div\" id=\"F14472623\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     20 mg in 50 mL (concentration: 0.4 mg/mL)",
"     <b>",
"      or",
"     </b>",
"     40 mg in 50 mL (concentration: 0.8 mg/mL) of D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR, or NS",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     0.4 mg/mL",
"     <b>",
"      or",
"     </b>",
"     0.8 mg/mL",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F166947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Short-term (4-8 weeks) treatment of erosive esophagitis; maintaining symptom resolution and healing of erosive esophagitis; treatment of symptomatic gastroesophageal reflux disease (GERD); as part of a multidrug regimen for",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication in patients with duodenal ulcer disease (active or history of within the past 5 years); prevention of gastric ulcers in patients at risk (age &ge;60 years and/or history of gastric ulcer) associated with continuous NSAID therapy; long-term treatment of pathological hypersecretory conditions including Zollinger-Ellison syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Canadian labeling: Additional use (not in U.S. labeling): Oral: Treatment of nonerosive reflux disease (NERD); treatment of NSAID-induced gastric ulcers",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     I.V.: Short-term (&le;10 days) treatment of gastroesophageal reflux disease (GERD) when oral therapy is not possible or appropriate",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F7734343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V.: Prevention of recurrent peptic ulcer bleeding postendoscopy",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5730363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Esomeprazole may be confused with ARIPiprazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       NexIUM&reg; may be confused with NexAVAR&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F166991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-right:0em;margin-top:0em;text-align:justify;display:inline\">",
"     Unless otherwise specified, percentages represent adverse reactions identified in clinical trials evaluating the oral formulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Central nervous system: Headache (I.V. 11%; oral 2% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (I.V. 3%; oral &lt;1%), somnolence (adults &lt;1%; children 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Pruritus (I.V. 1%; oral &lt;1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Flatulence (I.V. 10%; oral &le;5%), diarrhea (I.V. 4%; oral 2% to &lt;7%), abdominal pain (I.V. 6%; oral 1% to &le;6%), nausea (I.V. 6%; oral 2% to &le;6%), xerostomia (I.V. 4%; oral 3%), constipation (I.V. 3%; oral 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reaction (I.V. 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Aggression, agranulocytosis, alopecia, anaphylaxis, anemia, angioedema, anorexia, arthritis exacerbation, asthma exacerbation, benign polyps/nodules, blurred vision, carcinoid tumor of stomach, cervical lymphadenopathy, chest pain,",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD), conjunctivitis, creatinine increased, cystitis, depression, dermatitis, dysmenorrhea, epistaxis, erythema multiforme,  fibromyalgia syndrome, fracture, fungal infection, gastroenteritis, GI candidiasis, GI dysplasia, goiter, gynecomastia, hallucinations, hematuria, hepatic encephalopathy, hepatic failure, hepatitis, hernia, hyperhidrosis, hyperparathyroidism, hypersensitivity reactions, hypertension, hypertonia, hyperuricemia, hypoesthesia, hypokalemia, hypomagnesemia, hyponatremia, impotence, insomnia, interstitial nephritis, jaundice, leukocytosis, leukopenia, microscopic colitis, migraine, moniliasis, osteoporosis-related fracture, otitis media, pancreatitis, pancytopenia, parosmia, phlebitis, photosensitivity, pneumonia, polymyalgia rheumatica, proteinuria, pruritus ani, rash (erythematous and maculo-papular), rigors, serum gastrin increased, Stevens-Johnson syndrome, stomatitis, tachycardia, thrombocytopenia, thrombophlebitis, thyroid-stimulating hormone increased, tinnitus, toxic epidermal necrolysis, tremor, vaginitis, vertigo, visual field defect, vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency, weight changes",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F166951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to esomeprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F166936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Atrophic gastritis: Long-term omeprazole therapy has caused atrophic gastritis (identified by biopsy); this may also occur with esomeprazole.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carcinoma: No reports of enterochromaffin-like (ECL) cell carcinoids, dysplasia, or neoplasia have occurred.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;",
"     <i>",
"      Clostridium difficile",
"     </i>",
"     -associated diarrhea (CDAD): Use of proton pump inhibitors (PPIs) may increase risk of CDAD, especially in hospitalized patients; consider CDAD diagnosis in patients with persistent diarrhea that does not improve. Use the lowest dose and shortest duration of PPI therapy appropriate for the condition being treated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of osteoporosis-related bone fractures of the hip, spine, or wrist may occur with proton pump inhibitor (PPI) therapy. Patients on high-dose or long-term therapy should be monitored. Use the lowest effective dose for the shortest duration of time, use vitamin D and calcium supplementation, and follow appropriate guidelines to reduce risk of fractures in patients at risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypomagnesemia: Reported rarely, usually with prolonged PPI use of &gt;3 months (most cases &gt;1 year of therapy). May be symptomatic or asymptomatic; severe cases may cause tetany, seizures, and cardiac arrhythmias. Consider obtaining serum magnesium concentrations prior to beginning long-term therapy, especially if taking concomitant digoxin, diuretics, or other drugs known to cause hypomagnesemia; and periodically thereafter.  Hypomagnesemia may be corrected by magnesium supplementation, although discontinuation of esomeprazole may be necessary; magnesium levels typically return to normal within 1 week of stopping.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal infection (eg,",
"     <i>",
"      Salmonella, Campylobacter",
"     </i>",
"     ): Use of proton pump inhibitors may increase risk of these infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Patients with severe liver dysfunction may require dosage reductions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Clopidogrel: Proton pump inhibitors (PPIs) may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole).  In contrast to these warnings, others have have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically-significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham, 2010; Levine, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for other interactions: Concomitant use of esomeprazole with some drugs may require cautious use, may not be recommended, or may require dosage adjustments.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asian ethnicity: Bioavailability may be increased in patients of Asian descent.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Bioavailability may be increased in the elderly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intravenous: Safety and efficacy of I.V. treatment beyond 10 days have not been established; transition from I.V. to oral therapy as soon possible.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use:",
"     <i>",
"      Helicobacter pylori",
"     </i>",
"     eradication: Short-term combination therapy (&le;7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10-14 days of therapy (triple or quadruple) for eradication of",
"     <i>",
"      H. pylori",
"     </i>",
"     (Chey, 2007).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Stop esomeprazole treatment temporarily before CgA test; if CgA level high, repeat to confirm. Use same commercial laboratory for testing to prevent variable results.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F166987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F166940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: Proton Pump Inhibitors may increase the serum concentration of Amphetamines. Specifically, data indicate that Proton Pump Inhibitors may increase the rate at which Amphetamines are absorbed.  Total exposure to Amphetamines is not significantly changed.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atazanavir: Proton Pump Inhibitors may decrease the serum concentration of Atazanavir.  Management: Avoid concurrent PPI in HIV treatment-experienced patients.  For treatment-naive patients, atazanavir/ritonavir dose should be given approximately 12 hours after the PPI, and the PPI should not exceed the equivalent of 20 mg omeprazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Proton Pump Inhibitors may increase the serum concentration of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Proton Pump Inhibitors may diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: Proton Pump Inhibitors may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors, such as antacids or H2 receptor antagonists.  Administer alternative agents more than 2 hours before or after bosutinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefditoren: Proton Pump Inhibitors may decrease the serum concentration of Cefditoren.  Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Esomeprazole may enhance the adverse/toxic effect of Cilostazol. Esomeprazole may increase the serum concentration of Cilostazol. Esomeprazole may increase the serum concentration of OPC-13015, an active metabolite of Cilostazol.  Management: Monitor for increased cilostazol effects when coadministered with esomeprazole. The manufacturer recommends considering a 50% dose reduction of cilostazol (eg, 100 mg twice daily to 50 mg twice daily) with concomitant use of these agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Citalopram: CYP2C19 Inhibitors (Moderate) may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with a moderate CYP2C19 inhibitor.  Patients using this combination should be monitored closely for evidence of citalopram toxicity (e.g., serotonin syndrome, QT prolongation, etc.).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Esomeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Substrates: CYP2C19 Inhibitors (Moderate) may decrease the metabolism of CYP2C19 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Dabigatran Etexilate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: Proton Pump Inhibitors may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of the proton pump inhibitor if some acid-reducing therapy is needed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: Proton Pump Inhibitors may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with proton pump inhibitors (PPIs) should be avoided in patients treated with delavirdine.  The clinical significance of short-term PPI therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dexmethylphenidate: Proton Pump Inhibitors may increase the absorption of Dexmethylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Focalin XR brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Proton Pump Inhibitors may decrease the serum concentration of Erlotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Proton Pump Inhibitors may decrease the serum concentration of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: Proton Pump Inhibitors may decrease the serum concentration of Indinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: Proton Pump Inhibitors may decrease the absorption of Iron Salts.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Itraconazole: Proton Pump Inhibitors may decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ketoconazole (Systemic): Proton Pump Inhibitors may decrease the serum concentration of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Proton Pump Inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mesalamine: Proton Pump Inhibitors may diminish the therapeutic effect of Mesalamine. Proton pump inhibitor-mediated increases in gastrointestinal pH may cause the premature release of mesalamine from specific sustained-release mesalamine products.  Management: Consider avoiding concurrent administration of high-dose proton pump inhibitors (PPIs) with sustained-release mesalamine products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrexate: Proton Pump Inhibitors may increase the serum concentration of Methotrexate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: Proton Pump Inhibitors may increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Proton Pump Inhibitors may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mycophenolate: Proton Pump Inhibitors may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nelfinavir: Proton Pump Inhibitors may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: Proton Pump Inhibitors may decrease the serum concentration of Nilotinib.  Management: Avoid this combination when possible since separation of doses is not likely to be an adequate method of minimizing the interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: Proton Pump Inhibitors may decrease the serum concentration of Ponatinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Posaconazole: Proton Pump Inhibitors may decrease the serum concentration of Posaconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltegravir: Proton Pump Inhibitors may increase the serum concentration of Raltegravir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rilpivirine: Proton Pump Inhibitors may decrease the serum concentration of Rilpivirine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Risedronate: Proton Pump Inhibitors may diminish the therapeutic effect of Risedronate. Proton Pump Inhibitors may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Proton Pump Inhibitors may increase the serum concentration of Saquinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May decrease the serum concentration of Esomeprazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Proton Pump Inhibitors may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose adjustment may be required. Rabeprazole, pantoprazole, or selected H2-receptor antagonists (i.e., ranitidine or famotidine) may be less likely to interact. Genetic testing may predict patients at highest risk.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May decrease the serum concentration of Proton Pump Inhibitors. These data are derived from studies with Ritonavir-boosted Tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vismodegib: Proton Pump Inhibitors may decrease the serum concentration of Vismodegib.  Management: Carefully consider the need for any medication that increases the pH of the upper GI tract (PPIs, H2RAs, antacids), as these could significantly reduce vismodegib systemic exposure. Vismodegib dose increases are unlikely to compensate for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Esomeprazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F166968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: Absorption is decreased by 43% to 53% when taken with food. Management: Take at least 1 hour before meals at the same time each day, best if before breakfast.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herb/Nutraceutical: St John's wort may decrease the efficacy of esomeprazole. Management: Avoid St John's wort.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F166942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F166955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects were not observed in animal studies. However, there are no adequate and well-controlled studies in pregnant women. Congenital abnormalities have been reported sporadically following omeprazole use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F166982\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F166956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Esomeprazole excretion into breast milk has not been studied. However, omeprazole is excreted in breast milk, and therefore considered likely that esomeprazole is similarly excreted; breast-feeding is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F166957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Take at least 1 hour before meals; best if taken before breakfast.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F166954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, delayed release",
"     </b>",
"     (NexIUM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (90): $717.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (90): $717.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (NexIUM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $239.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (30): $239.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $239.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (NexIUM I.V. Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg (1): $41.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (1): $41.60",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F166944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Susceptibility testing recommended in patients who fail",
"     <i>",
"      H. pylori",
"     </i>",
"     eradication regimen. Monitor for rebleeding in patients with peptic ulcer bleed.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F166958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ceso (IN);",
"     </li>",
"     <li>",
"      Emozul (GB);",
"     </li>",
"     <li>",
"      Esofag (IN);",
"     </li>",
"     <li>",
"      Esoflux (PH);",
"     </li>",
"     <li>",
"      Esomep (PH);",
"     </li>",
"     <li>",
"      Esorest (IN);",
"     </li>",
"     <li>",
"      Ignis (IN);",
"     </li>",
"     <li>",
"      Inexium (FR);",
"     </li>",
"     <li>",
"      Milenium (CR, GT, PA, SV);",
"     </li>",
"     <li>",
"      Nedox (CO, PE);",
"     </li>",
"     <li>",
"      Neksium (IN);",
"     </li>",
"     <li>",
"      Neopral (PE);",
"     </li>",
"     <li>",
"      Nexazol (KP);",
"     </li>",
"     <li>",
"      Nexiam (BE);",
"     </li>",
"     <li>",
"      Nexium (AR, AT, AU, BB, BF, BG, BJ, BM, BO, BR, BS, BZ, CH, CI, CL, CN, CO, CZ, DE, DK, DO, EE, ES, ET, FI, GB, GH, GM, GN, GR, GY, HK, HN, ID, IE, IL, IT, JM, KE, KP, LR, MA, ML, MR, MU, MW, MY, NE, NG, NI, NL, NO, NZ, PE, PH, PL, PR, PT, PY, RU, SC, SD, SE, SG, SL, SN, SR, TH, TN, TR, TT, TW, TZ, UG, UY, VE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Nexium IV (MX);",
"     </li>",
"     <li>",
"      Nexium-MUPS (MX);",
"     </li>",
"     <li>",
"      Nexpro (IN);",
"     </li>",
"     <li>",
"      Nexum (PK);",
"     </li>",
"     <li>",
"      Raciper (IN);",
"     </li>",
"     <li>",
"      Somed (KP);",
"     </li>",
"     <li>",
"      Sompraz (IN);",
"     </li>",
"     <li>",
"      Ulcium (EC);",
"     </li>",
"     <li>",
"      Xsom (PH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F166935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Proton pump inhibitor suppresses gastric acid secretion by inhibition of the H",
"     <sup>",
"      +",
"     </sup>",
"     /K",
"     <sup>",
"      +",
"     </sup>",
"     -ATPase in the gastric parietal cell. Esomeprazole is the S-isomer of omeprazole.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F166950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      dss",
"     </sub>",
"     : 16 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 97%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C19 primarily and (to a lesser extent) via 3A4 to hydroxy, desmethyl, and sulfone metabolites (all inactive)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 90% with repeat dosing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: ~1-1.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: 1.5-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (80%, primarily as inactive metabolites; &lt;1% as active drug); feces (20%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham NS, Hlatky MA, Antman EM, et al, &ldquo;ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use: A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(24):2619-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/21060077/pubmed\" id=\"21060077\" target=\"_blank\">",
"        21060077",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Andersson T, Hasan-Alin M, Hasselgren G, et al, &ldquo;Drug Interactions Studies With Esomeprazole, the (S)-Isomer of Omeprazole,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 2001, 40(7):523-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/11510629/pubmed\" id=\"11510629\" target=\"_blank\">",
"        11510629",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barkun AN, Bardou M, Kulpers EJ, et al, &ldquo;International Consensus Recommendations on the Management of Patients With Nonvariceal Upper Gastrointestinal Bleeding,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2010, 152(2):101-113.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/20083829/pubmed\" id=\"20083829\" target=\"_blank\">",
"        20083829",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bell AD, Roussin A, Cartier R, et al, &ldquo;The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2011, 27(Suppl A):1-59.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/21640290/pubmed\" id=\"21640290\" target=\"_blank\">",
"        21640290",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Blume H, Donath F, Warnke A, et al, &ldquo;Pharmacokinetic Drug Interaction Profiles of Proton Pump Inhibitors,&rdquo;",
"      <i>",
"       Drug Saf",
"      </i>",
"      , 2006, 29(9): 769-84.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/16944963/pubmed\" id=\"16944963\" target=\"_blank\">",
"        16944963",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chey WD and Wong B, &ldquo;American College of Gastroenterology Guideline on the Management of",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2007 102(8):1808-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/17608775/pubmed\" id=\"17608775\" target=\"_blank\">",
"        17608775",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cockayne SE, Glet RJ, Gawkrodger DJ, et al, &ldquo;Severe Erythrodermic Reactions to the Proton Pump Inhibitors Omeprazole and Lansoprazole,&rdquo;",
"      <i>",
"       Br J Dermatol",
"      </i>",
"      ,1999, 141(1):173-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/10417548/pubmed\" id=\"10417548\" target=\"_blank\">",
"        10417548",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jager CP, Wever PC, Gemen EF, et al, &ldquo;Proton Pump Inhibitor Therapy Predisposes to Community-Acquired",
"      <i>",
"       Streptococcus pneumoniae",
"      </i>",
"      Pneumonia,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2012, 36(10):941-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/23034135/pubmed\" id=\"23034135\" target=\"_blank\">",
"        23034135",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Carlet JM, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2008,&rdquo; [published correction appears in",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(4):1394-6],",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2008, 36(1):296-327.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/18158437/pubmed\" id=\"18158437\" target=\"_blank\">",
"        18158437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dellinger RP, Levy MM, Rhodes A, et al, &ldquo;Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 2013, 41(2):580-637.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/23353941/pubmed\" id=\"23353941\" target=\"_blank\">",
"        23353941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldstein JL, Johanson JF, Hawkey CJ, et al, &ldquo;Clinical Trial: Healing of NSAID-Associated Gastric Ulcers in Patients Continuing NSAID Therapy &ndash; A Randomized Study Comparing Ranitidine With Esomeprazole,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2007, 26(8):1101-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/17894652/pubmed\" id=\"17894652\" target=\"_blank\">",
"        17894652",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, &ldquo;American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2008, 135(4):1383-91.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/18789939/pubmed\" id=\"18789939\" target=\"_blank\">",
"        18789939",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kupiec TC, Aloumanis V, Ben M, et al, &ldquo;Physical and Chemical Stability of Esomeprazole Sodium Solutions,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2008, 42(9):1247-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/18614750/pubmed\" id=\"18614750\" target=\"_blank\">",
"        18614750",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lanza FL, Chan FK, and Quigley EM, &ldquo;Guidelines for Prevention of NSAID-Related Ulcer Complications,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2009, 140(3):728-38.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/19240698/pubmed\" id=\"19240698\" target=\"_blank\">",
"        19240698",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau JY, Leung WK, Wu JC, et al, &ldquo;Omeprazole Before Endoscopy in Patients With Gastrointestinal Bleeding,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007, 356(16):1631-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/17442905/pubmed\" id=\"17442905\" target=\"_blank\">",
"        17442905",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lau JY, Sung JJ, Lee KK, et al, &ldquo;Effect of Intravenous Omeprazole on Recurrent Bleeding After Endoscopic Treatment of Bleeding Peptic Ulcers,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(5):310-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/10922420/pubmed\" id=\"10922420\" target=\"_blank\">",
"        10922420",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin HJ, Lo WC, Lee FY, et al, &ldquo;A Prospective Randomized Comparative Trial Showing That Omeprazole Prevents Rebleeding in Patients With Bleeding Peptic Ulcer After Successful Endoscopic Therapy,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1998, 158(1):54-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/9437379/pubmed\" id=\"9437379\" target=\"_blank\">",
"        9437379",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Li X-Q, Anderson TB, Ahlstrom M, et al, &ldquo;Comparison of Inhibitory Effects of the Proton Pump-Inhibiting Drugs Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, and Rabeprazole on Human Cytochrome P450 Activities,&rdquo;",
"      <i>",
"       Drug Metab Disp",
"      </i>",
"      , 2004, 32(8):821-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Natsch S, Vinks MH, Voogt AK, et al, &ldquo;Anaphylactic Reactions to Proton-Pump Inhibitors,&rdquo;",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2000, 34(4):474-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/10772433/pubmed\" id=\"10772433\" target=\"_blank\">",
"        10772433",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Paoluzi P, Iacopini F, Crispino P, et al, &ldquo;2-Week Triple Therapy for",
"      <i>",
"       Helicobacter pylori",
"      </i>",
"      Infection is Better Than 1-Week in Clinical Practice: a Large Prospective Single-Center Randomized Study,&rdquo;",
"      <i>",
"       Helicobacter",
"      </i>",
"      , 2006, 11(6):562-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/17083378/pubmed\" id=\"17083378\" target=\"_blank\">",
"        17083378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sung JJ, Barkun A, Kuipers EJ, et al, &ldquo;Intravenous Esomeprazole for Prevention of Recurrent Peptic Ulcer Bleeding: A Randomized Trial,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2009, 150(7):455-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/19221370/pubmed\" id=\"19221370\" target=\"_blank\">",
"        19221370",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Talley NJ and Vakil N, &ldquo;Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the Management of Dyspepsia,&rdquo;",
"      <i>",
"       Am J Gastroenterol",
"      </i>",
"      , 2005, 100(10):2324-37.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/16181387/pubmed\" id=\"16181387\" target=\"_blank\">",
"        16181387",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wolfe MM and Sachs G, &ldquo;Acid Suppression: Optimizing Therapy for Gastroduodenal Ulcer Healing, Gastroesophageal Reflux Disease, and Stress-Related Erosive Syndrome,&rdquo;",
"      <i>",
"       Gastroenterology",
"      </i>",
"      , 2000,118(2 Suppl 1):9-31.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zargar SA, Javid G, Khan BA, et al, &ldquo;Pantoprazole Infusion as Adjuvant Therapy to Endoscopic Treatment In Patients With Peptic Ulcer Bleeding: Prospective Randomized Controlled Trial,&rdquo;",
"      <i>",
"       J Gastroenterol Hepatol",
"      </i>",
"      , 2006, 21(4):716-21",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/16677158/pubmed\" id=\"16677158\" target=\"_blank\">",
"        16677158",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zhao J, Li J, Hamer-Maansson JE, et al, &ldquo;Pharmacokinetic Properties of Esomeprazole in Children Aged 1 to 11 Years With Symptoms of Gastroesophageal Reflux Disease: A Randomized, Open-Label Study,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 2006, 28(11): 1868-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?15/39/15993/abstract-text/17213007/pubmed\" id=\"17213007\" target=\"_blank\">",
"        17213007",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9104 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-1AFF26D322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15993=[""].join("\n");
var outline_f15_39_15993=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16572476\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166971\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166972\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166993\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166975\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2934196\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166976\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166977\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166978\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166946\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5940148\">",
"      Dosage Forms: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166932\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15241701\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166948\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472623\">",
"      Usual Infusion Concentrations: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472624\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166947\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7734343\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5730363\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166991\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166951\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166936\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166987\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166940\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166968\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166942\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166955\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166982\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166956\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166957\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166954\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166944\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166958\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166935\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F166950\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9104\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9104|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?24/25/24981?source=related_link\">",
"      Esomeprazole: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/38/21095?source=related_link\">",
"      Esomeprazole: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_39_15994="Operative vaginal delivery";
var content_f15_39_15994=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Operative vaginal delivery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15994/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15994/contributors\">",
"     Elisabeth K Wegner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15994/contributors\">",
"     Ira M Bernstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15994/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15994/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/39/15994/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/39/15994/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/39/15994/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Operative vaginal delivery refers to a delivery in which the operator uses forceps or a vacuum device to assist the mother in transitioning the fetus to extrauterine life. The instrument is applied to the fetal head and then the operator uses traction to extract the fetus, typically during a contraction while the mother is pushing. A new alternative instrument, the Odon device, is being tested in multicountry trials [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/1\">",
"     1",
"    </a>",
"    ]. It is a low cost device that may be safer and easier to apply than",
"    <span class=\"nowrap\">",
"     forceps/vacuum",
"    </span>",
"    extractor for assisted deliveries in low resource areas.",
"   </p>",
"   <p>",
"    The first instrumental deliveries were performed to extract fetuses from parturients who were at high risk of maternal mortality due to prolonged",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    obstructed labor. In these cases, saving the mother's life took precedence over possible harm to the fetus. The focus of these procedures has changed as a result of modern obstetrical practices that have drastically reduced the risk of intrapartum maternal mortality and major morbidity. Decisions regarding use of instrumental delivery are now based primarily upon the",
"    <span class=\"nowrap\">",
"     fetal/neonatal",
"    </span>",
"    impact of these procedures and are weighed against the alternative options of cesarean birth, expectant management (prolonging the second stage), and augmentation of contractions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, 3.6 percent of all deliveries are accomplished via an operative vaginal approach [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/2\">",
"     2",
"    </a>",
"    ]. The overall rate of operative vaginal delivery has been diminishing, but the proportion of operative vaginal deliveries conducted by vacuum assisted births has been increasing and is more than four times the rate of forceps assisted births. Forceps deliveries account for 1 percent of vaginal births and vacuum deliveries account for about 4 percent of vaginal births.",
"   </p>",
"   <p>",
"    In recent years, the success rate for operative vaginal deliveries has been quite high (99 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/3\">",
"     3",
"    </a>",
"    ]. This likely reflects appropriate choice of candidates for this intervention. However, the wide range of operative vaginal delivery rates (1 to 23 percent), both across and within geographic regions in the United States, suggests that evidence based guidelines for operative vaginal delivery are either inadequate or randomly applied [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An American College of Obstetricians and Gynecologists (ACOG) practice bulletin outlined the following indications for operative vaginal delivery (forceps or vacuum), recognizing that no indication is absolute; cesarean delivery is also an option in these clinical settings [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prolonged second stage of labor &mdash; In nulliparous women, this is defined as lack of continuing progress for three hours with regional anesthesia or two hours without anesthesia. In multiparous women, it refers to lack of continuing progress for two hours with regional anesthesia or one hour without anesthesia. However, nonsurgical interventions should be attempted before resorting to operative delivery. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link&amp;anchor=H22#H22\">",
"       \"Abnormal labor: Protraction and arrest disorders\", section on 'Poor progression in the second stage'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Nonreassuring fetal status &mdash; Suspicion of immediate or potential fetal compromise (eg, nonreassuring fetal heart rate pattern, abruption) is an indication for use of forceps or vacuum when expeditious vaginal delivery can be readily accomplished; otherwise, cesarean delivery may be the safer and more effective option.",
"     </li>",
"     <li>",
"      Maternal cardiac or neurological disease &mdash; Forceps or vacuum can be used to shorten the second stage of labor if the Valsalva maneuver is contraindicated because of maternal cardiovascular or neurologic disease, or if pushing is ineffective because of maternal neurological or muscular disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the past, shortening the second stage was an acceptable option, independent of any specific maternal or fetal indications, because early studies suggested the risk of fetal morbidity was higher when the second stage of labor exceeded two hours. More recent evidence does not support this practice. The ability of fetal heart rate monitoring to identify the fetus who is not tolerating labor has generally made the arbitrary termination of labor because of any elapsed period of time unwarranted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maternal risks of a prolonged second stage (eg, pelvic floor injury, postpartum hemorrhage) appear to be increased, but are more related to instrumental intervention than the specific length of the second stage (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Maternal complications'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/7-12\">",
"     7-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PREREQUISITES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The operator should be an individual experienced in operative vaginal delivery. This individual should determine the following prerequisites prior to application of instruments (",
"    <a class=\"graphic graphic_table graphicRef53086 \" href=\"UTD.htm?0/4/69\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The cervix is fully dilated.",
"     </li>",
"     <li>",
"      The membranes are ruptured.",
"     </li>",
"     <li>",
"      The head is engaged.",
"     </li>",
"     <li>",
"      Fetal presentation, position, lie, and any asynclitism are known. The fetus must be in a vertex presentation (unless the purpose is to use forceps to assist in delivery of an after-coming head).",
"      <br/>",
"      <br/>",
"      If fetal presentation or position is uncertain, intrapartum ultrasound examination should be performed, as it is more accurate than digital examination in this setting. Sonographic visualization of fetal intracranial structures, including the cerebellum, orbits, and midline falx, can be used to confirm fetal head position. In one study, digital examination incorrectly defined fetal head position in over 25 percent of cases about to undergo operative vaginal delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/14\">",
"       14",
"      </a>",
"      ]. Large infants, extreme molding, extension of the fetal head, pelvic deformities, and asynclitism may falsely suggest engagement of the vertex. In these cases, the leading bony part is at the ischial spines, although the biparietal diameter has not passed through the pelvic inlet.",
"      <br/>",
"      <br/>",
"      If ultrasound is not available, no more than one-fifth of the fetal head should be palpable abdominally if the vertex is engaged [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The fetal size has been estimated and clinical pelvimetry shows adequate mid and outlet pelvic dimensions, and no obstructions or contractures exist.",
"     </li>",
"     <li>",
"      Maternal anesthesia is satisfactory.",
"     </li>",
"     <li>",
"      Maternal bladder is empty.",
"     </li>",
"     <li>",
"      The patient consents to the procedure. The risks of the procedure should be explained to the woman and documentation of the indication and maternal and fetal assessments should be made in the medical record [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/16\">",
"       16",
"      </a>",
"      ]. The record should also document the informed consent discussion (with specific risks, benefits, and alternatives delineated), and that her questions were answered.",
"     </li>",
"     <li>",
"      The option of performing an immediate cesarean delivery should be available if complications arise.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Antibiotic prophylaxis is unnecessary [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most contraindications to instrumental delivery are related to the potential for unacceptable fetal risks. Fetal prematurity is a relative contraindication. Some other contraindications include known fetal demineralizing diseases (eg, osteogenesis imperfecta), fetal bleeding diatheses (eg, hemophilia, alloimmune thrombocytopenia), unengaged head, unknown fetal position, malpresentation (eg, brow, face), and suspected fetal-pelvic disproportion [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/18\">",
"     18",
"    </a>",
"    ]. A nonreassuring fetal heart rate pattern is not a contraindication to operative vaginal delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=see_link\">",
"     \"Fetal blood sampling\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, vacuum devices should not be used to assist delivery prior to 34 weeks of gestation because of the risk of fetal intraventricular hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"     5",
"    </a>",
"    ]. Prior scalp sampling or multiple attempts at fetal scalp electrode placement are also relative contraindications to vacuum extraction since these procedures may increase the risk of cephalohematoma or external bleeding from the scalp wound [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vacuum is also not recommended to perform a rotation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Minimum and maximum estimated fetal weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus regarding the minimum and maximum estimated fetal weights that should preclude operative vaginal delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98685947\">",
"    <span class=\"h4\">",
"     Upper threshold",
"    </span>",
"    &nbsp;&mdash;&nbsp;Instrumental delivery of the macrosomic infant may be associated with an increased risk of injury. As an example, a study of 2924 macrosomic infants (birth weight &gt;4000 g) found the risk of persistent significant injury was higher after forceps than after spontaneous delivery (relative risk [RR] 2.6) or cesarean birth (RR 4.2), although the overall rate of persistent injury was low (0.3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/22\">",
"     22",
"    </a>",
"    ]. The risk of persistent injury at six months of age was seven-fold higher among macrosomic infants compared with appropriate-for-gestational-age (AGA) controls (birth weight 3000 to 3999 g) and was related to vaginal birth (operative or spontaneous). Persistent injury was not observed in infants delivered by cesarean delivery.",
"    <br/>",
"    <br/>",
"    The authors did not recommend a policy of elective cesarean birth for macrosomia because it would necessitate 148 to 258 cesarean deliveries to prevent a single persistent injury; avoidance of operative vaginal delivery would require 50 to 99 cesarean births per injury prevented. Furthermore, there is no precise method for determining which mothers have macrosomic infants prior to delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=see_link\">",
"     \"Fetal macrosomia\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"    A trial of labor and careful use of forceps or vacuum extraction are acceptable for most fetuses suspected to be macrosomic [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"     5",
"    </a>",
"    ]. Under these circumstances, the obstetrician should be aware of the risk of shoulder dystocia, especially when the second stage of labor is prolonged. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=see_link\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98685955\">",
"    <span class=\"h4\">",
"     Lower threshold",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, vacuum devices should not be used to assist delivery prior to 34 weeks of gestation (mean birth weight 2500 g [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/23\">",
"     23",
"    </a>",
"    ]) because of increased risks of fetal intraventricular hemorrhage in premature infants. Premie sized forceps have been used on fetuses as small as 1000 g [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/24\">",
"     24",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"    There are no prospective randomized trials examining the impact of prophylactic low forceps delivery in low birth weight infants. Observational studies have reported conflicting findings. In 1965, the Collaborative Study of Cerebral Palsy reported that prophylactic low forceps delivery was associated with neurologic benefits in infants between 1000 and 2500 g when compared to spontaneous vaginal or cesarean deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/25\">",
"     25",
"    </a>",
"    ]. However, this report was limited by the lack of a rigorous statistical analysis.",
"    <br/>",
"    <br/>",
"    Another study that performed immediate and later head ultrasound examinations of 230 infants with estimated fetal weights of less than 1750 g observed that the overall incidence of cerebral hemorrhage was the same after vaginal and cesarean deliveries (41 and 44 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/26\">",
"     26",
"    </a>",
"    ]. However, a lower incidence of hemorrhage was noted after vaginal delivery with forceps (17 percent). More grades 3 to 4 hemorrhages were observed after vaginal birth without forceps and in cesarean births following active phase labor compared to other modes of delivery.",
"    <br/>",
"    <br/>",
"    In contrast, several other studies have suggested an increased risk of intraventricular hemorrhage with prophylactic low forceps [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/27-29\">",
"     27-29",
"    </a>",
"    ] while one report on 1065 infants between 1000 to 2500 g identified no differences in neonatal outcome between the 394 infants delivered by low forceps and the 671 that delivered spontaneously [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the evidence does not clearly identify a superior mode of delivery in cephalic presenting low birth weight infants and very little data address the very low birth weight infant. Reassuringly, larger trials do not demonstrate any increase in neurologic injury with the use of low forceps in low birth weight infants, and a role for low forceps in clinically indicated situations would appear reasonable in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20374?source=see_link\">",
"     \"Intrapartum management of the low birthweight vertex fetus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two forceps are available which are smaller in dimension than standard forceps and are intended for use in the low birth weight or very low birth weight populations. \"Baby\" Elliot and \"baby\" Simpson forceps are among these instruments. Unfortunately, we were unable to identify any published studies or manufacturer guidelines regarding the estimated fetal weights or gestational ages at which these instruments might be most useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ALTERNATIVES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Possible alternatives to operative vaginal delivery are cesarean birth, expectant management (possibly with delayed pushing, maternal rest, change in maternal position, reduction in neuraxial anesthesia, emotional support), and augmentation of contractions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/0/5125?source=see_link\">",
"     oxytocin",
"    </a>",
"    . The choice depends upon the clinical situation, taking into account factors such as whether the fetal heart rate pattern is nonreassuring, the quality and frequency of contractions, estimated fetal size, and fetal position. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=see_link\">",
"     \"Abnormal labor: Protraction and arrest disorders\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=see_link\">",
"     \"Timing and route of delivery in pregnancies at risk of shoulder dystocia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TRIAL OF INSTRUMENTAL DELIVERY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although one can never be certain of a successful outcome, an operative vaginal delivery should only be considered when the likelihood of success is high, given there may be a higher rate of birth trauma after failed attempts at operative delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5,30,31\">",
"     5,30,31",
"    </a>",
"    ]. As an example, in one study, the rates of subdural or cerebral hemorrhage, facial nerve injury, convulsions, central nervous system depression, and mechanical ventilation were higher in infants delivered by cesarean birth after a failed instrumental delivery than in those delivered by cesarean with no prior attempt at operative vaginal delivery (",
"    <a class=\"graphic graphic_table graphicRef69438 \" href=\"UTD.htm?17/29/17883\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/32\">",
"     32",
"    </a>",
"    ]. However, other studies have not shown adverse effects from failed operative vaginal delivery as long as cesarean delivery followed promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/33\">",
"     33",
"    </a>",
"    ]. No randomized trials have been performed comparing a trial of instrumental vaginal delivery (vacuum extraction or forceps) to immediate cesarean delivery for women with failure to progress in the second stage of labor.",
"   </p>",
"   <p>",
"    Multiple variables have been associated with an increased risk of failed operative delivery; two common causes are occiput posterior position and macrosomia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/30,34-39\">",
"     30,34-39",
"    </a>",
"    ]. Other purported factors include one fifth of the head palpable abdominally, the presenting part only as far as the ischial spines, excessive molding of the fetal head, protracted labor, and maternal obesity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF FORCEPS DELIVERIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACOG redefined the classification of forceps delivery in 1988 to better reflect the degree of difficulty and attendant risk (eg, lower fetal station and smaller degrees of head rotation are associated with reduced maternal and fetal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/40\">",
"     40",
"    </a>",
"    ]) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"     5",
"    </a>",
"    ]. The criteria for different types of forceps deliveries are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Outlet forceps &mdash; The application of forceps when the scalp is visible at the introitus without separating the labia, the fetal skull has reached the pelvic floor, the sagittal suture is in anteroposterior diameter or a right or left occiput anterior or posterior position, the fetal head is at or on the perineum, rotation does not exceed 45 degrees.",
"     </li>",
"     <li>",
"      Low forceps &mdash; The application of forceps when the leading point of the fetal skull is 2 cm or more beyond the ischial spines (ie, at least + 2 cm station; the maximum possible distance beyond the ischial spines using this system is 5 cm), but not on the pelvic floor. Low forceps have two subdivisions: (a) rotation is 45 degrees or less (left or right occiput anterior to occiput anterior, or left or right occiput posterior to occiput posterior), and (b) rotation more than 45 degrees.",
"     </li>",
"     <li>",
"      Midforceps &mdash; The application of forceps when the head is engaged, but the leading point of the skull is higher than +2 cm station.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Under very unusual circumstances, such as the sudden onset of severe fetal or maternal compromise, application of forceps above +2 cm station may be attempted while simultaneously initiating preparations for a cesarean delivery in the event the forceps maneuver is unsuccessful. Under no circumstances, however, should forceps be applied to an unengaged presenting part or when the cervix is not completely dilated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CHOICE OF INSTRUMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of instrument is determined by level of training with the various forceps and vacuum equipment. Factors that might influence choice are the availability of the instrument, the degree of maternal anesthesia, and knowledge of the risks and benefits associated with each instrument. Differences between the two instruments in the types and rates of maternal and fetal morbidity are reviewed below (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Data from comparative trials'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    In general, vacuum delivery is probably safer than forceps for the mother, while forceps are probably safer than vacuum for the fetus. Vacuum devices are easier to apply, place less force on the fetal head, require less maternal anesthesia, result in less maternal soft tissue trauma, and do not affect the diameter of the fetal head compared to forceps.",
"   </p>",
"   <p>",
"    By comparison, the advantages of forceps are that they are unlikely to detach from the head, can be used on premature fetuses or for a rotation, result in less cephalohematoma and retinal hemorrhage, and do not aggravate bleeding from scalp lacerations.",
"   </p>",
"   <p>",
"    A meta-analysis of randomized trials found that forceps were less likely to fail to achieve vaginal birth than vacuum (RR 0.65, 95% CI 0.45-0.94; 7 trials, 2419 participants), but with more maternal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/41\">",
"     41",
"    </a>",
"    ]. The authors suggested use of vacuum extraction when a relatively easy procedure is anticipated (eg, occipito-anterior position with no signs of relative cephalopelvic disproportion).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Vacuum",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of eight trials involving 1076 women compared soft (silicone, plastic, rubber) vacuum extractor cups to rigid (metal, plastic) ones [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/41\">",
"     41",
"    </a>",
"    ]. Soft cups were more likely to fail in achieving vaginal delivery (OR 1.63, 95% CI 1.17-2.28). However, there were fewer scalp injuries and cephalohematomas with the soft cup and no differences between groups in regard to maternal injury. The authors concluded that metal or rigid cups were more suitable for occiput posterior, transverse, and difficult occiput anterior deliveries, whereas the soft cup was appropriate for uncomplicated deliveries.",
"   </p>",
"   <p>",
"    Two randomized prospective trials compared conventional vacuum devices to the Kiwi Omnicup. Both showed a statistically significant higher failure rate with the Kiwi Omnicup compared to conventional vacuum: failure rates in one trial were 30.1 and 19.2 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/42\">",
"     42",
"    </a>",
"    ], and in the other trial, failure rates were 34 and 21 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Forceps",
"    </span>",
"    &nbsp;&mdash;&nbsp;A detailed discussion of the hundreds of types of instruments available for forceps delivery is beyond the scope of this review. In general, the instrument selected should have cephalic and pelvic curves appropriate to the size and shape of the fetal head, maternal pelvis, and planned procedure. Midpelvic deliveries are facilitated by an instrument that can be used with a traction handle (eg, Bill's axis traction handle) and a sliding lock is helpful when there is asynclitism. Simpson type forceps tend to fit a long molded head, Elliott or Tucker-McLane type forceps are better suited to a round unmolded head, and Kielland forceps are useful for rotations because of their minimal pelvic curve and sliding lock (",
"    <a class=\"graphic graphic_picture graphicRef56439 graphicRef79792 graphicRef80795 graphicRef73043 graphicRef66054 graphicRef58167 \" href=\"UTD.htm?36/44/37578\">",
"     picture 1A-F",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623906680\">",
"    <span class=\"h3\">",
"     Spatula",
"    </span>",
"    &nbsp;&mdash;&nbsp;An unarticulated forceps (ie, Thierry spatula) has become popular in many European, African, and Latin American countries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/44\">",
"     44",
"    </a>",
"    ]. Outcome data are limited, but maternal and neonatal complication rates appear to be similar to, or slightly higher than, rates with other instruments [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     APPLICATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Forceps",
"    </span>",
"    &nbsp;&mdash;&nbsp;Appropriately applied forceps grasp the occiput anterior (OA) fetal head such that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The long axis of the blades corresponds to the occipitomental diameter",
"     </li>",
"     <li>",
"      The tips of the blades lie over the cheeks (",
"      <a class=\"graphic graphic_figure graphicRef72994 \" href=\"UTD.htm?6/16/6401\">",
"       figure 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      The blades are equidistant from the sagittal suture, which should bisect a horizontal plane through the shanks",
"     </li>",
"     <li>",
"      The posterior fontanelle should be one finger breadth anterior to this plane",
"     </li>",
"     <li>",
"      Fenestrated blades should admit no more than one finger breadth between the heel of the fenestration and the fetal head",
"     </li>",
"     <li>",
"      No maternal tissue has been grasped.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rotation, when needed, is performed between contractions. These deliveries are more difficult and associated with a higher risk of maternal and fetal complications than simple traction applied to the non- or minimally rotated vertex. Forceps application and rotation when the fetal vertex is not directly OA is beyond the scope of this topic review.",
"   </p>",
"   <p>",
"    To reduce the risk of laceration, forceps are disarticulated and removed when expulsion is certain, but before the widest diameter of the fetal head passes through the introitus. The vertex can then be delivered with no or minimal maternal assistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vacuum",
"    </span>",
"    &nbsp;&mdash;&nbsp;The procedure for vacuum extraction is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42903?source=see_link\">",
"     \"Procedure for vacuum assisted operative vaginal delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Traction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traction with forceps (or vacuum) should be steady (not rocking) and in the line of the birth canal. Traction should be exerted with each contraction and in conjunction with maternal expulsive efforts; the forceps can be relaxed between contractions to reduce fetal cranial compression. In most cases, progress is noted with the first or second pull and delivery occurs by the third or fourth pull [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/47\">",
"     47",
"    </a>",
"    ]. The procedure should be abandoned if descent does not occur with appropriate application and traction.",
"   </p>",
"   <p>",
"    An observational study of 560 vacuum assisted deliveries using an omnicup vacuum device with a traction force indicator found that 86 percent of extractions occurred with 11.5 kg (25 lbs) or less traction and 14 percent with greater than 11.5 kg traction [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/48\">",
"     48",
"    </a>",
"    ]. A similar series found that neonatal scalp abrasion and cephalhematoma were more common in infants born with traction greater than 11.5 kg [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SEQUENTIAL ATTEMPTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;ACOG has suggested that multiple attempts at operative vaginal delivery using different instruments (vacuum, different types of forceps) be",
"    <strong>",
"     avoided",
"    </strong>",
"    due to the greater potential for maternal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fetal injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"     5",
"    </a>",
"    ]. Population based evidence has shown increased risks from sequential application of vacuum and forceps while a few small studies have not demonstrated increased risk, but these may be limited by their study sizes. In one large study, the incidence of subdural or cerebral hemorrhage in infants delivered by vacuum and forceps, vacuum alone, or forceps alone was approximately 21, 10, and 8, per 10,000 births, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings were corroborated by another analysis based upon state-wide birth certificate data [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/50\">",
"     50",
"    </a>",
"    ], and a study on asymptomatic term infants who underwent routine magnetic resonance imaging within 48 hours of birth [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/51\">",
"     51",
"    </a>",
"    ]. Nine of 111 asymptomatic infants had subdural hematomas with the highest proportion in the group exposed to failed vacuum followed by successful forceps delivery (five subdural hematomas among 18 infants). In addition, three subdural hematomas occurred in 49 infants spontaneously delivered from vertex presentation and one subdural hemorrhage occurred after a failed vacuum delivery. No subdurals were noted in the remaining infants (25 infants delivered by cesarean, 4 delivered by forceps, 13 delivered by vacuum, and 1 delivered by cesarean after failed forceps). All hematomas had resolved without clinical sequelae when reevaluated four weeks later.",
"   </p>",
"   <p>",
"    However, two other small studies did not show adverse effects from sequential use of vacuum and forceps, even when vaginal delivery was not achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/33,52\">",
"     33,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We feel sequential delivery may be appropriate in rare, carefully selected cases, as long as none of the indications for abandonment of operative delivery are present. We would not consider it a sequential delivery in situations where proper placement of forceps cannot be achieved or a vacuum device fails to achieve suction and no traction has been applied and then a second instrument is used (see",
"    <a class=\"local\" href=\"#H18\">",
"     'When to abandon the procedure'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     WHEN TO ABANDON THE PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to proceed with operative vaginal delivery is ongoing and decided moment by moment based on assessment of the success of the various steps in the procedure. Operative vaginal delivery should be abandoned if it is difficult to apply the instrument, descent does not easily proceed with traction, or the baby has not been delivered within a reasonable time (eg, 15 to 20 minutes) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/15\">",
"     15",
"    </a>",
"    ]. Some experts have recommended abandoning the procedure after three pulls. A cohort study found that 82 percent of completed operative deliveries occurred with one to three pulls, and that pulling more than three times was associated with infant trauma in 45 percent of such deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/53\">",
"     53",
"    </a>",
"    ]. Based on these data, it seems prudent to abandon the procedure if good instrument placement is followed by no progress in descent over three attempts. If descent has occurred and delivery is clearly imminent, then proceeding with instrumental delivery after three pulls may be appropriate and less morbid than a cesarean delivery of an infant with its head on the perineum.",
"   </p>",
"   <p>",
"    The operator should not be fixated on affecting a vaginal delivery. It is essential that the operator be willing to abandon a planned or attempted operative delivery and have the ability to perform a cesarean birth if evaluation or reevaluation of the clinical status shows that an instrumental delivery is contraindicated (eg, the fetal head is not engaged, the position is uncertain, the procedure is not succeeding).",
"   </p>",
"   <p>",
"    It is important to remember to examine the mother for possible tissue trauma after a failed attempt at operative delivery, as well as after successful attempts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     OUTCOME AFTER FAILED PROCEDURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A secondary analysis of an observational study of women who underwent second stage cesarean delivery compared outcomes of infants delivered abdominally after a failed attempt at operative vaginal delivery (n = 640) with those who underwent cesarean delivery without such attempts (n = 2549) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/54\">",
"     54",
"    </a>",
"    ]. Overall, a failed operative delivery was associated with significantly higher rates of umbilical pH &lt;7.0 (4.7 versus 1.7 percent), Apgar score &le;3 at 5 minutes (1.7 versus 0.6 percent), seizures in the first 24 hours of life (0.9 versus 0.1 percent), and hypoxic ischemic encephalopathy (HIE) (1.1 versus 0.1 percent).",
"   </p>",
"   <p>",
"    The authors attributed these differences, at least in part, to the higher proportion of nonreassuring fetal heart rate tracings as the indication for cesarean in the attempted operative vaginal delivery group (18 versus 14 percent); unfortunately, the indications for attempted instrument delivery were not reported. There was no evidence of fetal cranial trauma in neonates with HIE, which suggests that the HIE was related to the nonreassuring fetal status rather than trauma. This hypothesis is supported by the observation that significant differences in neonatal outcome did not occur when the instrumental procedures were performed for indications other than a nonreassuring tracing (eg, dystocia); however, the number of adverse events in these settings was small, with a wide confidence interval around the odds ratio. This study did not report outcomes of pregnancies in which attempted operative vaginal delivery was successful; incorporating these data might change the overall results reported for attempted operative vaginal delivery and impact conclusions about the safety of attempting this procedure. Data from randomized trials which include outcomes of all women undergoing attempted operative vaginal delivery are needed before one can conclude that a failed instrumental delivery has any adverse neonatal effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     RISKS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal and fetal complication rates depend on a number of factors, which are not entirely independent. These include parity,",
"    <span class=\"nowrap\">",
"     forceps/cup",
"    </span>",
"    position, head position at application, and station.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Data from comparative trials",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risks associated with operative vaginal delivery need to be evaluated with respect to appropriate control groups and reasonable alternative procedures. This was illustrated by a study assessing the incidence of intracranial hemorrhage related to labor and mode of delivery in 583,340 singleton infants born to nulliparous women in California (",
"    <a class=\"graphic graphic_table graphicRef50481 \" href=\"UTD.htm?14/54/15211\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/32\">",
"     32",
"    </a>",
"    ]. The rate of subdural or cerebral hemorrhage associated with vacuum extraction was equivalent to that associated with forceps use or cesarean delivery during labor, but higher than after spontaneous delivery or a cesarean delivery performed prior to labor. This suggests that the intrapartum indication for intervention was the major risk factor for this complication, rather than mode of delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=see_link\">",
"     \"Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Comparative data on the risks of instrumental delivery are illustrated by the following examples from large studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of 10 trials comparing vacuum with forceps delivery found vacuum deliveries were associated with less maternal soft tissue trauma (OR 0.41, 95% CI 0.33-0.50), required less general and regional anesthesia, and resulted in fewer cesarean deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/55\">",
"       55",
"      </a>",
"      ]. However, use of a vacuum device was less likely to result in successful vaginal delivery than forceps. The lower cesarean delivery rate after attempted vacuum extraction was likely due to follow-up trial of forceps, whereas failed forceps typically resulted in a cesarean delivery. Patient selection may have also been a factor; the vacuum approach may have been used in patients more likely to deliver with minimal assistance.",
"      <br/>",
"      <br/>",
"      Neonates delivered by vacuum extraction had more neonatal cephalohematoma (OR 2.38) and retinal hemorrhages (OR 1.99) than those delivered by forceps [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/55\">",
"       55",
"      </a>",
"      ]. These problems generally are not associated with long-term complications (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Maternal complications'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      A population-based analysis of singleton births in the United States provided crude",
"      <span class=\"nowrap\">",
"       morbidity/mortality",
"      </span>",
"      data for over 11 million unassisted, forceps assisted, and vacuum assisted births (",
"      <a class=\"graphic graphic_table graphicRef70509 \" href=\"UTD.htm?15/60/16331\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/56\">",
"       56",
"      </a>",
"      ]. Vacuum-assisted deliveries were associated with significantly lower rates of birth injury, seizures, and assisted ventilation than forceps-assisted deliveries, after adjustment for confounders; neonatal death rates were equivalent.",
"      <br/>",
"      <br/>",
"      State-based data for California and New Jersey are shown in the tables (",
"      <a class=\"graphic graphic_table graphicRef63989 \" href=\"UTD.htm?29/26/30124\">",
"       table 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef50159 \" href=\"UTD.htm?7/3/7228\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/32,56\">",
"       32,56",
"      </a>",
"      ]. Although patients contained in these reports might represent a biased sample, relative to the choice of tool for operative vaginal delivery, it seems likely that this is a reasonable representation of injuries to be expected with the application of the different tools, given current clinical indications for different types of operative vaginal delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Maternal complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Short-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Short-term maternal risks from instrumental delivery include pain at delivery, perineal pain at 24 hours, lower genital tract lacerations and hematomas, urinary retention and incontinence, anemia, anal incontinence, and rehospitalization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/57-61\">",
"     57-61",
"    </a>",
"    ]. A randomized trial reported at least one adverse maternal outcome",
"    <span class=\"nowrap\">",
"     (periurethral/labial",
"    </span>",
"    laceration, vaginal laceration, 3rd or 4th degree laceration, vulvar or vaginal hematomas, or cervical lacerations) occurred in 48 percent of forceps, 36 percent of silastic vacuum extractor, and 22 percent of Mityvac vacuum extractor deliveries [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/62\">",
"     62",
"    </a>",
"    ]. Severe maternal trauma is primarily associated with rotational and midforceps operations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/40,63\">",
"     40,63",
"    </a>",
"    ]; direct bladder injury, ureteral",
"    <span class=\"nowrap\">",
"     lacerations/transections,",
"    </span>",
"    and uterine rupture have been reported in such cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although maternal complications can occur with spontaneous delivery, they are more likely to be associated with vacuum or forceps delivery. This was illustrated by a retrospective review of 50,210 vaginal deliveries and a cohort study of 87,267 vaginal deliveries in which the rates of third and fourth degree lacerations were: spontaneous delivery (2 percent), vacuum extraction (10 to 11 percent), and forceps delivery (17 to 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/65,66\">",
"     65,66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional maternal morbidities occur when episiotomy is performed at the time of the operative vaginal delivery. These morbidities include an increased risk of postpartum hemorrhage and perineal infection, and a greater need for moderate or strong analgesia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies show performing an episiotomy (midline [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/68,69\">",
"     68,69",
"    </a>",
"    ] or mediolateral [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]) appears to increase, rather than decrease, the risk of perineal trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/68-72\">",
"     68-72",
"    </a>",
"    ] when employed in association with operative vaginal deliveries. As an example, a study that calculated odds ratios (OR) for severe perineal laceration in nulliparous women undergoing various types of delivery reported [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/69\">",
"     69",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Vacuum extraction without episiotomy (OR 9.4)",
"     </li>",
"     <li>",
"      Forceps delivery without episiotomy (23.2)",
"     </li>",
"     <li>",
"      Vacuum extraction with episiotomy (34.7)",
"     </li>",
"     <li>",
"      Forceps delivery with episiotomy (41.8)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar results have been reported in multiparous women.",
"   </p>",
"   <p>",
"    However, one large cohort study found that mediolateral episiotomy during operative vaginal delivery protected against anal sphincter injury [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/73\">",
"     73",
"    </a>",
"    ]. Of note, the only randomized trial comparing routine versus restrictive episiotomy did not show a difference in outcomes, including anal sphincter tear or postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of third and fourth degree lacerations have decreased over several decades in the US [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/75\">",
"     75",
"    </a>",
"    ]. Observational data suggest that more than 50 percent of this reduction can be accounted for by decreased use of forceps and episiotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/76\">",
"     76",
"    </a>",
"    ]. The effects of episiotomy are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=see_link\">",
"     \"Approach to episiotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fetal position also has an impact on the risk of maternal trauma during delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/77-79\">",
"     77-79",
"    </a>",
"    ]. The rate of rectal injury is higher for instrumental delivery from the occiput posterior (OP) compared with the occiput anterior (OA) position (for forceps delivery: 72 versus 54 percent; for vacuum delivery: 33 versus 27 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/77\">",
"     77",
"    </a>",
"    ]. A logistic regression model adjusting for a number of factors showed that OP was four times more likely than OA to be associated with anal sphincter injury; the unadjusted rates of anal sphincter injury for the OP and OA positions were 42 and 22 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that surgical trauma is intrinsic to all cesarean deliveries. Although spontaneous vaginal delivery is less traumatic for the mother than operative vaginal delivery, the latter is associated with less short-term maternal morbidity than cesarean delivery. As an example, a retrospective analysis of 358 midforceps and 486 cesarean deliveries reported febrile morbidity followed 25 percent of cesareans, but only 4 percent of forceps deliveries, and all cases of thromboembolism occurred in women who underwent cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/80\">",
"     80",
"    </a>",
"    ]. Unexpected cervical and vaginal lacerations and episiotomy extensions occurred in 45 percent of forceps deliveries, while 21 percent of women delivered by cesarean had an unexpected hysterotomy extension.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Long-term maternal sequelae from operative delivery are primarily related to potential disturbances in urinary and anal function, such as urinary incontinence, fecal incontinence, pelvic organ prolapse, and, occasionally, fistula formation. As an example, a trial that randomly assigned 75 women to forceps or vacuum delivery and surveyed them five years postpartum reported 47 percent had some degree of urinary incontinence and 20 percent had loss of bowel control \"sometimes\" or \"frequently\" [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/81\">",
"     81",
"    </a>",
"    ]. The long-term rates of morbidity were similar regardless of the instrument used to assist delivery. This study was limited by the lack of a control group of women who underwent cesarean delivery following a dysfunctional labor.",
"   </p>",
"   <p>",
"    Any increase in risk of long-term maternal morbidity from different types of operative vaginal delivery cannot be accurately quantitated and compared because of the lack of adequate randomized trials with appropriate control groups. The most appropriate control group when evaluating sequelae of operative vaginal delivery is probably cesarean delivery during dysfunctional labor because prelabor cesarean delivery and spontaneous vaginal delivery are not possible alternatives to instrumental delivery in the setting of labor complications. Data from longitudinal cohort studies suggest that cesarean delivery after full dilation is associated with less urinary incontinence, anal incontinence, and prolapse symptoms than operative vaginal delivery, but these differences were not consistently statistically significant [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. The relationships between method of delivery and long-term risk of pelvic relaxation and urinary and fecal incontinence are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=see_link\">",
"     \"Fecal incontinence related to pregnancy and vaginal delivery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=see_link\">",
"     \"Pelvic floor disorders associated with pregnancy and childbirth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Risk of recurrent operative vaginal delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mode of delivery after a previous operative vaginal delivery has not been extensively evaluated. A three-year follow-up study that surveyed women who had undergone a successful, term, operative vaginal delivery in the second stage reported 42 of 54 (78 percent) women achieved vaginal delivery in the subsequent pregnancy and 3 of the 54 (5.6 percent) women had another instrumental delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/84\">",
"     84",
"    </a>",
"    ]. Another study of nulliparas who underwent operative vaginal delivery for their first birth observed 4.7 percent had a repeat operative vaginal delivery in their subsequent delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Neonatal complications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Short-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postdelivery, the neonatal care provider should be informed that the birth was attempted or assisted by vacuum or forceps. Since a serious complication, such as a subgaleal hematoma, can occur within hours of delivery, it is important that the infant care providers be informed by either a reliable charting method or direct notification. A prospective study that follows 79 term infants after vacuum assisted delivery found all delivery related complaints were identified within the first 10 hours of life [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The short-term complications to the fetus from operative vaginal delivery are usually caused by head compression and traction on the fetal intracranial structures, face, and scalp. The most serious complication is intracranial hemorrhage. The relative frequency of intracranial hemorrhage according to type of delivery and labor status was best illustrated in a study of 583,340 singleton infants born to nulliparous women in California (",
"    <a class=\"graphic graphic_table graphicRef63989 \" href=\"UTD.htm?29/26/30124\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/32\">",
"     32",
"    </a>",
"    ]. Similar trends have been reported by others [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/87\">",
"     87",
"    </a>",
"    ]. Other complications include: bruises, abrasions and lacerations, facial nerve palsy, cephalohematoma, retinal hemorrhage, subgaleal hemorrhage, and skull fracture [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/15,88\">",
"     15,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Virtually all of these complications can also occur in the course of a spontaneous vaginal delivery, but the incidence is lower than with instrumental delivery. The reported incidence of each complication varies widely and depends on a number of factors, such as the equipment used (metal, plastic, vacuum, forceps), fetal station, and the experience of the operator.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vacuum-assisted deliveries",
"      </strong>",
"      &mdash; The incidence of serious neonatal complications with vacuum extraction is approximately 5 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/89\">",
"       89",
"      </a>",
"      ]. Torsion and traction of the vacuum cup can cause fetal scalp abrasions and lacerations, separation of the scalp from underlying structures leading to cephalohematoma, subgaleal hematoma (26 to 45 per 1000 vacuum deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/5\">",
"       5",
"      </a>",
"      ]), intracranial hemorrhage, hyperbilirubinemia, and retinal hemorrhage (",
"      <a class=\"graphic graphic_figure graphicRef53176 \" href=\"UTD.htm?15/3/15411\">",
"       figure 2",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/32,48,90\">",
"       32,48,90",
"      </a>",
"      ]. In general, the incidence of retinal hemorrhage is higher for vacuum-assisted than for spontaneous vaginal or cesarean deliveries (75, 33, and 7 percent, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/91\">",
"       91",
"      </a>",
"      ]. These hemorrhages typically resolve without sequelae within four weeks of birth. Cephalohematoma, in particular, is more common after vacuum-assisted extraction than forceps delivery (approximately 15 versus 2 percent) (",
"      <a class=\"graphic graphic_table graphicRef50159 \" href=\"UTD.htm?7/3/7228\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/55,56,62\">",
"       55,56,62",
"      </a>",
"      ]. A study of 913 term newborns who were successfully delivered using a vacuum device, and who had a skull x-ray and head ultrasound, reported skull fracture in 46 (5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/92\">",
"       92",
"      </a>",
"      ]. All of the fractures were linear (nondepressed) and no infant was symptomatic.",
"      <br/>",
"      <br/>",
"      Death from intracranial hemorrhage has been reported. The Food and Drug Administration (FDA) issued an advisory (May 21, 1998) regarding the possibility of two major life-threatening complications following use of vacuum assisted devices: (1) subgaleal hematoma (ie, collection of blood between the aponeurosis covering the scalp and the periosteum; blood can extend across suture lines and beneath the scalp and into the neck) and (2) intracranial hemorrhage (subdural, subarachnoid, intraventricular,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      intraparenchymal hemorrhage) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/93\">",
"       93",
"      </a>",
"      ]. The FDA also recommended these devices be used only when a specific obstetric indication is present and when five criteria could be met (",
"      <a class=\"graphic graphic_table graphicRef69813 \" href=\"UTD.htm?34/12/35019\">",
"       table 7",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Shoulder dystocia also appears to be more common with vacuum-assisted than forceps deliveries [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/56,94\">",
"       56,94",
"      </a>",
"      ]. This is likely the reason that vacuum-assisted deliveries are at higher risk of brachial plexus injury than forceps-assisted deliveries or cesarean delivery [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/87\">",
"       87",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Forceps-assisted deliveries",
"      </strong>",
"      &mdash; Short-term complications resulting from forceps deliveries include skin markings and lacerations, external ocular trauma, intracranial hemorrhage, subgaleal hematomas, hyperbilirubinemia, retinal hemorrhage, lipoid necrosis, nerve injury, skull fractures, and death [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/18,32,89,95\">",
"       18,32,89,95",
"      </a>",
"      ]. Facial palsies (",
"      <a class=\"graphic graphic_table graphicRef50159 \" href=\"UTD.htm?7/3/7228\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/87,95\">",
"       87,95",
"      </a>",
"      ] and depressed skull fractures [",
"      <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/95\">",
"       95",
"      </a>",
"      ], in particular, are more common with use of forceps than vacuum devices; both complications can also occur after a non-instrumental delivery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Long-term",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute fetal injuries with potential long-term sequelae include intracranial hemorrhage (subdural, subarachnoid, intraventricular",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraparenchymal hemorrhage) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/96\">",
"     96",
"    </a>",
"    ] and neuromuscular injury; however, these sequelae are rare.",
"   </p>",
"   <p>",
"    Developmental outcome appears to be equivalent for both forceps and vacuum assisted births. In one trial, 313 maternal-infant pairs were randomly assigned to delivery by forceps or vacuum extraction and followed for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/81\">",
"     81",
"    </a>",
"    ]. There was no difference in child development between the groups. Another randomized trial of 300 women delivered by forceps or vacuum evaluated the infants at nine months of age and found no differences in infant testing results, such as hearing or vision [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/97\">",
"     97",
"    </a>",
"    ]. Both of these trials lacked a comparison to infants delivered spontaneously or by cesarean delivery. A third trial compared neurodevelopmental outcome at age 5 for children born by successful instrumental vaginal delivery, failed instrumental delivery, and cesarean delivery in the second stage of labor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/98\">",
"     98",
"    </a>",
"    ]. Neurodevelopmental morbidity was low with no significant differences among the three groups, but the study was underpowered.",
"   </p>",
"   <p>",
"    One of the few follow-up evaluations comparing outcome at school age after operative or spontaneous delivery among 3413 5 year-olds found no differences in cognitive testing [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/99\">",
"     99",
"    </a>",
"    ]. This series included 1192 forceps deliveries, of which 114 were midforceps. Another study compared the neurological outcome of 295 10-year-old children delivered by vacuum extraction with that of 302 children delivered spontaneously in the same hospital by the same doctors and matched for maternal age, gestational age, and birthweight [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/100\">",
"     100",
"    </a>",
"    ]. Both groups had similar results for tests of fine and gross motor control, perceptual integration, behavioral maturity, scholastic performance, speech ability, and self-care.",
"   </p>",
"   <p>",
"    Lastly, a cohort study of almost 25,000 births did not find any association between forceps delivery and adult epilepsy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/39/15994/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For each patient, the risks and benefits of operative vaginal delivery need to be balanced against those for cesarean delivery and less invasive interventions. Situations where operative vaginal delivery may be preferable to cesarean delivery or less invasive interventions include prolonged second stage of labor despite intervention with less invasive measures, nonreassuring fetal status where expeditious delivery is desirable, and maternal cardiac or neurological diseases where pushing (Valsalva) needs to be avoided. Nonmedically indicated shortening of the second stage is not an indication for operative vaginal delivery. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before resorting to an operative vaginal delivery, the clinician should ensure that prerequisites are met (eg, head is engaged, membranes ruptured, presentation and position known, anesthesia is satisfactory, the fetus is of appropriate gestational age and size, maternal bladder is empty) and there are no contraindications (eg, malpresentation, fetal bleeding diathesis). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Prerequisites'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Forceps deliveries are classified as outlet, low, or mid, depending on the fetal station and degree of head rotation. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Classification of forceps deliveries'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is inadequate evidence upon which to base a recommendation for use of either vacuum or forceps for all circumstances when operative vaginal delivery is attempted. In general, vacuum devices are easier to apply, place less force on the fetal head, require less maternal anesthesia, and do not increase the diameter of the fetal head compared to forceps. By comparison, the advantages of forceps are that they are unlikely to detach from the head, can be sized to a premature cranium, may be used for a rotation, and do not aggravate bleeding from scalp lacerations. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of instrument'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Vacuum should not be applied to fetuses less than 34 weeks of gestation.",
"      <br/>",
"      <br/>",
"      For women who are to undergo an operative vaginal delivery at greater than 34 weeks and have a high likelihood of success (eg, outlet procedure), we suggest use of vacuum over forceps because of lower maternal morbidity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). When success is uncertain, primary use of forceps may reduce the morbidity associated with combined sequential instrumental delivery. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Choice of instrument'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H17\">",
"       'Sequential attempts'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Vacuum assisted deliveries are associated with an increased risk of neonatal cephalohematomata and retinal hemorrhage compared with forceps or spontaneous deliveries. These complications generally resolve without sequelae. Forceps assisted deliveries cause significantly more acute maternal injury and fetal facial nerve injury than vacuum assisted operative deliveries or spontaneous deliveries. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Risks'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The decision to proceed with operative vaginal delivery is ongoing and decided moment by moment based on assessment of the success of the various steps in the procedure. Operative vaginal delivery should be abandoned if it is difficult to apply the instrument, descent does not easily proceed with traction, or the baby has not been delivered within a reasonable time (eg, 15 to 20 minutes) or after three pulls with no progress. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'When to abandon the procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is unclear whether a failed attempt at operative vaginal delivery followed by cesarean delivery is associated with a poorer neonatal outcome than cesarean delivery without the attempt. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Outcome after failed procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although short-term neonatal morbidity varies between procedures, developmental outcome appears to be equivalent for both forceps and vacuum assisted births. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Neonatal complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization, Odon Device. www.odondevice.org/ (Accessed on June 12, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/2\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/3\">",
"      Menacker F, Martin JA. Expanded health data from the new birth certificate, 2005. Natl Vital Stat Rep 2008; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/4\">",
"      Clark SL, Belfort MA, Hankins GD, et al. Variation in the rates of operative delivery in the United States. Am J Obstet Gynecol 2007; 196:526.e1.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Operative vaginal delivery. ACOG Practice Bulletin number 17, American College of Obstetricians and Gynecologists, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/6\">",
"      Cohen WR. Influence of the duration of second stage labor on perinatal outcome and puerperal morbidity. Obstet Gynecol 1977; 49:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/7\">",
"      Myles TD, Santolaya J. Maternal and neonatal outcomes in patients with a prolonged second stage of labor. Obstet Gynecol 2003; 102:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/8\">",
"      Gerber S, Vial Y, Hohlfeld P. [Maternal and neonatal prognosis after a prolonged second stage of labor]. J Gynecol Obstet Biol Reprod (Paris) 1999; 28:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/9\">",
"      Cheng YW, Hopkins LM, Caughey AB. How long is too long: Does a prolonged second stage of labor in nulliparous women affect maternal and neonatal outcomes? Am J Obstet Gynecol 2004; 191:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/10\">",
"      Yancey MK, Herpolsheimer A, Jordan GD, et al. Maternal and neonatal effects of outlet forceps delivery compared with spontaneous vaginal delivery in term pregnancies. Obstet Gynecol 1991; 78:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/11\">",
"      Cheng YW, Hopkins LM, Laros RK Jr, Caughey AB. Duration of the second stage of labor in multiparous women: maternal and neonatal outcomes. Am J Obstet Gynecol 2007; 196:585.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/12\">",
"      Allen VM, Baskett TF, O'Connell CM, et al. Maternal and perinatal outcomes with increasing duration of the second stage of labor. Obstet Gynecol 2009; 113:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/13\">",
"      Society of Obstetricians and Gynaecologists of Canada. Guidelines for operative vaginal birth. Number 148, May 2004. Int J Gynaecol Obstet 2005; 88:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/14\">",
"      Akmal S, Kametas N, Tsoi E, et al. Comparison of transvaginal digital examination with intrapartum sonography to determine fetal head position before instrumental delivery. Ultrasound Obstet Gynecol 2003; 21:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/15\">",
"      Edozien LC. Towards safe practice in instrumental vaginal delivery. Best Pract Res Clin Obstet Gynaecol 2007; 21:639.",
"     </a>",
"    </li>",
"    <li>",
"     Dennen, PC. Dermen's Forceps Deliveries, 3rd ed, FA Davis Co, Philadelphia 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/17\">",
"      Liabsuetrakul T, Choobun T, Peeyananjarassri K, Islam M. Antibiotic prophylaxis for operative vaginal delivery. Cochrane Database Syst Rev 2004; :CD004455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/18\">",
"      Gei AF, Belfort MA. Forceps-assisted vaginal delivery. Obstet Gynecol Clin North Am 1999; 26:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/19\">",
"      Lucas MJ. The role of vacuum extraction in modern obstetrics. Clin Obstet Gynecol 1994; 37:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/20\">",
"      Thiery M. Fetal hemorrhage following blood samplings and use of vacuum extractor. Am J Obstet Gynecol 1979; 134:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/21\">",
"      Roberts IF, Stone M. Fetal hemorrhage: complication of vacuum extractor after fetal blood sampling. Am J Obstet Gynecol 1978; 132:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/22\">",
"      Kolderup LB, Laros RK Jr, Musci TJ. Incidence of persistent birth injury in macrosomic infants: association with mode of delivery. Am J Obstet Gynecol 1997; 177:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/23\">",
"      Zhang J, Bowes WA Jr. Birth-weight-for-gestational-age patterns by race, sex, and parity in the United States population. Obstet Gynecol 1995; 86:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/24\">",
"      Schwartz DB, Miodovnik M, Lavin JP Jr. Neonatal outcome among low birth weight infants delivered spontaneously or by low forceps. Obstet Gynecol 1983; 62:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/25\">",
"      Bishop EH, Israel SL, Briscoe CC. Obstetric influences on the premature infant's first year of development. A report from the collaborative study of cerebral palsy. Obstet Gynecol 1965; 26:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/26\">",
"      Shaver DC, Bada HS, Korones SB, et al. Early and late intraventricular hemorrhage: the role of obstetric factors. Obstet Gynecol 1992; 80:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/27\">",
"      Haesslein HC, Goodlin RC. Delivery of the tiny newborn. Am J Obstet Gynecol 1979; 134:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/28\">",
"      O'Driscoll K, Meagher D, MacDonald D, Geoghegan F. Traumatic intracranial haemorrhage in firstborn infants and delivery with obstetric forceps. Br J Obstet Gynaecol 1981; 88:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/29\">",
"      Beverley DW, Chance GW, Coates CF. Intraventricular haemorrhage--timing of occurrence and relationship to perinatal events. Br J Obstet Gynaecol 1984; 91:1007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/30\">",
"      Murphy DJ, Liebling RE, Verity L, et al. Early maternal and neonatal morbidity associated with operative delivery in second stage of labour: a cohort study. Lancet 2001; 358:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/31\">",
"      Baskett TF, Allen VM, O'Connell CM, Allen AC. Fetal trauma in term pregnancy. Am J Obstet Gynecol 2007; 197:499.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/32\">",
"      Towner D, Castro MA, Eby-Wilkens E, Gilbert WM. Effect of mode of delivery in nulliparous women on neonatal intracranial injury. N Engl J Med 1999; 341:1709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/33\">",
"      Revah A, Ezra Y, Farine D, Ritchie K. Failed trial of vacuum or forceps--maternal and fetal outcome. Am J Obstet Gynecol 1997; 176:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/34\">",
"      Gopalani S, Bennett K, Critchlow C. Factors predictive of failed operative vaginal delivery. Am J Obstet Gynecol 2004; 191:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/35\">",
"      Al-Kadri H, Sabr Y, Al-Saif S, et al. Failed individual and sequential instrumental vaginal delivery: contributing risk factors and maternal-neonatal complications. Acta Obstet Gynecol Scand 2003; 82:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/36\">",
"      Saropala N, Chaturachinda K. Failed instrumental delivery: Ramathibodi Hospital, 1980-1988. Int J Gynaecol Obstet 1991; 36:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/37\">",
"      Ben-Haroush A, Melamed N, Kaplan B, Yogev Y. Predictors of failed operative vaginal delivery: a single-center experience. Am J Obstet Gynecol 2007; 197:308.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/38\">",
"      Olagundoye V, MacKenzie IZ. The impact of a trial of instrumental delivery in theatre on neonatal outcome. BJOG 2007; 114:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/39\">",
"      Bhide A, Guven M, Prefumo F, et al. Maternal and neonatal outcome after failed ventouse delivery: comparison of forceps versus cesarean section. J Matern Fetal Neonatal Med 2007; 20:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/40\">",
"      Hagadorn-Freathy AS, Yeomans ER, Hankins GD. Validation of the 1988 ACOG forceps classification system. Obstet Gynecol 1991; 77:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/41\">",
"      O'Mahony F, Hofmeyr GJ, Menon V. Choice of instruments for assisted vaginal delivery. Cochrane Database Syst Rev 2010; :CD005455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/42\">",
"      Groom KM, Jones BA, Miller N, Paterson-Brown S. A prospective randomised controlled trial of the Kiwi Omnicup versus conventional ventouse cups for vacuum-assisted vaginal delivery. BJOG 2006; 113:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/43\">",
"      Attilakos G, Sibanda T, Winter C, et al. A randomised controlled trial of a new handheld vacuum extraction device. BJOG 2005; 112:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/44\">",
"      Mazouni C, Bretelle F, Collette E, et al. Maternal and neonatal morbidity after first vaginal delivery using Thierry's spatulas. Aust N Z J Obstet Gynaecol 2005; 45:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/45\">",
"      Boucoiran I, Valerio L, Bafghi A, et al. Spatula-assisted deliveries: a large cohort of 1065 cases. Eur J Obstet Gynecol Reprod Biol 2010; 151:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/46\">",
"      Parant O, Simon-Toulza C, Capdet J, et al. [Immediate fetal-maternal morbidity of first instrumental vaginal delivery using Thierry's spatulas. A prospective continuous study of 195 fetal extractions]. Gynecol Obstet Fertil 2009; 37:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/47\">",
"      Sjostedt, JE. The vacuum extractor and forceps in obstetrics. A clinical study. Acta Obstet Gynecol Scand 1967; 46 Suppl 10:Suppl.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/48\">",
"      Baskett TF, Fanning CA, Young DC. A prospective observational study of 1000 vacuum assisted deliveries with the OmniCup device. J Obstet Gynaecol Can 2008; 30:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/49\">",
"      Vacca A. Vacuum-assisted delivery: an analysis of traction force and maternal and neonatal outcomes. Aust N Z J Obstet Gynaecol 2006; 46:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/50\">",
"      Gardella C, Taylor M, Benedetti T, et al. The effect of sequential use of vacuum and forceps for assisted vaginal delivery on neonatal and maternal outcomes. Am J Obstet Gynecol 2001; 185:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/51\">",
"      Whitby EH, Griffiths PD, Rutter S, et al. Frequency and natural history of subdural haemorrhages in babies and relation to obstetric factors. Lancet 2004; 363:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/52\">",
"      Ezenagu LC, Kakaria R, Bofill JA. Sequential use of instruments at operative vaginal delivery: is it safe? Am J Obstet Gynecol 1999; 180:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/53\">",
"      Murphy DJ, Liebling RE, Patel R, et al. Cohort study of operative delivery in the second stage of labour and standard of obstetric care. BJOG 2003; 110:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/54\">",
"      Alexander JM, Leveno KJ, Hauth JC, et al. Failed operative vaginal delivery. Obstet Gynecol 2009; 114:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/55\">",
"      Johanson RB, Menon BK. Vacuum extraction versus forceps for assisted vaginal delivery. Cochrane Database Syst Rev 2000; :CD000224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/56\">",
"      Demissie K, Rhoads GG, Smulian JC, et al. Operative vaginal delivery and neonatal and infant adverse outcomes: population based retrospective analysis. BMJ 2004; 329:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/57\">",
"      Liu S, Heaman M, Joseph KS, et al. Risk of maternal postpartum readmission associated with mode of delivery. Obstet Gynecol 2005; 105:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/58\">",
"      Meyer S, Schreyer A, De Grandi P, Hohlfeld P. The effects of birth on urinary continence mechanisms and other pelvic-floor characteristics. Obstet Gynecol 1998; 92:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/59\">",
"      Meyer S, Hohlfeld P, Achtari C, et al. Birth trauma: short and long term effects of forceps delivery compared with spontaneous delivery on various pelvic floor parameters. BJOG 2000; 107:1360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/60\">",
"      Fitzpatrick M, Behan M, O'Connell PR, O'Herlihy C. Randomised clinical trial to assess anal sphincter function following forceps or vacuum assisted vaginal delivery. BJOG 2003; 110:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/61\">",
"      Pretlove SJ, Thompson PJ, Toozs-Hobson PM, et al. Does the mode of delivery predispose women to anal incontinence in the first year postpartum? A comparative systematic review. BJOG 2008; 115:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/62\">",
"      Dell DL, Sightler SE, Plauch&eacute; WC. Soft cup vacuum extraction: a comparison of outlet delivery. Obstet Gynecol 1985; 66:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/63\">",
"      Hankins GD, Rowe TF. Operative vaginal delivery--year 2000. Am J Obstet Gynecol 1996; 175:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/64\">",
"      Rajasekar D, Hall M. Urinary tract injuries during obstetric intervention. Br J Obstet Gynaecol 1997; 104:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/65\">",
"      Angioli R, G&oacute;mez-Mar&iacute;n O, Cantuaria G, O'sullivan MJ. Severe perineal lacerations during vaginal delivery: the University of Miami experience. Am J Obstet Gynecol 2000; 182:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/66\">",
"      Landy HJ, Laughon SK, Bailit JL, et al. Characteristics associated with severe perineal and cervical lacerations during vaginal delivery. Obstet Gynecol 2011; 117:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/67\">",
"      Macleod M, Strachan B, Bahl R, et al. A prospective cohort study of maternal and neonatal morbidity in relation to use of episiotomy at operative vaginal delivery. BJOG 2008; 115:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/68\">",
"      Robinson JN, Norwitz ER, Cohen AP, et al. Episiotomy, operative vaginal delivery, and significant perinatal trauma in nulliparous women. Am J Obstet Gynecol 1999; 181:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/69\">",
"      Kudish B, Blackwell S, Mcneeley SG, et al. Operative vaginal delivery and midline episiotomy: a bad combination for the perineum. Am J Obstet Gynecol 2006; 195:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/70\">",
"      Youssef R, Ramalingam U, Macleod M, Murphy DJ. Cohort study of maternal and neonatal morbidity in relation to use of episiotomy at instrumental vaginal delivery. BJOG 2005; 112:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/71\">",
"      Hudelist G, Gelle'n J, Singer C, et al. Factors predicting severe perineal trauma during childbirth: role of forceps delivery routinely combined with mediolateral episiotomy. Am J Obstet Gynecol 2005; 192:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/72\">",
"      de Tayrac R, Panel L, Masson G, Mares P. [Episiotomy and prevention of perineal and pelvic floor injuries]. J Gynecol Obstet Biol Reprod (Paris) 2006; 35:1S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/73\">",
"      de Leeuw JW, de Wit C, Kuijken JP, Bruinse HW. Mediolateral episiotomy reduces the risk for anal sphincter injury during operative vaginal delivery. BJOG 2008; 115:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/74\">",
"      Murphy DJ, Macleod M, Bahl R, et al. A randomised controlled trial of routine versus restrictive use of episiotomy at operative vaginal delivery: a multicentre pilot study. BJOG 2008; 115:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/75\">",
"      Frankman EA, Wang L, Bunker CH, Lowder JL. Episiotomy in the United States: has anything changed? Am J Obstet Gynecol 2009; 200:573.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/76\">",
"      Kudish B, Sokol RJ, Kruger M. Trends in major modifiable risk factors for severe perineal trauma, 1996-2006. Int J Gynaecol Obstet 2008; 102:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/77\">",
"      Damron DP, Capeless EL. Operative vaginal delivery: a comparison of forceps and vacuum for success rate and risk of rectal sphincter injury. Am J Obstet Gynecol 2004; 191:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/78\">",
"      Wu JM, Williams KS, Hundley AF, et al. Occiput posterior fetal head position increases the risk of anal sphincter injury in vacuum-assisted deliveries. Am J Obstet Gynecol 2005; 193:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/79\">",
"      Benavides L, Wu JM, Hundley AF, et al. The impact of occiput posterior fetal head position on the risk of anal sphincter injury in forceps-assisted vaginal deliveries. Am J Obstet Gynecol 2005; 192:1702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/80\">",
"      Bashore RA, Phillips WH Jr, Brinkman CR 3rd. A comparison of the morbidity of midforceps and cesarean delivery. Am J Obstet Gynecol 1990; 162:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/81\">",
"      Johanson RB, Heycock E, Carter J, et al. Maternal and child health after assisted vaginal delivery: five-year follow up of a randomised controlled study comparing forceps and ventouse. Br J Obstet Gynaecol 1999; 106:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/82\">",
"      Bahl R, Strachan B, Murphy DJ. Pelvic floor morbidity at 3 years after instrumental delivery and cesarean delivery in the second stage of labor and the impact of a subsequent delivery. Am J Obstet Gynecol 2005; 192:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/83\">",
"      Handa VL, Blomquist JL, Knoepp LR, et al. Pelvic floor disorders 5-10 years after vaginal or cesarean childbirth. Obstet Gynecol 2011; 118:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/84\">",
"      Bahl R, Strachan B, Murphy DJ. Outcome of subsequent pregnancy three years after previous operative delivery in the second stage of labour: cohort study. BMJ 2004; 328:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/85\">",
"      Melamed N, Ben-Haroush A, Chen R, et al. Pregnancy outcome and mode of delivery after a previous operative vaginal delivery. Obstet Gynecol 2009; 114:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/86\">",
"      Smit-Wu MN, Moonen-Delarue DM, Benders MJ, et al. Onset of vacuum-related complaints in neonates. Eur J Pediatr 2006; 165:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/87\">",
"      Werner EF, Janevic TM, Illuzzi J, et al. Mode of delivery in nulliparous women and neonatal intracranial injury. Obstet Gynecol 2011; 118:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/88\">",
"      Doumouchtsis SK, Arulkumaran S. Head trauma after instrumental births. Clin Perinatol 2008; 35:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/89\">",
"      Robertson PA, Laros RK Jr, Zhao RL. Neonatal and maternal outcome in low-pelvic and midpelvic operative deliveries. Am J Obstet Gynecol 1990; 162:1436.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/90\">",
"      Wen SW, Liu S, Kramer MS, et al. Comparison of maternal and infant outcomes between vacuum extraction and forceps deliveries. Am J Epidemiol 2001; 153:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/91\">",
"      Emerson MV, Pieramici DJ, Stoessel KM, et al. Incidence and rate of disappearance of retinal hemorrhage in newborns. Ophthalmology 2001; 108:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/92\">",
"      Simonson C, Barlow P, Dehennin N, et al. Neonatal complications of vacuum-assisted delivery. Obstet Gynecol 2007; 109:626.",
"     </a>",
"    </li>",
"    <li>",
"     Center for Devices and Radiological Health. FDA Public Health Advisory: Need for caution when using vacuum assisted delivery devices. May 21, 1998. www.fda.gov/cdrh/fetal598.html (Accessed 3/26/2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/94\">",
"      Caughey AB, Sandberg PL, Zlatnik MG, et al. Forceps compared with vacuum: rates of neonatal and maternal morbidity. Obstet Gynecol 2005; 106:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/95\">",
"      Dupuis O, Silveira R, Dupont C, et al. Comparison of \"instrument-associated\" and \"spontaneous\" obstetric depressed skull fractures in a cohort of 68 neonates. Am J Obstet Gynecol 2005; 192:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/96\">",
"      Schot MJ, Halbertsma FJ, Katgert T, Bok LA. Development of children with symptomatic intracranial hemorrhage born after vacuum extraction. J Child Neurol 2013; 28:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/97\">",
"      Carmody F, Grant A, Mutch L, et al. Follow up of babies delivered in a randomized controlled comparison of vacuum extraction and forceps delivery. Acta Obstet Gynecol Scand 1986; 65:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/98\">",
"      Bahl R, Patel RR, Swingler R, et al. Neurodevelopmental outcome at 5 years after operative delivery in the second stage of labor: a cohort study. Am J Obstet Gynecol 2007; 197:147.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/99\">",
"      Wesley BD, van den Berg BJ, Reece EA. The effect of forceps delivery on cognitive development. Am J Obstet Gynecol 1993; 169:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/100\">",
"      Ngan HY, Miu P, Ko L, Ma HK. Long-term neurological sequelae following vacuum extractor delivery. Aust N Z J Obstet Gynaecol 1990; 30:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/39/15994/abstract/101\">",
"      Murphy DJ, Libby G, Chien P, et al. Cohort study of forceps delivery and the risk of epilepsy in adulthood. Am J Obstet Gynecol 2004; 191:392.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4474 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-201.77.166.39-CA557B663F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15994=[""].join("\n");
var outline_f15_39_15994=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PREREQUISITES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Minimum and maximum estimated fetal weight",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H98685947\">",
"      Upper threshold",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H98685955\">",
"      Lower threshold",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ALTERNATIVES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TRIAL OF INSTRUMENTAL DELIVERY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLASSIFICATION OF FORCEPS DELIVERIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CHOICE OF INSTRUMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Vacuum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Forceps",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H623906680\">",
"      - Spatula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      APPLICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vacuum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Traction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SEQUENTIAL ATTEMPTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      WHEN TO ABANDON THE PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      OUTCOME AFTER FAILED PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      RISKS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Data from comparative trials",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Maternal complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Short-term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Long-term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Risk of recurrent operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Neonatal complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Short-term",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Long-term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/4474\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4474|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/16/6401\" title=\"figure 1\">",
"      Correct position forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/3/15411\" title=\"figure 2\">",
"      Neonatal extracranial and intracranial birth injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4474|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/48/44800\" title=\"picture 1A\">",
"      Piper type forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/7/125\" title=\"picture 1B\">",
"      Delee Simpson type forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/15/16624\" title=\"picture 1C\">",
"      Kielland forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/13/40144\" title=\"picture 1D\">",
"      Elliot type forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?32/29/33232\" title=\"picture 1E\">",
"      Luikart forceps",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?42/49/43792\" title=\"picture 1F\">",
"      Tucker-McLane forceps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/4474|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/4/69\" title=\"table 1\">",
"      Mnemonic vacuum extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/29/17883\" title=\"table 2\">",
"      Morbidity rate after failed forceps vacuum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/54/15211\" title=\"table 3\">",
"      Incidence of intracranial hemorrhage by mode of delivery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/60/16331\" title=\"table 4\">",
"      United States birth data by delivery type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?29/26/30124\" title=\"table 5\">",
"      Birth trauma by delivery type",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/3/7228\" title=\"table 6\">",
"      Birth outcome data New Jersey",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/12/35019\" title=\"table 7\">",
"      FDA advisory on vacuum",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/2/11306?source=related_link\">",
"      Abnormal labor: Protraction and arrest disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/42/13992?source=related_link\">",
"      Approach to episiotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42697?source=related_link\">",
"      Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/56/9097?source=related_link\">",
"      Fecal incontinence related to pregnancy and vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11768?source=related_link\">",
"      Fetal blood sampling",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/38/31337?source=related_link\">",
"      Fetal macrosomia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/57/20374?source=related_link\">",
"      Intrapartum management of the low birthweight vertex fetus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/18/19753?source=related_link\">",
"      Pelvic floor disorders associated with pregnancy and childbirth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/57/42903?source=related_link\">",
"      Procedure for vacuum assisted operative vaginal delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/1/16408?source=related_link\">",
"      Timing and route of delivery in pregnancies at risk of shoulder dystocia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_39_15995="Classification SRs to SCIT";
var content_f15_39_15995=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F67718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F67718&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Classification of systemic reactions to subcutaneous immunotherapy (SCIT)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        AAAAI/ACAAI Surveillance Study",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade I &rarr; Mild systemic reactions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Generalized urticaria and/or upper respiratory symptoms (eg, itching of the palate and throat, sneezing)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 2 &rarr; Moderate systemic reactions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asthma (eg, PEFR falls 20 to 40 percent) with or without generalized urticaria, upper respiratory symptoms, or abdominal symptoms (nausea, cramping)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Grade 3 &rarr; Severe life threatening anaphylaxis:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe airway compromise due to severe bronchospasm (eg, PEFR falls more than 40 percent) or upper airway obstruction with stridor, and/or hypotension (with or without loss of consciousness)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    AAAAI: American Academy of Allergy, Asthma, and Immunology. ACAAI: American College of Allergy, Asthma, and Immunology",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15995=[""].join("\n");
var outline_f15_39_15995=null;
var title_f15_39_15996="Cyanide sources";
var content_f15_39_15996=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F76365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F76365&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sources of cyanide",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Industrial exposures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plastics production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Photography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fumigation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pesticides/ Rodenticides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Synthetic rubber production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fertilizer production",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metal polish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hair removal from hides",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Electroplating",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Metallurgy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Plants and fruits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bamboo sprout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Macadamia nuts",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hydrangea",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rosaceae family (plum, peach, pear, apple, bitter almond, cherry)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cigarette smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Phencyclidine synthesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Artificial nail glue remover",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Product tampering",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suicide/ Terrorist attack",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium Nitroprusside",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Laetrile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Combustion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wool",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Silk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyurethanes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Polyacrylonitriles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nylon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Melamine resins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plastics",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15996=[""].join("\n");
var outline_f15_39_15996=null;
var title_f15_39_15997="Formation of porphobilinogen";
var content_f15_39_15997=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77451&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Enzymatic formation of porphobilinogen",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 253px; background-image: url(data:image/gif;base64,R0lGODlh9QH9ANUAAP///4CAgP+AgAAz/wAAAKCgoMDAwICZ/0Bm/8DN///AwEBAQODm/9DZ/6Cz/xBA//Dz/5Cm/yBN/1Bz/2CA/9DQ0DAwMGBgYODg4PDw8LDA/zBZ/7CwsBAQEHCN/yAgIHBwcJCQkFBQUP9AQIBAQKBwcJ8wMKBgYN9mgF8fnz9G34BZvwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD1Af0AAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7i5uru8vb6/wMHCw8TFxsfIycrLzM3Oz9DR0tPU1YQMEQcOEEIQ2RHcQwkHBwlDDQncEAkN1u7vUQ4D8wMIAA0PDwgDD+0AFAM2SBhAQcg+cwnqwVvI8AgDfuYaHAAwsF2DARIAyJsgZMIABwAOAkhor6FJhhEGeCByccOQDQMaeNQgRMMAjvsoHABY8qRP/2sHBkwUp9DggAQiRyrcR6/oz6fS5PVkAIHfkAcDIHgYEEFIypUiSUIdG20gggMT7G2dkMDjSgb5HDjIxyDkUaU9yepVxsAjxq4ADgyUMPSe3wn+wjrdy7ix48eQI0ueTLkyJwMGLGuGFiDA5s/MOoMejUw06dPDTKNe7Us169e5XMOeTUs27duvbOPerUo379+lfAMfDgoz8ePIk//Gpo0bOnXsapIzp7x6Inn07Cm2l5AeTeucmG/r9i2ckHHlzqUDsM5ftYcPIk7cDoCBuZR5wV/CPs8ePn38+AOQQAQZhdBi03xVRE47LSZPQfphAp98FMV0D0Ya3dTRR3YdmP+fNEEVZlRTPUEgwQN1RXiJgucE9FJMM9WkIYM8uSPVEHXRd8+J7qlYSYhEiGVgUmIxld07ZqGl3V1iJYCVTiL6KMmNQlBllRBYacWVVyp1iNc7fc0jQVf0BdWUlJYkmRYAa7XVJVwPyEWXl0KiaecaYf4lhGAYFSbTPIgZ+OWdhBZq6KGMGJdLBor6gVmjiFIiXCwgEEAAB39YamkHFUQqqWe5fGDpBUMYcMECF3Rqh6UAhECACAAEUEAFoHrKyKSvcEBACB0QkAEABhBgQQAL1EoHq8EuAAABvRIwC6Sa4erKBQRgQG0BAIhQrRAY3GFpABYQgK2wtUj7mLmrZGD/6QKiWgDAAs7qse4C2C6rbG3GRpvvLK5e0FmvFfRrALppsEoEAffOQjBjC6MS7q8AVApCrKJ2gOmq8Q6BcLn7Vtawrbd2TNnHICtC8lgnl3xIyk+xrDIhLvsU88uBQGvZzDTnPAXOOvfshM0+Bw0V0EIXnQXPZBDdinjOrdeedOkZ7QfSY1C9H4l0KtTdPN89xfQ9TkcHgAbTKSzyHVZXMuE98zGpkH0A4AcVf0u5zV1TXed2th1pU8LiEDQ6WOBPa0uUtT1wyx1L318wLgmQRBjZ3xAmovjU30bpVOMQD8rieBefQ0JlfYcL0QCPUEEOeFNOVZ4iLKFvEfsjai7p/+FIT5Lz1Og52m066p7vXcfsjuQ5Zulm0gNV7aU7SZDuiwtPB/FSY2E8mb4nP0/wf1BfvUneWxH+9wuNT4X55LuDvhTrI6K0ZO/j0j4U8xtSfzH3Q5I/E/sL0n8w/7tVsTpDwAIa8IAITKACF5jAYtkigL+AoMkGyMAKWvCCDHQgx0YjwUR0EFiZiZX0ejPCKyhAAChMoQoVgIQTqvCFLDyCC1+YwhgaYYY0FIANi4BDGu6QCD2EYQtR+MMofHBloIofG0xzRD2ELogrHGIOiSjFKRZRCFCsYRVzeEUAZJGKMhTACAQgvhLiSwgBZKIZT9HEUKCwjMJQI9pA1UY81P/xE2+swh39R8c1nkGOGzRJHs/nx+ihsZBlAOQZBUlGPSJSb4ecYyRroUQsKKCLsBjkFCoZyDT2sSGapEUoq6HI6X2SIaMUB3XsUxcIOIAcr8NjI99RyjnU0h2pFML2AiMUXs7DcqC4ZPlOOTxiyuJrYcglAHYJpATUxSNRUgQDyAESIgwMgxUMYX2yMZ7WGNOW33wF3T7EBWXOgxz7EBFAqskIeUgAJhswzzWxucAQjjOC4YzDLZcGEbYdYZ70PCAJSFBAbS6TdX5yUSMeIgFupARCYChcNGOTTzjskxWY+2dAEzjQghKBmb3UyAPi6QgWVeUBYsioNydZTJbCQnX/YzDnAPbUy5Q8wAPaaITqdgmsjSowMzCVA6O0yShVWdMAEAMhJ81w0Tc0VRW8E4NMadq2IzHCJhy5kEuEAFCfejSqcajUpbi6MSLoigATE4KmmFUvi1bUqW9dBfOSOUtRwOQAGoBJ3r4wVziIigCkAlZZh0AtAnxAY87CQLgM2oanNjauqrieGIRJCghQACsb2OsXJAsHXfHKV4JNGADUJQJtXcxgBXiVPiG7RNamTwuUVQS1rCWu0BIhtQVIbWANlqzVuhScv30tGJQpCHUhrF22HUK4LBAu0KIWsL4VoSSlK9yY1vUQ/foXASoQrA90ZlYI60y4QrAsAhigAB3o/0C33Brc6O7RTsRlwlLJ8DAhSCxYmlpApS6mK3etVQRGhWt72Uvd6tIVjgB0rRocu4r5OiO+S3hvFjCQVDEweA0XToWENwFhJWz4ChfowAUuFoYMp8HEbHykMjqchA9b4a+GBUGAuYDiPyoYFU+cIhhvqGMdbtGHPxZiGHXcxS/6OIxjRHAm1qopC4RgvbK7MRpqHBwVP8HIRe5xlokc5CgO2Ypd1uKQMdmE+nXVqxhkMpNFUIAKI9iTA3aFi2Fn5S2cGc0WVPN/24oFKidSyk2glayMwN1fFVUIHOiMNjEQggCQ2I51llmkB6FnJ0NZC34mQ6a5la+1pnUI8MpMb//xaylMYSC94fr0dD8zZyrA+AMyBsOmLQzoIgSrCNiqgMFAbV7bYiAzrlJWpcjbKzebkoOTFkSIR1y1Wv85zk24tREwYNgiwMtf1BKtbt/V61DnodVyTnYgKPzsAh/b3FCA11qNZVprMzlhGfiAermdGW9DGtlxdLam9c1dV2FmvRmAF5+F4O3eAqAC8lZVu8M143OzWtwphvZjJb4EaXMrXAO8dME3ZoBe+cszqRWBrg77bYgPM98Ux7C+hVAB0ZLaUgbduLICwGT79soCDXf4ZsBd8pQveOWh4DkrhD5dOKPbkKAhOt+AXmKmf0LpGjZ5lX1+Yqd7Auo4ljopZt3/dKpHPOlaHwXXZW31TjhYL1gH7tHdG3YDa+HsdPa6jeXu9siMvXFlrztU7u4Fvuu9ZXmnceD/bj1uNg06/iBb1JBu9LQj6p702doANDv0wWPa8oSfgkRLlzgEtcLvgqf7KJA5mYwGLi+dY3zb37z6KWGNMkGVXOtOFMtwi37f9lX1KzZPmajq6HT9kEUBmIstOON2FiqlDPMin7uJpiK1IKhUAeCetPPWdhZBrYxky8S6VxwfAN+/Q/hlAdbM42H8459D+mXRV/PXYf3rf0P8Y8FZJOTW/WqY//zXsH9g9P8d9/cL/fd/ZkCAAnh9J2GAwoeASaCAYeCAvgCBziCB/66ggBS4BRd4CwEIfgwIgB2oCxCYgVcggqrwPuFHgsSAgqhAgSoYBS34dQ2IgC8YgR+YCxk4g0yAg1O3BCdYg8+gg4tQaKNlAKoiaHwmaCS2gVMAhEfAhGI3Qj04cD/og6Egc2qlKWlVWN+CgVSoBU74hE4QhdLwhYlgheB3cKySWhbQLRwghVbwhWQoCgQjhlPohqRwbQGQbURAbYfVbmDAhHEoh2tEh8wQiIigbvlFBO1mb3/YhUvoiLvQMISYDIZ4iL1mcAF3fdRSK5fGhXb4iJ+4Ui4og5BIg6F4h5e4MYoVXgGAAdQGWOASdi1YiYIIikNAi6GAi4dghS93if/NZQGMxQUoqIugcDKTKAzEaIpVkIxPp2LHeICn6BMXyIzN+IakGI22QI3QOIrYiE8jeI3+V4q5QH1S4IDaWI3f2Fbn+AjreAnEY4Dt2Akz84zZKI66QD0EqITLgDM9WAJc9mVcFGY7xkNaJpBHxmNgloP2eI+tZwQBOFTcglTTwDM9aAIJiZAXSZD/iJEBCZBA5pEplGQ8uJAM2Qb4RV40F4zNQI5NeH0KcAIkiQmxZX8xSVEmuSkZkJKacXwopI+wEI+agD7J8io6uZPiwmIrWJMlyQbBkocI02ubkVoWWQtAuQlCSQABkAHNopK68BzsITYSkVPnQA6UhwWpVQL/tFCVVtmQSdCUsQJzwaAjTbES/9AUzncFJaCUn+CTysCSV+CWACAqXJkLOgISFzFT8rABdaEB7FROJtCN+KcZp0cEDAUAMSJV15UJCbBKzgQ1nOkP6BCZjCB7eREjSXFgnQBSEyF5NGEm7bAPorkIOgIB+1BNAFEYtacFqTRNYhkJqlkf9zEAKqAAZrIksakI9MEAMHEWB8AAD/E8G3CXVjBK7gRP5uEI53QA6UQE8pACAhAU+xABsHkbh3ZwEgkMkcc6CAETAUEdXTCT9YERDjU4j8A6IcUeJ4IC33kUJwITuGFwjLgaJnUl9TlTvDQUwNcAKBQUm6k8twGgUMka/ztloAVKVbjzPCuwn+bAFP9pWJ0hmLCBVaajUBV6oL5EDxoanxQ6G70YoaxxV3k1eZ6AlKgBoYMJGpaFWWV5CTR6GjYqDX6JCz1KGj8aDY7nB0N6nI9wpH2QpEraCI4Dn6YgpU+aCY7jpFVKGleamVn6G1vapcjxpWBKHFc6RmLGkR+JpkKmpl7GpmeqkRk5pkG5ej20ZXE6BFhmkHbakW46kHJqpWz5p14aqIK6G0xaqNRwqIgqDYq6qJxBqI7aBY+iTdz1b3vYaCGQc8TQqPi3VpzCbZpCXhx4XC5qDJzqfqziKrASarqiLNT2qQDAAZqKcpEqCMiyMdcmAhbTKv9o9Qynan7fEi7YAi/MtTE05xmacqPA8KuZNy/14m2synGLpQzMSni7RnC7wgG90i3hcgEGMK3JUK1/d62galgXkwEhxiwi0InFEKS1+q7wGq/yOq/0Wq/2eq/VsZnQUResdB7UEZaNia+4AShKMRGQs0tzKbC8QQ8NarAhtUuGyVMKSxsB8QASYBMOy5wSW5kTexv1IBW9pD0Se5kdOxt1E7IPa6C0ySElS7F3g7JDsT3KWQ+w1LKwURS3aaIHpRRN4Z42+7NAG7RCO7REW7RGe7RIm7RKu7RM27RO+7RQG7VSO7VUW7VWe7VYm7Vau7Vc27Ve+7VgG7ZiO7ZkW7YJZnu2aJu2TxoEADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This schematic diagram shows the enzymatic formation of one molecule of the monopyrrole porphobilinogen (PBG, in black) from two molecules of 5-aminolevulinic acid (ALA, in blue), under the catalytic direction of the enzyme ALA dehydratase (ALAD). Bond lengths are not to scale.",
"    <div class=\"footnotes\">",
"     Ac: acetyl; Pr: propionyl.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15997=[""].join("\n");
var outline_f15_39_15997=null;
var title_f15_39_15998="Pathogenesis of MEN 1";
var content_f15_39_15998=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F52594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F52594&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 562px\">",
"   <div class=\"ttl\">",
"    Steps involved in tumor formation in patients with MEN1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 542px; height: 252px; background-image: url(data:image/gif;base64,R0lGODlhHgL8ANUAAP///4CAgMDAwAAAAEBAQPwBKAAzmYCZzDAwMPDw8CBzOdDQ0ODg4FBQUGBgYCAgIKCgoHBwcLCwsJCQkP6AlBAQEPv+1AAz/5C5nIuL74CZ//t/fjBZrCBNpsDN/8DN5vDz+UBm//Dz//7Ayr5NehBA/yBN/+Dm/7DA/zBZ/9DZ/2CA/6Cz/8jczlBz/3CN/5Cm/8XF91CGg1NovQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAAeAvwAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2t7iHDBEPA76/wMHCw8TFxsQIEQy5zM2pCRG+CAEC1dbX2Nna29zd2QEIvhEJzuXmnQnhCAKBAurk56QMEwEQ5AQRhgILRQvs8VbSDXBQyMEABPAAfoIAjACAAQ4HLQgAcQgDCBUGKKwSjaAhg/k2dmIwoAK7iQ8JTCDggFw9lNBY8gMAIYAEfAkcEJgpoYHK/yEr8S1b2UCCEAE2GzRIEIAABCEMdDqYOYSAr4gAKPoSKYUkgkThlnHVNGFAyCHSehEsuRVBBXAVlll90KvCXAASBjSIlg8kOAF8GwwwSrFCOMMZGTAwHKBCBSMCKhLZOvZJtH+HIp+tbIligCIVE1Q8KGSBWbwDJgCwCiDyZ9aCybkFILgBNQCGAYhukHUAu4oUBZR10NR3kchYhVDmzOTBV0UInjOvxBDrMsmjI7puPeC1xu2sWa/WmDPcYOwOg6fsjXRggPdihyAHrXH6ku6LKNq31ItAAJ/rrScZbg8IIBg/rIGnUVk26QWAAxMAlppgElCkmnrA+WYaAhIARv8VAAuUtQ45DETmW3z7gYYZIpGlSAkDgg3wgGroBQhiOA88NR533gkRQUZLZZVRBfkkIBiRQmCYnnESmIcAilb9wo5WvnzmooqLtHjlllx6Ud8iX3Yp5phThJmImWSmqSYSaB7S5ppwqvlmIXPGaSeXdQ6S55182rdnIH/2KShXgR7xwQdcHIpFoYM2eg6jRRxwABeSLuropdNBSkSlW3BqhaaYGqLoFqOGygSoQniahapUoGqqIKxeEeurRrg6axW3QuEqrX/kOoWvvNo6aafDfsrrJMBGkeyrwlJabBW7HsvHsk9QG2qzxFoqLSTWNtHtpdhq8e0R0W6bx7hKoDv/aLirPtuquY+oi4S8fbKLBb3KwesIvpG6C6+9svorRbn61sHvpgJvC7AV/BJc8BwHDxExnAvjmrCuDy8yMQAby2mxs9pmjMjGHadZMRUNi5wIyRcfe/KvLTvhsMpusCzyy1KkTLMhNmeMs7IxNzHzzmv0/PDPUOhM9CBGF4x0tUGfujQhTev7tBNKTw1I1f9+nO0VQ2ttBtfmXu1t1PeJHQjZCnstLtpKhK32GGxLi+oBHRigdwdwz5v33n1PNnevgS9RMpmagsCB3ozrzQEIUyjeOOOPDzy4H3W7LMXik1M+BeedG8CB5ZfvgTfjfMv6twGpd5106I0HfgDsjAcu/3fpW0jeeeVS6D4573ZHsTrsHQhP+95R3C6KCh4037wKJ3hwghDNU++BCEIwP70QLGigwfYAOH99JKDv/jnto3dZQQMTfEj6E8czHkX8eidfy/rtIxHCBfzzH4IGF9CAEPg3wAvAAAAn4J8ARZCCC4SgBBdgQQH7h4J4xU92F+wSMB7gAAigSGbzo18I42c/Wmywgyhi3gousAIPqACAAgQAAWV4ARMA4AUKBMAKDygCE1xgegRkgQMfMbzQFQ8KRezcEcHwniY68YlQjKIUp0jFKlrxiliUIjIiYBQQQoF+Bhjh8Ur4hCya8YxoTGMWt9hFAMBQCG+k4QB9iIIS+P9QgBDE3g0NKEcYsPARYBQj7cSgxkIa8pCIfA8x/OO+uBnveEt0QhInF0mhRSGRmMykIRcZAKrEMY4zdKALSlCCN87QjQGkIf9SoMdGBPKLIsTTL5LRRoy97ngYxCUZZQEMWh7hk6mUowxDgIILvOCNDVSBEFxwgQryD4cmaCUjXgm/WG6Jgx40VhTK97vzwS59tpwFNj9YhDh6oIYeAGAIBrjO672xmClAAQBTUEAA7M8FRIxfJZkwycbt01SJ46bjINc7gYqOoOGMRxwBwAIfXsAFehwiHIOJggaWYAURvQACISjBRsxOl7ekXeHidLfVtQ5XJh3pQ3CHB4M6zpv/oQOnGBJQkwmQswqKMYXZmJA1KQggPj+tQgIaGYWc7ORYvmsc8KCQVMohVAzTEM4DriCAiEBAR6TYqeFUKjhoaQc/kEkOEapams1MAUK62dbpAKc61HE1CmQVAjwgwBKx2AQnOmFHVAjQAH4E4AHUqIZudDIOUGg1XW/NF7QcwA4HEIcmy7hIVgD7U530dbLUkCxT/EMOAUggr0XY61MYwEErqTWx/VJDAogkgLkuRQBTfchTlMKABUy1tiCaKgTWwYD3AAABT5EAUTNx2CT0NHkLaACMfEsAdpB1tz/FrW1pwluyPjYABGlKbWM7hAIZyR4IiBC8MheG3hKgAgRp/8A/jlof366UJjr5TkTeswDphKK480LtrjRCgOYy17kOiSt8E6QdhzxGCI9xb5gWoB3eNFdf5CVDgR68mt8kyUoaiYADrtOa+VJDrJ/A7xGOizGy/rfDKAaAhjkcV7J+SSMKHmuBKwxh1CJMDf6Q6wPmUaTYthfDqzEKSVrznPesdhkJuClx3daukJWJCL4tCk0C/BwCCPk7zyGrlA2UFSAToQIuUQ2FzRVhL8DoAQTg0GCj08Uf58u2+KhPf2vymSb1V8mYELERSPyEMPkWtiyJyJzhHA0hzJmsDO6vX708hCYhoCU0Hq+NJTZpijH5XvplqR7KDNBLB8zJmjZYpf85NmqPoWzUfA41HDh9rSqUqslgU/UdWP2FCBDV1koYKhTMqoWcBkQnw82C8mAG6i2AWA3zsMmraO2FMRPB2Wgp6xMkwOsluNcI7r3qFdCaEC9BLNNbeDEcJAABA5n2UszWgoEaUKDB+sfQJ/GJUVzjwadsNgAkqslPhLDh1nx2JzfxiJUE298AlMgnkC54ifSqEx1BoCfKPY5S9FpaMQw7Z+Cmwrqd252nDIYlctWJlSAQohWt2+DuHjnE7coSciT33fI5tqDSjQUGPCkd7FiHil/z05s3lyT7sO5nsNsa7+5YN0UmQG0rMFuPX/hBjB3qUAji2Nb61rsNeApOJuD/EajsmLQMSId4w3BxoBX7CWBPu4ZkS5un6DwCr6GsRW6u87e/Zhxc3zleDLyABKhGrlIOFc2vMIGQNNe279FJhVfynnfXh6wHxk2KH6ztLivWt252r98bgID0WIm+DaaxgAFAjySJeUVfKHsRRkCB1rv+9SQgwetn//oROJIKpc8KjaLdZcRj1yHQLjy8fa/4B0O+iRp5QARaCxUrLxvVpW6Ce5vrDmsgCCmMrQaHUSzuuD4YIU9/L+af7t7wJsDEn//wUYAPYCinP9JkRwMFCkD/DdC/APav//3zj//9F4ACtzcF7jV+l0cN61AN11cE01cNB7gPoucQvmENujEB/w0AZq1xbpgyeFZwE0IwIhUwE9cHW/DADwPQWQ6xZbzhfZU1BDFmeRZ4XSFRglOWFSHhWxYYAKeXYqVRZQlocfJHfxZwf0EIhEJYhET4fwEoBfVlaCQIDz+2WiAIf0LAgb/VWh9YGg+4Gn/HD/+gc4LSAhgQhmI4hjIgA2N4hmPYAkPAerTnerHXhrRne1wQAY+mc/WVZjxHXWlGGMmAaP11VCqobOHnZhOAZrYBADa3ExCAZoqXiBNRZ9GRcO0HZdFhJdDmbWcwf0NYAJvYiUbIifcHgEmwK+AwDUmSDOL3GXdoipdIhw7QbquYh2RlJNHBG5yHijoYJxigALzYi/+++IvA6IsYMATzx3/G6H/6l4xIOAj2xQmqRwQUwH+eeISgSI0bIIpsQgfwcHREs4vB+I3gOIxCEI2fOI3VeI7XOAgJUEvO+IPUaI7wuIzZOAdoBlxT443gmI/CSIzl2I/vKI+O8oz8eI7x+I8AWSuytgb4qI/6KI4AMH8E6Y8ReZDr8oMFOZHniI3kkpBqsJAMGY78eJEXqZFzgHryIQe4lgTalpJFIHO7RAbkaJAYuYnpOIocmQYe+ZHB6JAxOZMSWZN1IHMumQaX6H5SyHuxlokSKZIU2VU3aQY5qZO/yJNLWZUkiQUGZ3BGpXJKsVl/FwH91UWfcRFN8XdjqW//f3dyKEKW+yZaQkByEeJZwBZwb1lw8DZWCOcSefhybTaFfBVsSQiTMsmUTYmUT0kGUSmVvUiVPjmY9HeVYOMfNscOcLcaeDciR2cUCXB032F0LOaZNhd2XngUngkAWKd1lKVdC8B0bdca5JB1UrgAU2d5P+dzFtYTSfYA3eZFZqCJVSmTkGmYhykGiamYCkCVhImRwQktpQFYv5eFogeWJrFSKkidgiYchmdy18lgR+Fg/9CCvmVegCWFm9d5tCkc/tEUn6ERDUAcf2WSUpOJ0vib6Lic7zWcY1CcismT8+mY1mifT0Zk1gedzdUkCShfd4mgFbaAMgZvLcZ+g3hh/6RFGHk4BOaHfguafUHFX3HJfC85BhDZf8p4jCNamIqFn8RpnN/ImI3pkwBKOlCIhcZ3nQFQJDqnoA+Go54VEaM5eexwgzloeanoDvxWocpBDnR1niKIhTDGG7qBZzZ5BmwIh28Ih7UXmCjqBfoplYyZnNP4omQUiwTaWp3HeRZWnTqqYo/WbjF3l44miRFqeQ5QpkZKE4zoeTS2W3v4XnSYZlA6j3GQalmaBVuqk1RJoiKaqIgKpnywjX/KCAJ5Nmc3qFoAhmgohjMwA5eKhmooBFPahlVqpa0nh4dQj1hVCZHKUxlHqWiQARkAMj7jaojyNdrEqq36qrTqNJ7GMP+raqtl4KqwmgbwaQdDeQS+pgW4Vqxpc2rBypy+egbAmqtnUKzXVqsB+gSVpwU5aq1mJ63X+qxkEK1vswZnWZYtKZkG0nKtIQDaRlePBSLyxiOnmhXqKpcU5q6PN3Gl4ROqAZcS+HC0lSTqSgQvpxpbmaDcmjTQN6ng6gXiCmtp0JmtxY38FnWySXrZRSQAm2QaEZoJ8HNrNwSVyYGqOVW4OWRp93UP0Hdilpp353cEMbLJQVosW4V6t63OSmze+j4NKwYPi2lrkKYsaCXliae00ZeMp573OQRvoUhCyp5I+3kTIHxV8Z2yaGDIRwRUm1uJB6H7tatgm1A9CwY/+2n/aiC04XehRkthMKah2zcZ1/C0kQZj6VetFHZiLha3QysfDXigCQs1zfouY+uzuDquZ+ujUBaDSGq0lSkaRTeCD7Gb+7Zo+dK4GrGEq+EPsdWDeAt8WzhWmxujIEJjX8usO/uhg8sFZcurQYu4c6eIdyqkHxtnb9l5agYOm0GLCMAbMTa7+pEVlXiKfBVpnasbt+ikLFimN4KHpPu3WLOwSZm6X7C6YduoXpcKepZa0Su9XUC9pisR9QiYIVa9GMew3GsF3quzR0O+3eq854u+hQuxuvq98iu477sF6Vu+sUq/QLu994sF+du+86u+9fut/3sFAaywN8O+Cuy/B1wF/wkMuPtLwP3rvg8MBRH8vAvMv2ZrwRfsBBksqRMsBa+GBSVswB8sBSGsqhsMJikMv4HrOi78wlQQAzGQKLO6vpBKwy+cqmXgwzw8N0A8BkMcxFpTxPFnxA+MxGDAxEpMM8ahCFryxPcbxYkwxVR8vmCVCL/7rNVADuf3qFIAll7wxaURVMcSHYugxuDqCym4xcYmN76gGiQBx1BmxUKjrApxGVd8Gm3sC9UAVkQhliT3GTVxE+MAbD7SX1OxI13gC1MVDfhRE29pcFbRQVPGV/NmEzphFAwBWGJ8Dl4BFgMQyjd5EBXwAHnxGYExGA+REfwlI3VxF6ZZo6nsyFwgI/+Dkcr4IR5WYVsHkQ978VelXBhRsgslcVT70RGHABI9CxHVgR+5sRsPIR0J0suPJ52x7CV85Rie4cisoR6I2BS90B6UaRwDsh8C0XWCYBDg17AVESXrGRHZURXfgc2oURThgMvhZmVm8c2+DGPGsRjAZRDmzB42kiIC0aN94A4HsZu+WhEm8hkUYiE2cs094hkS0Av8rAUSzRT4URs/ItCBpRdV5RvqgSEFYsrxAA3SEFgQLQfVAA7iENO2KhkG8RlGUhIxiBUYvSMCQRfb/MhY8c3AzHkd2wu8YRCGgdLGkdK+IL5jsQvmcQxWfdVYfQzJwNJZ3NVe/dVgHdZiPdb/ZF3WZn3WD/yIXaTHR8CSZHCs57sLmgwihNVZ1KAU/JB7OMgGci1lC1DXF7hueS21a9IUHfJYqFKUYKBtiv2sq/UWOkHQjfEVFOEfjvEgA7AApsHOZ/DYvyfZuVHZjfEYBqHZA6Em0zUE5FAf7hpZaLnIzieF9sqF7PoUG9edtoFkIveWK7eupPVYbkkTJUepZaEj8+DK0TARxnEZmpHca1DcUFEWRpHc6sHcZuHcaVKjCAkBrzVVsDWxy6CZR+dsTTFUCaaxKasYdJdzlPmyeWdk4cUOp7kacjeo4ozQwQHV8p3KzXgG963f+m2a/F3YGLhS6sWE1QkY58UO5G2J/0hhJXo9tdlJfBCKoQ/Gna3hnba6IezaVyb9AAmWGhJw2b2RGmzA4dxtGuoF4r0xASN+YFrxd2nC3QhJYdR3nQZKYw0ObwNYtw5efQiYhcWLYo19mE1SJXZ6EH6lyysLFb5g02Vw5JPcCwiw5L3Q5Ij45GuyWv/AAEaxID3mo9qNc1LoW6slpJgLcDxqhVE4o7TZRUB6lKl731N42nlA56jB2WSSXJ23reWhZiqYDnylc+RdjxSavKaopq94ErZ7tZZnZ3gRifcwrD2L54JB6XFg6Xi8NNW6BI6K1qB+SQWeBKYa6qZ+6qie6qoeB8laBG6NBK+OBIhsBZiuBLG+6v+Xg7NVywRF7nUJAOVJYONU0Ou4Di8Fm3II+2yUGZb7+hMPJgEX8pdQlppH4Vz/9g8F+9tDV5f9lhV0mckOXuxEQ7N+Z7OVqetuqhsqW7MF+oEUCCK1BF1DZnkli4gr63diZ2HcfX4+1nSu2ZrELu7HsrUU3rzK3hrSiZ3PVoj8sFskdxz0TH5AtrVzSxvrRYJPJ551KvAPc21A7oDoXmE57l/nRgDOAQ+AMZ5tmopya7f/wF/rZWFdNqHnyfEqA1ulIbp+q+xjfoCbu3gI0Xd716C4QQ7XBWQ4P7qxDebqXoBE+iAbb/P6Ag7DK6Yh31yCbqbAO7wPNqd6WuVEX4j/fDV0Xkb1vAHp5DGnasbyczr2ci71cB/3cj/3dF/3dn/397sA1Yb3qj56wV7rfH85aonsNNHb9AppUDbrwh0h9wbGTQEggpUVzW5TFRf4suaxddfelgmzekeFaGEU7EPf1HBdMWvIRpvULJvvtorGrcHVcNAUp1oiqt1a52cNy6DZJ2kEYXcnVHt4zll87de0XaxYZEVhkfcYFoihK0XxAZ+QkrEdYdVnZ0Dj3SYYYhEbSdtJBGKCoYURUr0lC/jxCZi3EthVxf/y0fZ4py+kd3nTjAV1huzamFVZ0s6WqkFvCigTU9ZvbAkEEIBEAAAIJEZjIkAIJAAEJ0MJqDiE/5DGA9AQKhcPRzIQqB4dlXNV0CA4oGv5nF633/F5/Z5flRCMEAQSKhaMDAmKBAAJJg7PBowiHBONGpLaAASHACciABgiBbgAEJP6UFNVV1lbXV/xBhYaGBrKohQBIQQZGAzDjh4GH3oHBAyVIhxKJbQSRoMXEh4W/owITo0czAKWHRwGwYQdZieWKyAEjgHMIZax17ToFqjMYe/x8/MjEByESxEQQGCm0iIACRogQNAAkkA4uA5JIfBroQNA0whEiAQgQECGEgLqEzmSZEmTdSJJEXCrICCDRtwREAUI4sYqFeJ0KRJlwctbxBiQUqLGiJpbVew9IMAAS5gyAZJ4mf8GYEDOZI7mJJiQkOZJr1/vxSHGyiZYs2fRpiU5kyPBXEdoKqPCtuaaspVw+TRjbhIkJZGOKsESJQkxd2fGIpiAQA4CZI0nPOuqlnJlJUoRfFlV1nJnz5/Vlr11CQAEl4wJg6JbqeoZAl8WeDrI5aXj2Q+sdsHEMLCRsUaCAhisJDjHB5/OEFIywViV1qZBR5c+nXp16yVFmxn1hqYUCGEyri7SEXlEKRISOFCIqYJAM9rKg5FoqHdxmMseBCTA8HCpAdksQaA9KrY4AwKlLLpOwQUZbNDBB0t6qYrfOkMHwgsxzFDDDTGU8L7PauFQxBFJLNHEE1FMUcUVWWzRxRf/YYxRxhlprNHGG3GMjrMceezRxx/VEmCAACBg4IsiS5OggQaYaMSINhrYKQAGplQivTcSMBImKpCwyJAuJwIlHTNmgYej/Qz5A54mnzhCAAg0A8WiAKTE8ggJLNrpjwYeA9LPPwHFI5RjXqokI60EmaYXoMYaYAolGnBEgp66G4+ABBYw6tJMj6jAFgYQYCCBRLZiJowshdiGo2UCqCCCODdRNQIzrGnCFy6UzBK3QHnt1deNCi2ipWsEmOC9ABzZ0YFLuKy0LWKPSuSlCZxogsjMDGGgggl2IsqKZ6tYALVbKngKsPciaWCbAP7x1d13ewTW2WFxOeqWHUtLQx1n/6Nd6T1paepGHQG4jOABM6gMyaZzz9CLqoHHQzcKbtXJDd6LMXaxNXEP2oTeRDjmiao1dpqV4wQ2uUU5ldV4aZQ4FpCGk14OSnc3cK3ECYBZJ37kKMAYOoiKjIkuOkXyuljI47cg6mggI3bsSAooEkpoPMzIwBouJXYRSAKQBKInoMxKmQ9nrhdy4qCEFgJ3I34EGtrouekmurfeSopjuLr57ttvI+5+7yT1EIjv78MRT1zxxRlv3PHHIT+8z1LsyJI4Y3eSA9M6ZF4jgsnp2ByPBQzvPPLTUReJ9K6MxFeJRQR/VQAEAAzX8DM+lwOvO0g/Ww4PdwY99eGJf31JKf//WMbABJ8MoCzTVD1T8Kvm0LLM6UujAqo3rtmKFsDtVAdOLaWosomHmnTDQO2TL9591INadC4hvCB5spFhYjIUJepTxuInAVEIrbimCAOgnxAOZQ+e1cpV6QDENwaxQEDwDDpVYM0B35dBxxkLcMkCHPa25hxIncImvZFM7V4HiOOEw4IF/CBEDFKuMjBsa0eRofOsAAXgseaFGvRh4uxlho3gLYR/UQJeSghC4KXwIFvR2RFd+KxhGWNg4DLIzyCGvx1GkYg/9OLcQhamISrxfjbhWQKS+DrAKa9NTNzJJqCIP5a8xUmUO8oVkVNHQ2zCGi2UIwi/GEi7KURivuP/R3sMYRpHCWFU4bnGA5QSoIVAARhsAATbDMdDKb4FIQrhzXsMAqqJdLJt4lLX/TTZRUGu0n2uW8MEsMJKWc5yQa48QxtpmUtd7pKXvfTlL4EZOYK9jgoMgFgCngEzi1lOFbmzkvDSQrNgTjNeNBESN6o1JQFcgVgNU5sqdleK23llR3Ci5jlxNABwCEdVvVnEUiBSBWuRzA0PMVITsAKldgFHCNczkJKY5CZz7skQV3oIQcWEzyMMKU7qSNKS5IZOia5IFrSwBTafYsxEvCNz/AMhPdixjFEMoxehQllHYyiNWF7jE6Vq1atyFRSESKoa+sPNSBU1qD6xJAJaUd5E/4GKopQk4hYCq5hBlhLOHlZBK1wJIanyiFIVRoCFcRzZUdRVhnEwqwvrEkaw8CdPtxQxqGUdEVuKOj2DCCBPayCiYiTzVH91k4lNfSJdadiIgUHBHRVYBMUGAdaojXWJZjXshbJztkLt06N24atLKtVHOALwCIHoaCWUBK4ABC1LJSsDZzXazdaIFYb3O+xpHZRYds3HZc2xICTvdyDuyHVn/Zjs1jDpGv3QJ3ZjS9jUahs3sCKtsfRC7XEdp1TkLheoymXuc6EbXelOl7rVbRAgehchVZjTmdb17ozokg+bmFYPc/zueVcUgfNAjaxn4pOcXgMTgDYJK+qFxzWF8P+ePdXufGlC0ybdC030DvhBSVDUyDxUqmoAQBgIQWBPF0PSIcymGOuIBEhQVQVlMCOmuJmjglFIYBE3SADq9SuCJ7OL75TtSQz5mCJMHMWRkWYNd80qu+aaCBULeMQ9pg5IEOFC4JX4YC5jBNMSAeS6sNe5dwEsEwhrMED6mMrRCcAnToricEHBGjpDVmmhheVNjBYwyutTfEux2SVQyS0y62OV4SwdlO1nzGQFm21A0g8ovHjOVuNI4UaWnoBMbwESSQLcQjXHO/M4zo129KMhHWlJT5rSlbb0pTGdaU1vmtOd9vSnQR1qUY+a1KU29alRnWpVr5rVrXb1q2Eda1kZz5rWtbb1rXGda13vmte99vWvgR1sYXsxCAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15998=[""].join("\n");
var outline_f15_39_15998=null;
var title_f15_39_15999="DIP joints psoriatic arthritis";
var content_f15_39_15999=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70503&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Distal interphalangeal joint involvement in psoriatic arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 375px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Psoriatic arthritis with distal joint involvement in the third and fifth digits (arrow). Onycholysis is also seen in most of the fingernails.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dafna D Gladman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_39_15999=[""].join("\n");
var outline_f15_39_15999=null;
